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Abstract 
Controlling Plasmodium parasite numbers in vivo is crucial for protection against malaria. 
However, immunological mechanisms that mediate this process remain incompletely 
defined. For example, although robust antibody responses are essential for controlling 
parasites, host immune factors that influence the development of these responses are not 
well understood. A second example is our limited understanding of the role of the 
mononuclear phagocyte system (MPS) during infection. In part, this is due to the lack of 
appropriate in vivo tools. This thesis examined cellular and molecular factors that 
influenced control of parasites in mouse models of blood-stage Plasmodium infection.  
 
Firstly, these studies established that CD4+ T-cells were vital for the development of 
humoral immune responses and parasite control during infection. CD4+ T-cell depleted 
mice were unable to generate plasmablasts, germinal centre (GC) B-cells or undergo class 
switching. Next, requirements for the inducible T-cell co-stimulatory molecule (ICOS) in T-
follicular helper (Tfh) cell formation, GC B-cell differentiation, immunoglobulin class 
switching and the production of parasite-specific antibodies were established.  
 
Next, the role of interleukin-6 (IL-6) IL-6 on the development of humoral responses was 
examined. These studies established that IL-6 was essential for optimal parasite control, 
and for the production of parasite-specific IgM, total IgG, IgG2b and IgG2c. Similarly, GC 
B-cell and plasmablast responses also required IL-6-signalling. IL-6 supported the 
positioning of CD4+ T-cells adjacent to splenic B-cells, and sustained ICOS expression by 
Tfh cells. Therefore, these data support the hypothesis that IL-6 supports ICOS-dependent 
humoral immunity to blood-stage Plasmodium infection. 
 
Next, these studies revealed that Type I interferon (IFN-I)-signalling, which proceeded via 
conventional dendritic cells, suppressed parasite control, delayed production of parasite-
specific IgM and IgG, and limited plasmablast, GC B-cell, and Tfh cell responses. IFN-I-
signalling acted early to limit activation, proliferation and ICOS expression by CD4+ T-cells, 
as well as restricting the positioning of ICOS+ CD4+ T-cells close to B-cell areas in the 
spleen. Improved humoral immune responses and parasite control elicited by IFNAR1-
deficiency depended on enhanced ICOS-signalling. Thus IFNAR1-signalling restricted the 
development of ICOS-dependent humoral immunity. 
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Finally, the role of the MPS during blood-stage malaria was examined. In these studies, a 
transgenic approach, LysMcre x iDTR, was assessed for its utility in depleting monocytes 
and macrophages. Using this system, studies revealed unexpected roles for monocytes 
and macrophages in restricting early parasite control and contributing to fatal pathology.  
 
Collectively, these findings have provided new insights into cellular and molecular 
mechanisms that influence parasite control during blood-stage infection. Thus, results from 
this thesis have implications for future efforts aiming to improve immune-mediated control 
of malaria. 
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1 CHAPTER ONE: LITERATURE REVIEW 
 
1.1 Humoral immunity 
The basis of most effective vaccines currently in use is their induction and maintenance of 
long-lived humoral immune responses. Key components of a humoral immune response 
include B-cells, antibody secreting cells (ASCs) and antibodies. Naïve B-cells localise 
organised niches within peripheral lymphoid tissues, including the spleen, lymph nodes 
and Peyer’s patches [1]. Mature B-cells are subdivided into marginal zone (MZ) B-cells, 
follicular B-cells and B1 B-cells [1-3]. Marginal zone B-cells localise the marginal sinus of 
the spleen. Here, they are suitably placed to rapidly encounter blood-borne pathogens and 
particulate antigens [4]. Similarly, B1 B-cells are localised in tissues such as the peritoneal 
and pleural cavities as well as mucosal sites, which are most susceptible to environmental 
pathogens. Given their strategic locations, both MZ and B1 B-cells sufficiently respond to 
T-cell independent (TI) antigens [4-6]. Follicular (FO) B-cells localise lymphoid follicles of 
the spleen and lymph node. Unlike MZ and B1 B-cells, the majority of FO B-cells are 
specialized to respond to T-cell dependent (TD) antigens.  
 
Antibodies are the major effector molecules of a humoral response. These molecules are 
crucial for protection against invading pathogens and/or driving autoimmune reactions 
upon recognition of self-antigens. Antibody production is a complex sequence of cellular 
and molecular events (illustrated in figure 1.1). During a TD response, these processes are 
initiated by activation of B-cells via antigen-mediated signals delivered through the B-cell 
receptor (BCR) and CD40L [7, 8]. Upon activation, B-cells undergo clonal expansion, class 
switching and somatic hypermutation [9, 10]. Some of the clonally expanded B-cells 
differentiate into plasmablasts (PBs), long-lived plasma cells (LLPCs) and/or memory B-
cells (MBCs) [10-12]. PBs readily secrete antibodies but are short lived. They are readily 
detected in blood and lymphoid organs during an active infection but are rare in the 
absence of circulating antigen [12, 13]. Upon their formation, some PBs may migrate to the 
bone marrow, differentiating into LLPCs [12-14]. MBCs, once generated, may either enter 
circulation or remain as resident cells within secondary lymphoid organs [15-19]. They may 
persist for a lifetime, contributing to the rapid clearance of pathogens following re-exposure 
of the host [14, 20, 21]. In addition, they rapidly and specifically respond to antigenic re-
stimulation, contributing to both the PB and plasma cell pool, thereby prolonging the period 
of high serum antibody levels [10, 22-24]. 
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Understanding the cellular and molecular mechanisms regulating B-cell differentiation and 
responses in infection and immunity remains a fundamental question in B-cell biology.  
 
 
Figure 1.1. A schematic view of extrafollicular and follicular B-cell responses in a 
mouse spleen. Naïve splenic B-cells localise marginal zones (CD21hiCD23lo MZ B-cells) and 
follicles (CD21loCD23hi Follicular B-cells). Naïve B-cells express high levels of IgD and IgM, as well 
as the activation marker CD38.  Upon T-cell activation, naïve B-cells down regulate IgD and CD38, 
and migrate towards the extrafollicular environment, losing surface expression of both CD21 and 
CD23. At the T-cell/B-cell border, CD4+ T-cells and B-cells interact, leading to the formation of 
plasmablasts (IgDloCD138hi cells). Further T-B interactions result in a GC reaction, which leads to 
the formation of long-lived plasma cells (B220loCD138hi cells) and memory B-cells. 
 
1.2 Extrafollicular B-cell responses 
Following early antigenic exposure and TD activation, B-cells are able to differentiate 
along three pathways – they either become extrafollicular plasma cells, germinal center 
(GC) B-cells that generate plasma cells or recirculating early MBCs [3, 25]. Extrafollicular 
B-cell responses occur within the medullary cords of lymph nodes and the red pulp of the 
spleen and are associated with rapid production of antibodies after antigenic encounter 
[26]. Extrafollicular B-cells are able to undergo immunoglobulin class-switching albeit with 
very low levels of somatic hypermutation [3, 26].  
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Extrafollicular B-cell responses occur under four phases, including B-cell encounter with 
antigen, B-cell proliferation within the T-cell zone, plasmablast formation and terminal 
differentiation and the formation of long-lived extrafollicular plasma cells [26]. Although 
mature B-cells are located within B-cell follicles of secondary lymphoid organs but are 
capable of migrating into blood and lymph. Upon antigenic encounter, such B-cells migrate 
from blood into T-cell zones of the spleen or lymph node [2]. B-cells in the follicles of 
lymph nodes are able to capture antigen from follicular dendritic cells (FDCs) within these 
areas [27-29]. This enables recirculating B-cells to respond to both follicular and 
extrafollicular antigens. However, other B-cells such as marginal zone (MZ) B-cells do not 
recirculate between blood and lymph. These mainly localise the marginal zones of the 
lymphoid tissue, where they are strategically located to capture antigen. Although 
recirculating B-cells are able to respond to both TD and TI antigens, MZ B-cells 
predominantly respond to TI antigens [4, 6, 30]. Indeed, recirculating B-cells can commit to 
both follicular and extrafollicular B-cell responses whereas MZ B-cells preferentially 
commit to extrafollicular B-cell responses. Upon activation, these cells migrate to the T-cell 
zone of the lymphoid organ. However, while these processes proceed, elsewhere in the T-
cell zone, DCs present antigen to naïve CD4+ T-cells, thereby priming them to deliver help 
to B-cells [31]. Activated B-cells process antigen and present it on their surfaces in order to 
interact with primed CD4+ T-cells. Cognate T-cell interactions with B-cells begin when T-
cells enter the cell cycle [32]. Activated B-cells either differentiate into extrafollicular 
plasmablasts or enter the germinal reaction to form a GC [33]. The commitment of B-cells 
towards a plasmablast or GC fate occurs early into the cell cycle. While in the T-cell zone, 
B-cells committed to the extrafollicular fate upregulate Blimp-1, a key transcription factor 
for plasmablast and/or plasma cell differentiation [34] and express the plasma cell marker 
syndecan-1 (CD138) [33]. However, B-cells entering a GC reaction upregulate the 
transcriptional repressor Bcl-6, which inhibits Blimp-1 expression [35].  
 
A number of factors have also been implicated in the commitment of B-cells to either 
extracellular plasma cell fate or GC fates. For instance, the strength of initial interactions 
between the BCR and antigen are critical in guiding these processes [33, 36]. These 
studies demonstrated that high affinity or abundant epitopes steered reactive B-cells 
towards extracellular plasma cell fate. In contrast, B-cells that reacted against lower affinity 
epitopes were directed towards GC B-cell fate, a process that facilitated their affinity 
maturation. In addition, interactions between blood DCs and MZ B-cells are also important 
in initiating TI extrafollicular humoral responses [4]. Immature DCs capture particulate 
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antigen in blood and transport it to the spleen, making it available for MZ B-cells. Antigen 
delivery to DC-inhibitory receptor 2 (DCIR2), expressed on MZ-associated CD8- DCs was 
essential for the robust production of extrafollicular, class-switched antibodies in mice, 
suggesting that MZ-associated DCs supported TD extrafollicular B-cell responses [37]. 
Newly formed plasmablasts have also been shown to interact with CD11chi DCs - these 
interactions are essential for plasma cell survival and proliferation [38]. B-cell lymphoma 6 
(Bcl-6) expression in T-cells is required in priming B-cells during TD extrafollicular antibody 
responses. The absence of Bcl-6 in T-cells is associated with significantly impaired 
extrafollicular antibody responses [39]. 
 
Innate signals in facilitate extrafollicular humoral responses. For instance, Toll like receptor 
(TLR) ligands influenced the magnitude of antibody responses by inducing intrinsic type I 
interferon (IFN-I) signalling in B-cells [40]. However, in a more recent study, 
overexpression of TLR7 promoted cell-intrinsic expansion of T1 B-cells as well as driving 
their antibody production in a IFN-I independent manner [41]. Mice immunized with 
synthetic nanoparticles containing antigens and ligands, signalling through TLR4 and 
TLR7 exhibited enhanced GC and plasma cell responses as well as increased levels of 
neutralizing antibodies, albeit with no effect on short-lived plasma cell responses [42]. 
Innate lymphoid cells may also support TI antibody responses [43]. These are thought to 
stimulate MZ B-cells, enhancing signalling via BAFF, CD40L and the Notch ligand Delta-
like 1 (DLL1). Innate-like B-cells such as B1 B-cells in mice injected with a TI antigen (NP-
Ficoll) potently differentiated into clones that sustained IgM and IgG3 antibody responses 
for months [5]. Despite this existing body of work, mechanisms regulating extrafollicular B-
cell responses and their roles in infection and immunity remain unclear.  
 
1.3 The Germinal reaction 
Secondary lymphoid organs such as the spleen and lymph node harbour B-cells and T-
cells, which are organised into B-cell follicles and T-cell zones. During a TD humoral 
response, transient structures known as ‘germinal centers’ (GCs) form within these 
peripheral lymphoid organs (illustrated in Figure 1.2). These structures are crucial for B-
cell differentiation into LLPCs and MBCs, as well as controlling processes necessary for 
the production of high affinity antibodies [3, 25, 44, 45]. It is now clear that commitment to 
the GC reaction by antigen specific T and B cells initiates rapidly and occurs outside the 
follicle [9]. Activation of naïve B-cells by exogenous antigen within the follicle initiates a 
sequence of events, which lead to GC reactions. Upon activation, B-cells migrate towards 
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the border of the T-cell zone and the B-cell zone (T-B border) or the inter-follicular region, 
where they are able to interact with T-cells [9, 46, 47]. Two-photon, intra-vital microscopy 
has revealed that this initial process occurs within the first 24 to 48 hours following 
infection or immunization [9, 47, 48]. These initial molecular interactions between B and T-
cells, are crucial for proliferation and survival of activated B-cells. For instance, CD86 
expression on B-cells insulates them against Fas-induced apoptosis through its 
interactions with CD28 on T-cells [49, 50]. While in the inter-follicular areas of the lymph 
node or the bridging channels of the spleen, activated B-cells capture antigen from DCs 
and may interact with other survival molecules such as BAFF and APRIL [51, 52].  
 
Figure 1.2. A schematic view of the cellular and molecular mechanisms controlling 
humoral immunity. Interactions between dendritic cells, CD4+ T-cells and B-cells in peripheral 
lymphoid organs are crucial for the development and maintenance of humoral immune responses. 
Dendritic cells are important in priming CD4+ cells to differentiate into follicular helper cells (Tfh 
cells). Committed Tfh cells upregulate Bcl-6 and ICOS facilitates their movement towards B-cell 
areas. At the T-B border, pre-Tfh cells interact with B-cells, leading to the formation of 
plasmablasts. Fully differentiated Tfh cells upregulate PD1 and CXCR5, migrating further into the 
B-cell follicle. While in the follicle, GC Tfh cells interact with GG B-cells, leading to the formation of 
long-lived plasma cells and memory B cells.  
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Within the first 48 hours post infection or immunization, DCs also prime some T-cells to 
become T-follicular helper (Tfh) cells [53], (reviewed in 1.6). It has been suggested that 
GC commitment occurs earlier in T-cells than it does in B-cells [9, 45]. DC-primed Tfh-cells 
begin to upregulate Bcl-6, a master transcriptional factor for the Tfh and GC programmes, 
express CXCR5 and the programmed cell death protein (PD1), and migrate from the inter-
follicular region into the follicle by day three post infection or immunization [9, 54]. 
Interestingly, precursor GC B-cells moved towards the centre of the follicle a day later (day 
four). At this time point, rapidly proliferating B-cell blasts are formed within the centre of the 
follicle and form a mantle around the GC by displacing naïve IgM+IgD+ B-cells [9, 47]. 
Within the next three days, B-cell blasts proliferate rapidly, increasing the size of the GC 
and establishing both the light and dark zones [9, 47]. That said, the kinetics and 
organisation of the GC response may differ depending on the nature of the stimulating 
antigen and the lymphoid organ being examined.  
 
Various intrinsic and extrinsic factors control GC reactions. These include transcriptional, 
post-transcriptional and/or post-translational factors as well as epigenetic modifiers. In 
addition, crucial roles for cytokines in controlling the GC reaction and GC responses 
(reviewed in 1.12) have been identified. As highlighted earlier, Bcl-6 is critical in initiating 
the GC reaction. A requirement for Bcl-6 in facilitating the migration of GC precursor cells 
to the centre of the follicle was previously revealed [54]. In this report, Bcl-6-deficient B-
cells were unable to enter the follicles. Moreover, Bcl-6-deficient GC precursor cells failed 
to express CXCR4, a key chemokine receptor for recruitment of B-cells into the GC dark 
zone [54, 55]. These studies also revealed roles for Bcl-6 in down regulating EBI2 or 
SIPR1, receptors that promote the retention of precursor GC cells out of the follicle.  
 
The interferon regulatory gene 4 (IRF4) acting in both T and B cells is also necessary for 
early GC formation [56-58]. Conditional depletion of Irf4 in mature B-cells abrogated GC 
formation following protein immunization and during infection [56]. IRF4 exhibits both 
activating and repressive effects on Bcl-6. IRF4 activated Bcl-6 expression in B-cells, early 
following immunization [59]. However, it repressed Bcl-6 during later GC stages [60]. 
Unlike IRF4, the transcription factor MYC is continuously required throughout the GC 
reaction. Mice with activated B-cells deficient in Myc are unable to form GCs after infection 
or immunization [61]. Similarly, the anti-apoptotic protein myeloid cell leukaemia 1 (Mcl-1) 
is required for GC formation, perhaps by supporting B-cell survival within the GCs [62]. 
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Conditional depletion of Mcl-1 abrogated GC B-cell responses and MBC formation 
following protein immunization.  
 
The transcription factor BACH2 has also been implicated in GC formation. Huang et al., 
demonstrated that BACH2 complemented Bcl-6 in initiating and maintaining GC responses 
[63]. In particular, BACH2 and Bcl-6 repressed Blimp1 and XBP1, which are necessary for 
plasma cell differentiation. Requirements for MicroRNAs in regulating GC reactions have 
also been reported. For instance, miR-155 deficient mice exhibit defective GC B-cell 
formation and affinity maturation [64]. Cell adhesion molecules, supporting interactions 
between T and B cells are also required for GC formation [65, 66]. For example, T-B cell 
interactions controlled by the slam-associated protein (SAP) underlie GC formation [65, 
67]. SAP deficiency selectively impaired GC formation due to inadequate interactions 
between CD4+ T-cells and antigen specific B-cells [67]. This limited contact dependent T-
cell help to B-cells. In addition, the recruitment and retention of T-cells within GCs is 
impaired in Sap-/- mice.   
 
1.4 Germinal center light and dark zones  
Germinal centers comprise of the light and dark zones, which are crucial for optimal GC 
function. These zones can phenotypically be distinguished based on their differential 
expression of CXCR4 and the activation markers CD83 and CD86 [68-70]. Light zone B-
cells express low levels of CXCR4 and high levels of both CD83 and CD86 
(CXCR4loCD83hiCD86hi) while B-cells in the dark zone express high levels of CXCR4 but 
low levels of CD83 and CD86 (CXCR4hiCD83loCD86lo). The light zone is characterised by 
a sparse population of B-cells, FDCs, Tfh cells and macrophages, all of which contribute to 
its light histological appearance. In contrast, the dark zone is densely packed with highly 
proliferative B-cells, which contribute to its dark appearance when analysed by histology. 
Inter-zonal movements of B-cells within the GC are postulated to occur in a cyclic manner 
[36, 45, 71-74]. These movements are critical in the selection of high affinity B-cells that 
are essential for production of high affinity antibodies. Selection of high affinity B-cells 
occurs in the light zone [36], which is predominantly colonized by FDCs, holding antigens 
on their surfaces in form of immune complexes [28]. Antigen-specific B-cells capture 
antigen off FDCs by interacting with these cells. While in the light zone, B-cells interact 
with Tfh cells, receiving cognate signals necessary for survival. Higher affinity B-cells are 
believed to possess better capacity to capture antigen on their BCRs and subsequently 
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presenting it to Tfh cells [36, 75]. This enables such B-cells to receive better help signals 
from the Tfh cells.  
 
Upon receiving these signals, B-cells migrate to the dark zone, a process mediated by 
chemokines [70]. CXCL12 and its receptor CXCR4 are believed to influence this process 
[73]. While in the dark zone, B-cells undergo multiple rounds of proliferation and somatic 
hypermutation of their immunoglobulin variable genes [73]. These processes result in the 
formation of B-cells with higher affinity for antigen. Following somatic hypermutation in the 
dark zone, mutant B-cells return to the light zone for further interactions with Tfh cells, 
receiving more signals important for survival and/or differentiation [70]. Selected B-cells 
return to the dark zone to undergo further proliferation rounds and somatic hypermutation. 
Identifying cellular and molecular factors regulating events within the light and dark zones 
as well as GC function may be crucial in identifying targets for improving humoral immunity 
against infections or suppressing antibody-mediated auto-immune responses.  
 
1.5 Memory B-cells and long-lived plasma cells  
Long-lived humoral responses are vital components of the most effective vaccines 
currently in use. These responses are primarily orchestrated by MBCs and LLPCs, 
following infection and/or vaccination. MBCs are quiescent but rapidly proliferate and 
differentiate into ASCs once activated by a secondary antigenic encounter [76]. However, 
LLPCs are terminally differentiated but readily secrete antibodies without requiring further 
antigenic stimulation [3]. Although most MBCs are circulatory in nature, a few are resident 
within secondary lymphoid organs. In contrast, plasma cells do not recirculate in blood or 
lymph but rather have established survival niches within the bone marrow. Well-
established in-vitro and in-vivo systems have led to a better understanding of some of the 
cellular and molecular mechanisms regulating MBC and LLPC differentiation.  
 
MBC differentiation is associated with transcription factors (summarised in Table 1 below), 
which prevent premature PC differentiation but rather promote the maintenance of B-cell 
phenotypes [3, 76]. The best characterized include the paired box protein 5 (PAX5) [77], 
BACH2 [78], Bcl-6 [55], SPIB [79] and IRF8 [80]. PAX5 binds to a variety of DNA sites 
within follicular B-cells, thus controlling many aspects within the B-cell transcriptional 
programme [81]. It also regulates components of the BCR such as the immunoglobulin 
heavy chain, CD19 and CD21 as well as transcriptional factors such as IRF8, BACH2 and 
SPIB [82, 83]. Indeed PAX5 loss of function in mature B-cells resulted in their loss of 
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identity and reversion to progenitor state [84]. Moreover, induced Pax5 expression in B-
cells mildly suppressed PC formation [85]. In addition, PAX5 positively regulated BACH2, 
a transcription repressor targeting BLIMP1 [83]. The absence of BACH2 associated with 
impaired GC formation, class switch recombination and somatic hypermutation [78, 86]. 
Furthermore, BACH2 deficiency associated with increased BLIMP1 expression and 
enhanced PC differentiation [78]. Recently, suppression of BACH2 in MBCs associated 
with their enhanced PC differentiation upon antigen re-exposure [87]. PU.1, IRF8 and 
SPIB are constitutively expressed in GC B-cells and downregulated in PCs [88]. The PU.1-
IRF8 complex has been shown to suppress BLIMP1 while promoting Bcl-6, Pax5 and 
Mef2c expression [89]. Enforced expression of SPIB in B-cells impaired class switch 
recombination and plasma cell differentiation [90].  
 
Transcription factors BLIMP-1 [34], IRF4 [59] and the X-box binding protein 1 (XBP1) [91] 
are required for plasma cell differentiation and responses (Table 1). BLIMP1 is a well-
defined transcriptional repressor in both T and B-cells. Within the B-cell lineage, it is 
mainly expressed in ASCs, with higher expression levels within PCs than PBs, both in 
mice and humans. However, although BLIMP1 is critical for PC maturation, it is not 
required for initiating the entire ASC programme [34, 92]. BLIMP-1 has been implicated in 
repressing genes encoding Bcl-6, MYC, ID3, SPIB and PAX5, key regulators in the B-
cell/MBC programme [92, 93]. High levels of IRF4 promote PC fate by activating BLIMP1 
and Bcl-6-related transcription factor Zbtb20, while repressing Bcl-6 [94, 95]. However, low 
IRF4 levels promote activation of Aicda, Pou2af1 and Bcl-6, leading to GC B-cell formation 
and class switch recombination [95]. Plasma cells also express high levels of the 
transcription factor XBP-1, which promotes Igh mRNA processing, immunoglobulin 
secretion and has been associated with remodelling of the endoplasmic reticulum [91, 92]. 
Pax5 deficiency associated with increased expression and activation of XBP-1 during PC 
formation [91]. Based on this observation, it was initially thought that XBP-1 was a direct 
target for Pax5 mediated repression. However, interactions between these two 
transcription factors remain unclear, hence warranting further studies.  
 
Mechanisms regulating the establishment and duration of humoral immune responses 
following infection or vaccination remain fundamental, yet unresolved in B-cell biology and 
vaccination. Studies aiming to elucidate such mechanisms may be crucial for strategies 
aiming to improve both natural and vaccine induced immunity against infections. 
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Table 1. Shows lists of genes associated with B-cell and Plasma cell phenotypes 
B-cell-associated 
genes 
Roles Plasma cell- 
associated genes 
Roles 
PAX5 -Controls BCR 
signalling and 
transcription factors 
such as Bach2, 
IRF8 and Spi-B 
[81,82] 
 
- Regulates Blimp-1 
via Bach2 
signalling [83] 
 
 
 
Blimp1 - Required for 
Plasma cell 
maturation [34,92] 
- Represses Bcl-6, 
PAX5, MYC, ID3 
and SPIB [92,93] 
Bach2 Directly represses 
Blimp-1 [78] 
IRF4 - Supports Blimp1 
expression [94] 
- Suppresses Bcl-6 
[95] 
Bcl-6 Represses Blimp1, 
supporting GC 
phenotypes [54] 
XBP-1 Highly expressed in 
plasma cells but its 
actual role remains 
unclear  
PU.1, IRF8 and 
SPIB 
Suppress Blimp1 
and promote Bcl-6, 
Mef2c and PAX5 
[88] 
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1.6 Follicular helper CD4+ T cells (Tfh cells) 
Follicular helper T-cells (Tfh-cells) are specialized T-cells, critical for the production of 
long-lived antibody responses [44, 96-102]. These cells localize to B-cell follicles, where 
they are able to interact with B-cells. These T-B cell interactions result in GC reactions, 
vital for somatic hypermutation, isotype class switching, affinity maturation and formation 
of LLPCs and MBCs [71, 102, 103]. Tfh cells are sources of cytokines such as IL-21, IL-4 
and CD40L, which are vital for GC B-cell survival and proliferation. In mice, Tfh cells 
express the lineage transcription factor, Bcl-6, the chemokine receptor CXCR5, the 
inducible co-stimulatory molecule (ICOS) and PD1, Maf, SAP and BTLA4 [44, 102, 104]. In 
addition, Tfh cells express low levels of PSGL1, CD200 and CCR7 [44]. In mice, humans 
and non-human primates, Tfh cells can be identified as CD4+Bcl-6hiPD1hiCXCR5hi cells 
[98, 100, 105]. Elucidating the mechanisms controlling Tfh differentiation and function 
remains a crucial goal in T and B-cell biology. 
 
1.7 Tfh cell differentiation  
Canonically, Tfh initiation occurs during the priming of naïve CD4+ T-cells by DCs [106]. 
These initial events occur within the first two rounds of cell division, resulting in the imprint 
of Bcl-6 and CXCR5 within naïve CD4+ T-cells [53]. Although less is known about the DC 
subtypes and mechanisms through which such DCs initiate Tfh formation, recent studies 
have suggested roles for CD8- CD11chi conventional DCs in driving these early Tfh 
processes [31, 107, 108]. Follicular DCs also support the establishment of follicular identity 
and B-cell retention within GCs [27]. The absence of FDCs associated with impaired ER-
TR7 and CCL21 expression despite normal CXCL13 levels. In addition, loss of GC-FDCs 
resulted in complete disintegration of established GCs. Follicular DCs are essential for 
high affinity antibody production and development of B-cell memory [28, 29]. Interactions 
between CD4+ T-cells and antigen-specific B-cells, in the interfollicular zone or at the T-B 
border of a follicle are also critical in Tfh differentiation [9, 46, 47]. These areas are 
colonised by subcapsular macrophages that are essential for driving humoral immunity to 
infection and protein antigens [46]. Such macrophages capture particulate antigens and 
pathogens, process and present their antigens to B-cells, in form of immune complexes. 
Disruption of the organisation of SCS macrophages in mice associated with diminished B-
cell responses during secondary Stapylococcus aureus infection [46].  
 
TCR and non-TCR signals are required for initiating early Tfh differentiation. In mice, the 
interplay between the strength of signals through the TCR, interleukin-6 (IL-6), IL-2 and the 
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inducible co-stimulatory molecule (ICOS) orchestrates these early processes. Previously, 
preferential development of antigen-specific Tfh cells was identified amongst helper T-cells 
with the most antigen TCR diversity and the highest specific peptide binding MHC-II 
molecule [109]. In a pigeon cytochrome c model, CD4+ T-cells with high affinity TCRs 
preferentially differentiated into Tfh cells [109], although this was not replicated in a Friend 
viral infection [110]. Moreover, persistent antigens and GC B-cells were found to be 
essential in sustaining Tfh responses [111]. Studies using an LCMV model identified IL-6 
as a key non-TCR signal important for initiating Tfh development [112, 113]. In these 
studies, IL-6 deficient mice displayed impaired Tfh formation, particularly exhibiting defects 
in Bcl-6 expression early following LCMV infection [112]. Elsewhere, it was demonstrated 
that IL-6 was not only required during early Tfh formation but also for their maintenance 
later during LCMV infection [113]. Unlike IL-6, IL-2 potently inhibits Tfh cell development 
[108, 114]. In a recent report, opposing roles for IFN-I and STAT3 in Tfh differentiation 
were identified [114]. Type I interferon-induced IL-2-dependent, STAT-5 signalling skewed 
CD4+ T-cells more towards Th1, repressing Tfh differentiation. In contrast, STAT-3 
signalling associated with enhanced Tfh and less Th1 differentiation during LCMV 
infection. Most recently, the G-coupled receptor EBI2 was implicated in enhancing Tfh cell 
development by facilitating interactions between T-cells and IL-2 quenching DCs [108]. 
The ICOS (extensively reviewed in section below) has also been implicated in Tfh cell 
formation, their migration and maintenance. Notably, ICOS is required in stabilising Bcl-6, 
inducing CXCR5 and supporting the recruitment of Tfh cells into B-cell follicles have been 
reported [53, 115, 116].   
 
B-cells are essential for Tfh cell formation and maintenance. In particular, B-cells act as 
the main APC following DC priming and are a source of ICOSL, which is important for 
maintenance of the Tfh phenotype [53, 111]. DC-primed CD4+ T-cells upregulate ICOS 
and CXCR5 and down regulate the expression of CCR7 and PSGL1 [53, 114]. This 
differential expression pattern initiates early migration of primed CD4+ T-cell to the T-B 
border or into the follicle. Interactions between committed Tfh- and B-cells initiates GC 
reactions and the formation of GCs. Within the GCs, adhesion molecules on GC Tfh cells 
regulate their interactions with GC B-cells. Signalling lymphocyte activation molecule 
(SLAM) family members and its associated proteins are required in sustaining T-B 
interactions, a process required for productive humoral immunity [65-67, 117]. For 
instance, CD84 prolonged T-B interactions, optimised Tfh function and supported GC 
formation in-vivo [65]. In the same report, CD84 and Ly108, sustained T-B interactions in-
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vitro. Slam associated protein (SAP) also plays multiple essential roles during the 
development of GC-Tfh cells and GC B-cells [66, 67, 117]. Its absence has been 
associated with substantial loss of these cell populations.  
 
1.8 Transcriptional control of Tfh cells 
Transcriptional control of Tfh development remains a fundamental research area in Tfh 
biology. Classically, the transcription factor Bcl-6 has been defined as the ‘master’ or 
lineage transcription factor for Tfh formation [35, 54, 118-120]. However, mechanisms 
through which Bcl-6 controls CD4+ T-cell function and differentiation largely remain 
unclear. Nonetheless, Bcl-6 expression in Tfh cells has been associated with the control of 
genes important in migration, repression of alternative cell fate, enhancing Tfh lineage 
commitment and driving the formation of Tfh products [119]. Bcl-6 deficiency abrogated 
Tfh and GC formation whereas its enforced expression in T-cells promoted their 
expression of CXCR5, PD1 and CXCR4 [120]. In humans, Bcl-6 and Maf initiated Tfh 
differentiation [121]. In addition, Bcl-6 may regulate Tfh responses by controlling AP1 
activity in helper CD4+ T-cells [119]. Elsewhere, Bcl-6 expression and CD28 signalling in 
NKT cells resulted in the formation of follicular NKT cells that potently induced GC 
formation via interactions with B-cells [122]. These follicular NKT cells were a source of IL-
21, which is required by cognate antigen-specific B-cell for their responses. Other reports 
suggested that Bcl-6 repressed alternative CD4+ T-cell fate (Th1, Th2, Th17, Treg) by 
targeting transcription factors, such as Blimp1 and cytokine genes important for formation 
of these effector T-cells [35, 120]. Although the fate of Bcl-6 expressing CD4+ T-cells is 
imprinted early, these cells have the capacity to form memory [118].  
 
While Bcl-6 controls many aspects of Tfh development, other transcription factors (Table 
2), acting upstream or downstream of Bcl-6, have been found to play critical roles in aiding 
this process. For instance, Maf activity in Tfh cells has been associated with the 
expression of CXCR5, IL-21 and IL-4 [121]. More recently, roles for the transcription 
factors LEF-1 and/or TCF-1 in initiating TFH differentiation and effector function during 
acute viral infection were identified [123, 124]. Selective loss of LEF-1 or TCF-1 led to 
defective Tfh responses [123]. Complete loss of both transcription factors significantly 
impaired Tfh and GC responses [123]. The absence of TCF-1 in CD4+ T-cells also 
associated with the upregulation of non-Tfh associated genes [124]. LEF-1 and TCF-1 
skewed CD4+-T differentiation towards Tfh fate by promoting ICOS and Bcl-6 expression 
while inhibiting Blimp1 expression [123] Transcription factors belonging to the STAT family 
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also control Tfh development and function. In mice, STAT3 supports IL-21 production and 
Tfh differentiation [114]. In this report STAT3 exerted its effects on the Tfh differentiation 
programme by suppressing IL-2-indued STAT5-signals that impaired Tfh differentiation. 
Elsewhere, TGF-b-induced STAT3 and STAT4 signals were implicated in supporting early 
Tfh differentiation in humans but not in mice [125]. These signals led to upregulation of 
Bcl-6, CXCR5 and IL-21 in human CD4+ T-cells. However, human Th17 cell was also also 
supported by these signals, suggesting roles for these transcription factors in bpth Tfh and 
Th17 differentiation in humans. A separate study by Nakamayada and colleagues also 
suggested that IL-12 acting via STAT4 drives Tfh formation by inducing both IL-21 and 
Bcl-6 genes in CD4+ T-cells [126]. However, they further showed that this pathway also 
supported Th1 responses via Tbet expression. This suggested a STAT4-mediated Th1 
and Tfh transitional state, which ultimately results in defined Th1 or Tfh fate depending on 
the balance of Th1-like or Tfh-like signals. For instance, increased STAT4-mediated Tbet 
signals suppress Bcl-6 expression and thus lead to Th1 differentiation. STAT1 can either 
support or inhibit Tfh differentiation through its effects on Bcl-6 expression [112, 127, 128]. 
A previous report implicated STAT1-induced IL-6 signals in supporting early Bcl-6 
expression in CD4+ T-cells, hence supporting Tfh differentiation [112]. However, a more 
recent suggested that type I interferons may induce STAT-I signals in CD4+ T-cells, which 
suppress Bcl-6 and IL-21 production and thus suppress Tfh differentiation. In contrast to 
STAT3, STAT5 potently represses Tfh differentiation [129]. In this report, IL-2-induced 
STAT5 signalling acted in tandem with Blimp1 to suppress Tfh differentiation and GC 
responses [129].  
 
Some transcription factors are capable of regulating the Tfh programme. Most of these 
transcription factors act by repressing genes important for Tfh differentiation and migration. 
A role for the transcription factor KLF2 in restraining Tfh differentiation has been reported 
[130]. KLF2 acted by controlling T-cell localization and regulated the expression of lineage-
defining transcription factors. KLF2 deficient mice exhibited reduced S1PR1, Blimp1, Tbet 
and GATA3, thereby increasing Tfh cell formation. Interestingly, overexpression of KLF2 in 
CD4+ T-cells cells led to loss of the Tfh phenotype. The transcription factor Foxp1 has also 
been implicated in limiting Tfh differentiation [131]. Foxp1 suppressed IL-21 and ICOS 
dependent signalling in CD4+ T-cells resulting in reduced Tfh differentiation. In addition, 
Foxp1 may act in tandem with Foxo1 to restrain Tfh differentiation.   
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Table 2. Shows a summary list of transcription factors controlling Tfh differentiation 
Transcription factor Roles 
Bcl-6 - Master regulator of Tfh formation [35] 
- Controls genes important for repressing 
alternative T-helper cell fate [118] 
- Supports genes important for enhancing Tfh 
commitment [119] 
- Supports Tfh migration through CXCR4 and 
CXCR5 expression [120] 
LEF-1 and TCF-1 - Combined, these genes repress alternative 
T-helper cell fates [123, 124] 
- Support early ICOS and Bcl-6 expression in 
primed Tfh cells [123] 
MAF - Associated with the production of IL-21, IL-4 
and CXCR5 [121] 
STAT1 - Supports early Tfh differentiation by 
supporting IL-6 induced Bcl-6 expression in 
T-cells [112] 
STAT3 - Insulates against IL-2 mediated repression 
of Tfh cell formation [114] 
- Antagonises STAT5 to support Tfh 
differentiation [129] 
- Supports IL-21 production in Tfh cells [126] 
STAT4 -Drives IL-12 induced Bcl-6 expression and 
IL-21 production in CD4+ T-cells [126] 
STAT5 - Represses Tfh differentiation via IL-2 
induced signalling in CD4+ T-cells [129] 
KLF2 - Supports expression of genes important for 
alternative T helper cell fates e.g. Tbet, 
SIPR1, Blimp1 and GATA3 [130] 
FoxP1 - Restrains ICOS expression, IL-21 
production and Tfh differentiation [131] 
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1.9 Regulation of Tfh responses 
Tfh responses are tightly regulated in order to maintain self-tolerance. A specialised helper 
T-cell subpopulation, known as a regulatory T-follicular (Tfr) cell, expressing Foxp3, 
Blimp1, CXCR5, and PD1 has been associated with regulating Tfh cell numbers and GC 
responses [132]. Similar to Tfh cells, Tfr cells require SAP, Bcl-6, CD28, ICOS and B-cells 
for their development [133]. Recent studies have revealed other mechanisms regulating 
Tfr development and function. For instance, TRAF3 was required for in Tfr formation in 
mice [134]. In the same report, genetic ablation of TRAF3 in regulatory T-cells (Tregs) 
enhanced Tfh formation, GC B-cell responses and antibody production. Elsewhere, 
NFAT2 expression in T-cells associated with increased Tfr formation and enhanced their 
expression of CXCR5 [135]. The absence of NFAT2 in mouse T-cells resulted in reduced 
Tfr cell numbers and consequently augmented Tfh and GC B cell responses, which 
exacerbated lupus-like symptoms.  
 
A recent study suggested roles for Tregs in restricting Tfh differentiation via CTLA-4-
mediated regulation of CD80 and CD86 [136]. In this report, depletion of Tregs, CTLA-4 
and Treg-specific CTLA-4 were associated with increased Tfh formation and GC reactions. 
In addition, MBC and plasma cell formation in these mice were boosted following 
vaccination. Elsewhere, the absence of CTLA-4 in mice boosted both Tfh and Tfr 
formation [137]. Depletion of CTLA-4 on both Tfh and Tfr cells augmented antibody 
responses. Intriguingly, CTLA-4-mediated suppression of B-cell responses within the GC 
occurred independently of CD80 or CD86, although these were required outside of the 
GC. Interactions between PD1 on Tfh cells and PD-L1 on GC B-cells associated with 
impaired GC B-cell function [138]. Therapeutic blockade of PD-L1 and LAG-3 also 
associated with better Tfh cell function and improved humoral responses in mice [139]. 
The E3 ubiquitin ligase Itch, acting early within T-cells was implicated in regulating Bcl-6-
mediated Tfh formation, GC responses and antibody responses to acute viral infection, via 
Foxo1 signalling [140]. Enforced Bcl-6 expression and depletion of Foxo1 in Itch-/- T-cells 
restored Tfh formation. Regulation of Tfh mediated humoral responses is critical for 
tolerance at mucosal surfaces. It was recently reported that the ATP-gated ionotropic 
P2X7 was important in regulating Tfh cell numbers in the Peyer’s patches and humoral 
responses at the mucosa, thus facilitating mucosal colonisation [141]. In this report, P2X7-
deficient Tfh cells potently supported GC reactions and enhanced IgA secretion and 
binding to commensal bacteria. However these processes were detrimental to commensal 
bacteria and resulted in increased susceptibility to polymicrobial sepsis at the mucosa. A 
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better understanding of mechanisms regulating Tfh cell responses may improve new 
vaccine strategies as well as assisting in the development of new therapies for antibody-
mediated autoimmune infections. 
 
1.10 Tfh cells in infection and disease 
The most important role of Tfh cells is their critical requirement for GC development and 
function. This is central for the generation of GC B-cells and higher affinity, long lasting 
antibody responses important for immunity against invading pathogens. However, Tfh cells 
are detrimental if their function is dysregulated [99]. Frequencies of circulating 
CXCR5+/ICOS+ and CXCR5+PD1+ circulating Tfh cells were associated with increased 
severity of sjogren’s syndrome and systemic lupus erythrometosus (SLE) [142]. Similar 
observations were made in patients with rheumatoid arthritis [143] and type 1 diabetes 
[144]. Patients with multiple sclerosis also display elevated frequencies of IL-17 producing 
Tfh cells [145]. However, defects in the expression of molecules required for Tfh 
development correlate strongly with the development of primary immunodeficiencies. For 
instance, ICOS deficiency strongly correlates with common variable immunodeficiency 
(CVID) [146]. In addition, impaired CD40-CD40L signalling is synonymous with the 
development of hyper IgM syndrome [147]. Similarly, impaired tyrosine kinase Btk, 
associates with the development of X-linked agammaglobulinemia [148].  
 
During viral infections, malfunction of Tfh cells was associated with impaired viral control. 
Defective Tfh responses associated with impaired antibody production and failure to 
control of LCMV infections [53, 113]. In humans, this has been demonstrated by the 
impaired production of neutralising antibodies in HIV patients [149, 150]. However, it has 
also been suggested that Tfh cells may act as HIV reservoirs, thereby propagating the 
virus within secondary lymphoid organs. Indeed, frequencies of HIV-specific Tfh cells were 
identified in lymph nodes of humans with chronic HIV infection [151]. Elsewhere, the 
induction of ICOS+CXCR3+CXCR5+CD4+ T-cells correlated with antibody production by 
MBCs following seasonal influenza vaccination [152]. Although the role Tfh cells in 
Plasmodium infection remains largely unclear, one study associated impaired Tfh function 
to enhanced susceptibility to Plasmodium infection [139]. Overall, roles of Tfh cells and 
mechanisms controlling their function in infection and immunity remain fundamental 
immunological research areas in B-cell biology. 
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1.11 ICOS and humoral immunity  
The inducible T-cell co-stimulatory molecule (ICOS) plays vital roles in initiating and 
maintaining humoral immunity across numerous model systems [53, 115, 153]. It is a 
member of the CD28 family of co-stimulatory molecules, including CD28, CTLA-4 and PD-
1. ICOS binds ICOS ligand (ICOSL) while CD28 binds CD86 and CD80, delivering positive 
signals through these ligands. In contrast, CTLA-4 and PD-1 deliver negative signals 
through their ligands, CD80 and CD86 (for CTLA-4) and PDL1 and PDL2 (for PD-1). ICOS 
is rapidly expressed on T-cells following activation. Although downstream signalling 
mechanisms employed by ICOS are relatively unclear, it has been associated with the 
activation of the phosphatidyl inositol-3-kinase (PI3K) pathway, through interactions with 
the p85a subunit [154]. ICOS stimulation is also associated with phosphorylation of the 
serine/theorine kinase Akt [155].  
 
In humoral immunity, ICOS is crucial for the initiation and maintenance of Tfh cells, GC B-
cell formation, isotype class switching and the formation of MBCs. Mice deficient in ICOS 
and/or ICOS-L exhibited profound defects in Tfh formation, GC B-cell responses and the 
production of class switched antibodies [53, 156]. Similarly, in humans, ICOS deficiency 
associated with severely impaired GC and antibody responses [157]. ICOS is required for 
CD40-mediated GC B-cell responses and class switching [156]. In this report, CD40 
stimulation fully restored GC B-cell formation and immunoglobulin class switching in ICOS-
deficient mice. Furthermore, in conjunction with CD40–CD40L mediated signals, ICOSL 
entanglement enhanced positive selection and development of plasma cells [158]. ICOS 
also supports extra-follicular humoral responses by inducing IL-21 production in T-cells. 
MRLlpr mice, which lack the ICOS gene exhibited defects in the formation of extrafollicular 
IgG+ plasma cells, CXCR4 expression and B-cell helper function in CD4+ T-cells [159].  
 
Recent data suggests that ICOS is essential for early Tfh differentiation [53, 115, 123, 
154].  Firstly, ICOS stabilized Bcl-6 and CXCR5 expression [53, 115]. In addition, ICOS 
insulated against Blimp-1 expression in T-cells, hence facilitating Bcl-6 expression [53, 
123, 154]. Further still, ICOS promoted Tfh development via activation of the PI3K 
pathway [160]. In this report, knock-in mice with selective loss of PI3K signalling displayed 
defects in Tfh generation, GC reaction, antibody class-switching and affinity maturation. 
Moreover, ICOS-induced PI3K signalling supported IL-21 and IL-4 production in pre-
activated CD4+ T-cells. In a more recent report, ICOS maintained the Tfh phenotype by 
down-regulating KLF2 [115]. In the absence of ICOS signalling, fully developed Tfh cells in 
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the GCs relocated to the T-cell zones and reverted to a non-Tfh phenotype.  
Consequently, this led to a breakdown of GC responses. A requirement for ICOS in 
controlling c-Maf and IL-21 expression during Tfh and Th17 development has also been 
reported [161]. ICOS-deficient mice exhibited reduced c-Maf expression, which associated 
with reduced IL-21 production, as well as displaying reduced frequencies of both Tfh and 
Th17 cells.  
 
The ICOS-ICOSL signalling pathway regulates interactions between T-cells and B-cells. 
Recent data demonstrates that ICOS-signalling is essential for trafficking of emerging Tfh 
cells towards ICOS ligand expressing B-cells, located either at the periphery or inside B-
cell follicles [116, 158]. This process is pivotal for GC B-cell formation and maintenance. 
ICOS facilitates CXCR5 expression, a chemokine receptor essential for Tfh migration into 
B-cell zones [53, 146, 162]. ICOS-deficient mice and humans exhibit reduced numbers of 
splenic and circulating CXCR5+ T-cells, which further associates with impaired GC 
responses and antibody production. ICOSL expression on bystander B-cells, which do not 
present antigen to cognate T-cells, has been implicated in facilitating direct ICOS-
dependent recruitment of activated T helper cells into B-cell follicles [116]. The absence of 
ICOSL on bystander B-cells resulted in impaired Tfh formation and GC responses. 
However, a more recent study suggested that limited antigen presentation by cognate B-
cells facilitated their ICOSL-dependent Tfh and GC B-cell differentiation [163]. During 
robust antigen delivery by B-cells, ICOSL expression on cognate B-cells was not required 
for Tfh differentiation.  
 
Regulation of ICOS signalling is necessary in order to maintain tolerance. However, our 
knowledge of the factors regulating ICOS signalling remains limited. Nonetheless, previous 
studies showed that Roquin suppressed ICOS mRNA expression, limiting Tfh 
accumulation and autoimmunity [164-166]. More recently, MicroRNA-146a was also 
implicated in limiting ICOS-mediated accumulation of Tfh cells and GCs [167]. MicroRNA-
146a deficiency associated with increased ICOSL-expression on DCs and GC B-cells, as 
well as accumulation of Tfh cells and GC B-cells. However, partial blockade of ICOS-
ICOSL signalling in miRNA-146a deficient mice restricted the accumulation of Tfh cells 
and GC B-cells. Identifying other factors regulating ICOS-signalling may be important in 
improving immunity against infections as well as enhancing tolerance during autoimmune 
responses.  
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The ICOS-ICOS-L pathway has been implicated in immune-mediated diseases. ICOS 
deficiency can result in both amelioration and exacerbation of disease. For instance, 
increased ICOS expression is detected on T-cells from SLE [142] and rheumatoid arthritis 
patients [168] and thus ICOS blockade has been suggested as a potential therapy for 
these conditions. Indeed, ICOS blockade in models of SLE significantly reduces the 
production of autoantibodies and nephritis [165, 166]. Elsewhere, polymorphisms in the 
ICOS promoter region were associated with allergic sensitization and coeliac disease 
[169]. In contrast, ICOS deficiency in humans correlates with onset of CVID [157]. ICOS-
deficient patients exhibit severe hypogamaglobulinemea, impaired B-cell homeostasis and 
are unable to generate switched MBCs. These patients are very susceptible to recurrent 
bacterial infections and the development of malignancies. Despite fundamental roles for 
ICOS on CD4+ T-cells in generating and optimizing B cell responses and antibody 
production, its role during parasitic diseases such as Plasmodium infection remains poorly 
elucidated. Furthermore, although T cell-intrinsic mechanisms have been defined for 
regulating CD4+ T cell ICOS levels, for example via Roquin1 and 2 [165, 166] and 
microRNA146a [167], whether or not T-cell extrinsic mechanisms can also modulate ICOS 
remains unclear.  
 
1.12 Cytokines and humoral immunity 
Cytokines are important mediators of immune responses. Studies have suggested roles 
for cytokines, including IL-6, IL-21, IFN-I and IL-27, in controlling different aspects of 
humoral immunity. Studies have identified fundamental roles for interleukin-21 (IL-21) in 
Tfh generation and GC development [170-173]. Firstly, Vogelzang and colleagues 
demonstrated that CD4+ T-cell intrinsic ICOS-induced IL-21 was essential for Tfh-
dependent GC formation and isotype class switching [172], findings that were corroborated 
elsewhere [171], using both in vitro and in vivo systems. In these study, naïve CD4+ T-cells 
were able to express Tfh associated genes when cultured in-vitro in the presence of IL-21. 
In-vivo, IL-21 deficient mice displayed reduced Tfh cell and GC B-cell numbers following 
immunization with KLH. IL-21 mediated Tfh cell development via STAT-3 signalling but 
these IL-21-induced signals were independent of IL-17 and TGF-b. Of note, Vogelzang et 
al., argued that IL-21 acted in Tfh cells but not B-cells to control GC B cell differentiation. 
However, Zotos and colleagues subsquently demonstrated that IL-21 acted directly on B-
cells to induce GC B-cell differentiation [173]. Consistently, a separate report that 
suggested that B-cell intrinsic IL-21 signals were required for maximal Bcl-6 expression 
and GC B-cell differentiation [170].  
 21 
 
 
Studies have purported different roles for IL-6 and IL-21 in controlling CD4+ T-cell-
dependent humoral immunity. For instance, IL-6 induced IL-21 production has been 
mediating antibody production during viral infection [174, 175]. In these studies, the 
absence of both IL-21 and IL-6 severely impaired plasma cell and GC B-cell development. 
Similarly, the combined loss of both IL-21 and IL-6 significantly impaired Tfh cell formation 
in LCMV-infected mice [176]. However, loss of IL-6 alone or IL-21 alone had no impact on 
Tfh differentiation, suggesting IL-6 and IL-21-mediated redundancy during Tfh formation. 
Moreover, while the absence of IL-6 restrained early plasma cell formation, GC B-cell 
responses remained intact. Conversely, the absence of IL-21 severely impaired GC B-cell 
formation. Together, these findings inferred that IL-6 and IL-21 regulated different aspects 
of humoral immunity and redundantly optimised Tfh cell development.  
 
Previously, late IL-6 signalling was implicated in promoting Tfh cell responses and 
antibody mediated control of a chronic viral infection [113]. Late IL-6 facilitated Bcl-6 
expression in Tfh cells, which enhanced GC B-cell formation and improved antibody 
responses. Although this report found no role for IL-6 in early Tfh development, a recent 
study demonstrated that IL-6 facilitated early Tfh cell differentiation by inducing Bcl-6 
expression [112]. Conversely, it was recently demonstrated that T-cell intrinsic IL-6 signals 
were not essential for Tfh development, but rather optimised Tfh function [177]. In this 
report, Tfh development remained intact in mice lacking IL-6 receptor on the CD4+ T-cells, 
following their immunization with ovalbumin. However, Bcl-6 and IL-21 production in these 
mice was significantly reduced when compared to their WT counterparts. In addition, these 
mice exhibited reduced plasma cell formation and serum antibody production suggesting a 
role for IL-6 in optimizing these processes.  
 
Some cytokines compensate for IL-6 loss in order to maintain Tfh-dependent humoral 
responses. These include IL-27, which has been previously implicated in supporting IL-21-
dependent GC B-cell function [178, 179]. In an earlier report, IL-27 mediated STAT3-
dependent IL-21 production in CD4+ T-cells, promoting Tfh cell function and the production 
of high affinity antibodies [178]. Recently, the genetic ablation of the common IL-6 family 
receptor, gp130 on T-cells significantly impaired IL-27-dependant Tfh cell formation and 
compromised IL-21 production, which subsequently limited anti-viral humoral immunity to 
chronic LCMV infection [179].  
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Type I interferons (IFN) also control humoral responses during infection and immunity. 
Although there are some contradicting observations in the literature, a large body of work 
conducted in protein, viral and autoimmune systems support the notion that IFN-I signals 
promote humoral immunity. IFN-I enhanced antibody production and immunoglobulin 
class-switching following protein immunization [180, 181]. Similar observations were made 
in mice during a viral infection [182]. Elsewhere, plasmacytoid dendritic cell (pDC)-derived 
IFN was implicated in facilitating plasmablast differentiation in human B-cells during an 
influenza viral infection [183]. It was later suggested that pDc-derived IFNa facilitated T-
cell dependent proliferation of naïve B-cells and their differentiation into ASCs [184]. 
Moreover, IFN-I responses are strongly associated with SLE, a disease predominantly 
mediated by dysregulated production of autoantibodies [185-187]. Direct IFN-I signalling 
on B-cells has previously been associated with regulation of B-cell responses within the 
respiratory tract [188]. Elsewhere, IFN-I dependent B-cell activation was crucial for early 
protective immunity against bacterial sepsis [189]. IFN-I signals also promoted Bcl-6, 
CXCR5 and PD1 expression on in-vitro stimulated CD4+ T-cells [128]. Recently, IFN-I 
signalling was also implicated in facilitating Tfh cell differentiation and B-cell responses 
during persistent viral infection [190]. However, a more recent report instead suggested a 
suppressive role for IFN-I on Tfh cell development during an LCMV infection [114].  
Th1 cytokines such as IFNg, IL-12 and TNF may also regulate humoral responses. In 
mice, a number of studies have demonstrated that IFNg and TNF potently repress the 
formation of Tfh cells, thereby impeding GC responses and production of class-switched 
antibodies [114, 191-193]. However, other studies have also identified roles for excessive 
IFNg and TNF in promoting humoral immunity in SLE and rheumatoid arthritis respectively 
[194, 195]. In humans, IL-12 induced IL-21-dependent Tfh cell formation and antibody 
production [196]. Cytokines such as the Th2 cytokine, IL-4 [197] and or the regulatory 
cytokines, TGFb [125] and IL-10 [198] support Tfh formation, more so in humans. Unlike 
these cytokines, IL-2 has been associated with repression of Tfh and GC B-cell 
development and responses, thereby limiting humoral immunity in both mice and humans 
[53, 108, 114]. In summary, cytokine regulation of humoral immune responses remains 
complex, yet fundamental for strategies aiming to improve immunity. This warrants further 
investigation to enhance our understanding of cytokine-mediated control of humoral 
immune responses during infection and immunity. 
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1.13 Malaria 
Malaria remains one of the most devastating public health problems in the world, with over 
200 million clinical cases and nearly half a million deaths per year, (WHO, malaria report 
2015). The vast majority of these morbidities and mortalities are amongst Sub-Saharan 
African children, below five years of age. The most severe forms of the disease are 
predominantly caused by Plasmodium falciparum (P. falciparum), an Apicomplexa 
protozoan, transmitted to human hosts via the saliva of infected female Anopheles 
gambiense mosquitoes. These mosquitoes inject infectious sporozoites into the skin tissue 
where 95% of these sporozoites remain lodged or may enter into draining lymphatics, from 
where they are eventually cleared (Figure 1.3). In contrast, a few of the surviving 5% enter 
the blood stream and travel to the liver, infecting hepatocytes. Here, sporozoites undergo 
asexual reproduction, differentiating into merozoites. Merozoites undergo further mitotic 
division, leading to the formation of hepatocyte-derived vesicles known as merosomes. 
Upon rupture, merosomes release large numbers of free merozoites into the bloodstream 
that subsequently invade red blood cells (RBCs). Within the RBC, these merozoites 
undergo further asexual division, differentiating into trophozoites and schizonts, 
respectively. Schizonts rupture, releasing newly formed merozoites into the blood stream, 
which reinvade new RBCs. However, a few freely circulating merozoites may differentiate 
into male and female gametocytes, completing the parasite life cycle in its human host. A 
female Anopheles mosquito ingests these gametocytes during its blood meal. Male and 
female gametocytes fuse and form zygotes (ookinetes) in the midgut. Ookinetes 
differentiate into sporozoites that invade the salivary glands of the mosquito for effective 
transmission into a new human host.  
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Figure 1.3. A schematic view of the lifecycle of Plasmodium falciparum. A female 
anophelese mosquito inoculates sporozites into the human skin, marking the beginning of pre-
erythrocytic stages of infection. These sporozoites migrate to the liver, where they develop into 
merozoites. These pre-erythrocytic stages are clinically silent. During the erythrocytic stage of 
infection, fully differentiated merozoites are released into the bloodstream, infecting red blood cells. 
Erythrocytic stages are associated with most severe symptoms of the disease. Within the red cells, 
merozoites undergo further asexual division which results in the formation of both male and female 
gametes. These are released into the blood-stream, marking the beginning of the transmission 
stage of the cycle. During a blood meal, a feeding mosquito ingests these gametes that fuse and 
form a zygote within its mid gut. Zygotes migrate to the salivary gland as fully differentiated 
sprozoites that are transmitted to the next human host. Figure adapted from [199]. 
 
Collectively, this lifecycle comprises the pre-erythrocytic, erythrocytic and transmission 
stages (Figure 1.3). 
 
Although anti-malarial drugs and vector control methods have contributed to a significant 
reduction in disease burden, these methods alone are unlikely to facilitate complete 
eradication of malaria. To achieve this, an effective anti-malarial vaccine is still considered 
crucial. However, such a vaccine remains elusive. Due to its complexity, the P. falciparum 
lifecycle has frustrated current efforts to design effective malaria vaccines. For instance, 
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successful identification of potential vaccine targets has been hampered by the complexity 
of stage-specific antigenic repertoire [199-205]. This partly contributes to the generation of 
inefficient stage and strain specific immune responses. It is thought that parasites within 
the pre-erythrocytic and transmission stages are poorly immunogenic, clinically silent and 
may not replicate, hence limiting their potential to induce and maintain anti-parasitic 
immunity [201]. Nonetheless, inoculation of irradiated sporozoites into healthy individuals 
[206, 207] or intact sporozoites into individuals treated with chloroquine confers sterile 
immunity against malaria [208]. Moreover, the RTS,S vaccine, currently the world’s most 
advanced vaccine against malaria, is based on the circumsporozoite protein, which is a 
dominant protein found on the sporozoite surface [209]. Erythrocytic parasites are believed 
to be highly immunogenic, replicate rapidly but induce immune-mediated pathology [202, 
203, 205]. A number of erythrocytic stage antigens have been targeted as vaccine 
candidates. For instance, P. falciparum apical memberane antigen-1 (PfAMA-1) and 
merozoite surface protein 1 (PfMSP1) were associated with protection against blood-stage 
merozoites [210-212]. More recently, P. falciparum reticulocyte-binding protein homolog 5 
(PfRH5) emerged as a promising vaccine candidate antigen against the blood-stage 
merozoite [213, 214]. Identification of highly immunogenic targets within the Pf life cycle, 
as well as understanding the mechanisms underlying immune responses elicited by such 
targets, are still fundamental in the drive for effective malaria vaccines.  
 
1.14 Mouse models of malaria 
Understanding immunological mechanisms underlying disease protection and pathology 
during Plasmodium infection is challenging in humans. However, mouse models of malaria 
have been invaluable resources in addressing this challenge. Currently, four major species 
of Plasmodium parasites are commonly used to mimick human parasites and pathological 
symptoms of human malaria. These include, Plasmodium chabaudi (P.chabaudi), 
Plasmodium berghei (P. berghei), Plasmodium yoelii (P. yoelii) and Plasmodium vinckei 
(P. vinckei), and were originally isolated from Thamnomys thicket rats in the Congo [200, 
215]. Although none of these models is perfect, genetic and phenotypic traits are 
significantly conserved between human and malaria parasites, thus making them useful in 
modelling human aspects of the disease [216]. These parasites can also be used in 
different strains of mice hence enabling studies on different disease syndromes. 
 
One of the most commonly used P. chabaudi lines is the non-lethal Plasmodium chabaudi 
chabaudi AS (PcAS), which is relatively similar to the human P. falciparum and P. vivax 
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parasites. Mice infected with this model display an increase in parasitemia that peaks at 
day 7 or 8 post infection [217]. These mice also display array of symptoms that start late in 
infection and resolve as the parasite is cleared. Due to its similarities with the human 
parasite, this model has been used to study pathology, immune mechanisms, influence of 
host genetics on disease severity and parasite genetics.  
 
Plasmodium berghei ANKA (PbANKA) also induces symptoms similar to those in the 
human disease and has been predominantly used to study pathology, in particular cerebral 
malaria during infection.  Similar to humans, it is thought that PbANKA-infected RBCs and 
host cells sequester in the brain, thus triggering a series of immunopathological events (as 
highlighted in section 1.16 below) that lead to cerebral malaria [218, 219]. Unlike PbANKA, 
only schizont stages of PcAS are able to sequester within tissues, mainly in the liver but 
not the brain [220, 221]. This is one possible explanation why PcAS does not cause 
cerebral malaria.  
 
Lethal (Py17XL) and non-lethal (Py17XNL) P. yoelii can also be used to dissect and 
identify important components involved in disease severity during Plasmodium infection. 
Similar to PbANKA, Py17XL has been used to investigate immunological mechanisms 
driving or regulating pathology during severe malaria. However, Py17XNL is a self-
resolving model that has been useful in understanding mechanisms important for parasite 
control and protection during infection. Unlike PcAS infection, B-cells are critical for 
controlling Py7XNL infection, making it a very suitable model to explore mechanisms 
controlling humoral immune response during infection. Given the similarities between 
mouse and human parasite species, it is strongly believed that mouse models are still 
invaluable tools for laboratory investigations of malaria.  
 
1.15 Innate immune responses to blood-stage Plasmodium infection 
The role of the innate immune system in malaria remains unclear. Nevertheless, innate 
immune mechanisms may be important in controlling different aspects of the adaptive 
immune responses and immunopathology during Plasmodium infection [199-201]. For 
instance, innate immune mechanisms may repress maximum parasite density, prior to 
activation of adaptive immune responses, which are essential for complete parasite 
elimination [199]. Innate mechanisms seem to limit the growth of all blood-stage parasites, 
irrespective of species and strains of Plasmodium [199, 222]. These responses are elicited 
through initial interactions of pattern recognition receptors (PRRs), on innate cells, such 
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as, toll-like (TLRs), with pathogen associated molecular patterns (PAMPs), e.g. 
glycosylphosphatidylinostol (GPI) anchors [201, 223].  
 
These interactions activate a cascade of distinct transcriptional programmes and multiple 
downstream signalling pathways that support parasite clearance. Among such pathways is 
the secretion of an early wave of pro-inflammatory cytokines, for example, IL-1b, IL-6 and 
TNF [200, 224-226]. Although their roles during infection remain unclear, these cytokines 
may modulate the recruitment and activation of other inflammatory cells. This partly 
contributes to induction of high temperature fevers that limit Plasmodium parasite load 
[227, 228]. Further interactions between Plasmodium and innate cells lead to IL-12 and 
IFNg production, which are important in activating effector functions of both natural killer 
(NK) cells and macrophages, respectively [229, 230]. Mice deficient in either cytokine are 
unable to control parasite growth [231]. Importantly, these inflammatory responses need to 
be regulated in order to avert systemic inflammation and immunopathology.  
 
Accumulating evidence supports the notion that DCs, NK cells, NKT cells and gd T-cells 
play important effector roles in innate immunity to malaria. It is thought that initial 
interactions between Plasmodium and the host immune system occur through DCs [200]. 
Therefore, DCs may play important roles in bridging the innate and adaptive immune 
systems during infection. Activation of DCs via TLRs and cytosolic sensors leads to 
production of cytokines that mediate host resistance to infection [232]. It is thought that 
DCs are an important source of IL-12, which activates IFNg production by NK cells [224, 
230]. IL-12 supports CD4+ T helper 1 (Th1) polarization, important for T-cell effector 
functions and long-term resistance to Plasmodium infection [233, 234]. DC malfunction 
may be an important mechanism of parasite escape. Virulent Plasmodium strains have 
been implicated in subversion of optimal DC function, impairing the development of T-cell 
mediated immunity in mice. For instance splenic DCs exhibited reduced antigen 
presenting capacity and impaired phagocytic capabilities in mouse models of severe 
malaria [235-237]. More recently, myeloid-derived IFNs were implicated in modulating DC 
function during experimental severe malaria [238].  
 
NK cells may play important roles in immunity to malaria given their presence in blood, the 
spleen and bone marrow [199]. NK cell-deficient mice displayed rapid increase in 
parasitemia and less efficient resolution of Plasmodium chabaudi chabaudi AS (PcAS) 
infection [239]. NK-cells are important sources of IFNg, essential for protective immunity to 
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malaria. They are highly cytotoxic, and thus may directly kill Plasmodium-infected RBCs 
and/or the parasite. It is unclear whether NKT cells are important for pre-erythrocytic 
immunity in humans. However, enhanced activation of NKT cells through a-
galactosylceramide impaired the development of intrahepatocytic parasites and their 
progression to blood-stage infection in mice inoculated with P. yoelli or P. berghei 
sporozoites [240]. 
 
gd T-cells may also play important roles in modulating immune responses to malaria. In 
humans, their clinical relevance remains unclear, though earlier reports indicated that 
these cells potently undergo polyclonal expansion during acute P. falciparum or P. vivax 
infections [241]. Moreover, activated gd T-cells were sources of large amounts of IFNg 
during P. falciparum infection [241]. In mice, they contributed to liver-stage immunity 
following immunization with irradiated sporozoites [240]. However, a role for gd T-cells in 
driving pathogenesis of cerebral malaria was reported in mice infected with P. berghei 
[242].  
 
Monocytes and macrophages (extensively reviewed in 5.1) may also interact with surface 
proteins expressed on infected RBCs, hence facilitating the clearance of infected cells and 
supporting the production of cytokines important for immunopathogenesis. Macrophages 
may phagocytose infected red blood cells by operating in the presence or absence of 
antibody-mediated mechanisms. During adaptive immunity, IFNg activated macrophages 
may mediate antibody-dependent cellular inhibition of parasites or produce molecules 
such as nitric oxide, which are toxic to parasites. CD36, which is expressed on 
macrophages/monocytes has been implicated in supporting phagocytosis in the absence 
of opsonising or cytophillic antibodies [243, 244].  
 
1.16 Pathogenesis and malaria-associated syndromes 
The clinical outcome of malaria depends on various factors including, age, previous 
exposure to infection, nutrition, parasite and host genetics, as well as different social and 
demographic factors [245]. In non-immune individuals, early infection is characterised by 
initial symptoms such as fever, headache, muscle pain, chills, vomiting and lethargy. The 
symptoms appear within 7-15 days post infection [205] and correlate with high levels of 
circulating cytokines and systemic inflammation [226]. If left untreated, uncomplicated 
malaria may develop into severe illness and lethality. In children, this is defined by 
symptoms such as respiratory distress, jaundice, severe anaemia, metabolic acidosis and 
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cerebral malaria. In adults, the illness may affect multiple organs especially in its later 
stages.  
 
Generally, the main syndromes of severe malaria include systemic inflammation, severe 
anaemia, metabolic acidosis as well as cerebral and placental malaria [203, 205, 225-228]. 
These syndromes are mainly due pro-inflammatory cytokine-induced endothelial activation 
that results in adhesion of infected RBCs onto small capillaries and venules [203, 205]. 
The infection induces the production of large amounts of pro-inflammatory cytokines, 
resulting in a cytokine storm [225-228]. These cytokines, in particular TNF, IL-6 and IFNg 
have also been implicated in aiding the sequestration of infected RBCs in tissues including 
the brain, lungs, placenta, liver and kidneys [225, 228]. Elevated levels of these cytokines 
support enhanced expression of adhesion molecules on endothelial cells of various host 
organs and tissues [227]. Such adhesion molecules include CD36 and intracellular 
adhesion molecule 1 (ICAM1) in the brain, as well as heparin sulphate and/or chondroitin 
sulphate A (CSA) in the placenta [201, 203, 246]. Complement receptor 1 and platelet 
endothelial cell adhesion molecule 1 may also play a similar role. These adhesion 
molecules bind onto a diverse family of receptors related to P. falciparum erythrocytic 
membrane protein 1 (PfEMP1), expressed on the surface of infected RBCs [201]. This 
interaction between PfEMP1 and adhesion molecules on host cells is the main 
determinant of parasite tissue tropism and pathogenicity [200]. Adherence onto endothelial 
tissues protects infected RBCs from clearance. However, the same process induces and 
amplifies local inflammation. The combined effects of obstruction of capillaries and venules 
and enhanced local inflammation contribute to the development of respiratory distress, 
metabolic acidosis and cerebral or placental malaria [202, 203, 205].  
 
PRRs may also promote the development of cerebral malaria and sepsis-like syndromes 
by stimulating extreme production of the same cytokines that are associated with 
resistance against parasites. For instance, IL-6 and TNF were associated with symptoms 
of severe pathology during infection [227, 228]. In human studies, positive associations 
between TNF and disease severity as well as risk of death have been reported [227]. 
Moreover, the risk of developing severe malaria is associated with polymorphisms within 
the TNF promoter gene [247]. Although anti-TNF therapy inhibited the development of 
fevers in humans with cerebral malaria, it had no effect on mortality[248]. The lack of an 
effect on mortality was attributed to the small sample size that was used in this study. In 
mice, IFNg-inducible adhesion molecules such as chemokine ligand 9 (CXCL9) and 
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CXCL10, important for CD8+ T-cell recruitment to the brain, have been associated with the 
development of experimental cerebral malaria [249, 250]. More recently, IFN-Is have also 
been implicated in enhancing susceptibility to cerebral malaria by suppressing Th1-
dependent parasite control and promoting pathology in the brains of PbANKA-infected 
mice [238, 251]. These data suggest that systemic inflammation remains key in driving 
severe malaria syndromes and thus a crucial target for new anti-malarial therapies. 
 
1.17 Naturally acquired immunity to human malaria 
In highly malaria endemic populations, the prevalence and parasite densities are higher in 
children below five years than in relatively older individuals [201, 252-255]. Despite having 
lived in such settings for over 25 years, previously infected adults as susceptible to new 
infections as the younger population or naïve adults [245]. Cases of severe malaria are 
highest in children between two to five years, though lower in those below two years. Mild 
malaria cases are higher in young adults whereas asymptomatic malaria is highest in the 
adult population. These observations suggest that anti-parasitic immunity does occur, but 
develops slowly and is not absolute. They further suggest that immune responses 
protecting individuals from infection (anti-parasitic immunity) may differ from those 
protecting them against severe disease or death (clinical immunity).  
 
Repeated exposure to infection may be important in maintaining malaria-specific immunity. 
Studies in endemic settings have shown that antibodies to several important Plasmodium 
proteins drop rapidly at the end of a malaria transmission season or once individuals have 
left such transmission areas [256, 257]. In addition, the rates of severe malaria are lower 
among children in high transmission settings compared to those in areas of low 
transmission [253]. Previously exposed African migrants, who had lived in Britain for more 
than 20 years, were more susceptible to malaria upon returning to endemic settings [258]. 
However, a separate study in Madagascar showed that previously infected individuals 
were more resistant to clinical disease than younger subjects, following a new malaria 
outbreak, 30 years post initial eradication of the disease [254], suggesting that certain 
components of malaria-specific immune responses may be long-lived.  
 
Antibodies are still the best correlate of protection against Plasmodium infections [214, 
259-261]. The relatively impaired immunity against Plasmodium parasites may be 
attributed to defects in the development and maintenance of humoral immune responses 
during infection. Delineating such defects may be crucial for improving immunity to 
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malaria. Considering that the innate immune system modulates adaptive immune 
responses against a number of pathogens and vaccinations, it is possible that defects in 
the development and maintenance of humoral responses could be due to initial 
interactions between Plasmodium and certain aspects of the innate immune system. 
Identifying such defective interactions may be crucial in improving both natural and 
vaccine induced immunity to malaria. 
 
1.18 Humoral immunity to malaria 
Immunity against blood-stage P. falciparum is acquired only after years of repeated 
infections, increasing the risk of severe malaria and death of children living in highly 
malaria endemic settings [201, 204]. A significant body of work from both human 
correlates and experimental mouse models demonstrates that B-cell responses are a 
critical component of immunity to Plasmodium infections [114, 139, 214, 259-269]. In 
addition, data from various epidemiological studies have strongly associated antibody 
titres with protection against malaria [261, 270, 271]. Vaccine-induced antibodies against 
P. falciparum reticulocyte-binding protein homolog 5 (PfRH5) inhibited tight attachment of 
merozoites to erythrocytes and were capable of blocking interactions of PfRH5 with its 
receptor basigin [214]. These processes were efficient in preventing merozoite invasion of 
RBCs. Elsewhere, antibodies against the P. falciparum egress antigen-1 (pfSEA-1) 
suppressed parasite replication by preventing schizont rupture [259]. In the same study, 
African children immunised with PfSEA-1 recombinant proteins were protected against 
severe malaria and displayed lower parasite densities in blood when compared with their 
unvaccinated counterparts. Elsewhere, it was suggested that young children residing in 
malaria endemic areas were less likely to generate long-lived plasma cells, necessary to 
maintain circulating antibodies that are important for protection against reinfection [272]. B-
cells and antibodies are also critical for immunity against blood-stage malaria. B-cell 
deficient mice were unable to clear blood-stage PcAS and non-lethal Plasmodium yoelii 
17XNL (Py17XNL) [139, 267]. However, adoptive transfer of B-cells into these mice 
restored full protection. Moreover, passively transferred hyper-immune sera were 
protective against infection in both mice and humans [263, 265]. 
 
Although critical for protection, cellular and molecular factors modulating the development 
and maintenance of humoral immune responses during Plasmodium infections are poorly 
defined. Considering that a highly effective malaria vaccine remains elusive, it is important 
to understand how the onset of humoral immunity to blood-stage Plasmodium parasites is 
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controlled and whether this process can be boosted, to accelerate or otherwise enhance 
antibody-mediated immunity to malaria. CD4+ T-cell dependent mechanisms are of critical 
important in the generation and maintenance of humoral responses [267, 273]. In highly 
malaria endemic regions, HIV patients with low CD4+ T-cell numbers were not only highly 
susceptible to malaria but also exhibited reduced antibody responses [274]. Moreover, 
CD4+ T-cell deficient mice were unable to resolve chronic PcAS infections [267, 275]. 
Further still, adoptively transferred CD4+ T-cells into SCID mice are insufficient for 
complete resolution of a chronic PcAS infection – however co transfer of CD4+ T-cells and 
B-cells confers full protection [275]. Together, these observations suggest that interactions 
between T- and B-cells may be critical in shaping humoral response during Plasmodium 
infections. However our knowledge on such interactions remains limited.  
 
Mouse models of resolving, non-lethal blood-stage Plasmodium infection are useful for 
studying humoral immunity to malaria, since mice fail to control parasitemias and display 
increased disease severity in the absence of parasite-specific antibodies [139, 276-279]. 
Nevertheless, our understanding of how humoral immune responses are generated in 
these models is currently modest. Tfh cells and their associated cytokines, such as IL-21, 
and GC B-cells are critical mediators of humoral immune responses in many systems [44, 
99], and appear to be similarly important during experimental malaria. For instance, an 
anti-parasitic role for T-cell-derived IL-21 was recently described during non-lethal PcAS 
infection [264]. Other recent studies using Py17XNL infection focused on co-stimulatory 
markers on CD4+ T-cells, and demonstrated that PD-1 and LAG-3 blockade, or stimulation 
via OX40 boosted Tfh and GC B-cell responses, with positive effects on parasite control 
[139, 193]. Elsewhere, studies in mice and humans have suggested roles for pro-
inflammatory cytokines in impairing the development of humoral responses [191-193]. For 
instance, mice infected with PbANKA displayed defects in splenic Tfh and GC B-cell 
development [192]. However, normal Tfh and GC B-cell differentiation was restored by 
blocking TNF and IFNg or the transcription factor T-bet. Similarly, elevated frequencies 
Th1-like Tfh cells, expressing PD1, CXCR5 and CXCR3, were detected in the peripheral 
blood of Malian children [191]. These Th1 cells exhibited limited ability to promote B-cell 
responses. Other longitudinal assessments demonstrated preferential activation of Th1 
responses, which correlated poorly with the production of antibody responses. With the 
exception of these reports, in vivo studies of Tfh and GC B-cell responses during 
experimental malaria remain sparse. Moreover, while these recent reports focused on 
molecules expressed by CD4+ T-cells themselves, less effort has been directed towards 
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determining whether T-cell extrinsic factors, such as innate or inflammatory cytokines, can 
control humoral immunity.  
 
It is becoming increasingly clear that inducible T-cell co-stimulatory (ICOS) receptor on 
CD4+ T-cells is vital for Tfh cell-dependent humoral immunity across numerous model 
systems [53, 115]. ICOS has been implicated in Tfh differentiation via the stabilization of 
the transcription factor B-cell lymphoma-6 (Bcl-6) [53, 123, 154]. Importantly, ICOS 
supports interactions of emerging Tfh cells with ICOS ligand (ICOSL)-expressing 
bystander B-cells at the periphery of B-cell follicles, a pivotal process for GC B-cell 
formation and maintenance [116, 158]. ICOS facilitates the expression of CXCR5, a 
chemokine receptor essential for Tfh migration into B-cell zones [53, 162]. Despite 
fundamental roles for ICOS on CD4+ T-cells in generating and optimizing B-cell responses 
and antibody production, its role during blood-stage Plasmodium infection was largely 
unexplored until recently [280], when Wikenheiser et. al., described weaker Tfh and B-cell 
responses in ICOS-deficient mice after the first week of PcAS infection. In addition, 
although T-cell-intrinsic mechanisms have been defined for regulating CD4+ T-cell ICOS 
levels, for example via Roquin1 and 2 [165, 166] and microRNA146a [167], whether or not 
T-cell extrinsic mechanisms can also modulate ICOS remains unclear.  
 
Type I interferon (IFN-I) signalling (exclusively reviewed in 4.1) can amplify adaptive 
immune responses [281-283], and drive humoral immunity in vivo, particularly in the 
context of immunization [180, 284], viral infection [183, 188] and autoimmunity [185, 281]. 
IFN-I signalling was reported to induce Bcl6, CXCR5 and PD1 expression in naïve CD4+ T 
cells following TCR stimulation in vitro [128]. In addition, IFN-I-related immune responses 
have also been observed in the peripheral blood of malaria patients, although their 
functional relevance in humans remains to be explored [285-287]. In mice, IFN-I signalling, 
acting via conventional dendritic cells (cDCs) [238], and employing the canonical IFN-I 
transcription factor, IRF7 but not IRF3 [217], suppressed Th1 responses and parasite 
control during experimental severe malaria caused by P. berghei ANKA (PbANKA). 
Recent data has also suggested that increased Th1 responses might suppress Tfh 
responses via IFNγ signalling in experimental malaria [193], and viral infection [114]. 
Therefore, the current literature suggests a model in which IFN-I signalling suppresses 
Th1 responses yet promotes Tfh-dependent humoral immunity during blood-stage 
Plasmodium infection. However, this is yet to be examined.  
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Interleukin-6 (IL-6) is a highly pleiotropic cytokine that can modulate adaptive immune 
responses (reviewed in 3.1), and has been purported to drive Tfh and humoral immune 
responses in concert with other cytokines [112, 113, 174, 176]. However, its impact on 
Plasmodium parasite control and humoral immunity to malaria remains poorly defined, 
although interestingly, early administration of recombinant IL-6 boosted antibody 
responses and protected mice against secondary PcAS infection [288]. Various reports 
have suggested complex, context-dependent relationships between IFN-I and IL-6 in 
controlling humoral immunity to viruses. For instance, virally-induced IFN-I and IL-6 from 
plasmacytoid DC were implicated in the generation of antibody-secreting plasma cells 
[183]. A recent report also revealed that IFN-I-dependent IL-6 production by cDCs 
stimulated Tfh responses following immunization [284]. Conversely, STAT3, a transcription 
factor triggered by several cytokines including IL-6, impaired IFN-I responses during viral 
infection [289]. More recently, IFN-I was shown to suppress STAT3-mediated Tfh and 
humoral responses during LCMV infection [114]. However the interplay between IFN-I and 
IL-6 during Plasmodium infection is yet to be determined.  
 
1.19 Hypothesis and project objectives 
Cellular and molecular mechanisms influencing parasite control during Plasmodium 
infection are not well defined and yet such factors could be manipulated to improve 
naturally acquired and vaccine-mediated immunity to malaria. Innate cytokines such as IL-
6 and IFN-I are purported to modulate immune responses in different models of infection 
and immunity [113, 281]. However, their effects on Plasmodium-specific immune 
responses remain incompletely understood. Similarly, innate cells such as DCs, 
monocytes and macrophages play important roles in the establishment of adaptive 
immune responses [290, 291]. However, their roles during Plasmodium infection remain 
unclear. Current studies in this thesis tested the hypothesis that early interactions between 
Plasmodium parasites and the innate immune system controlled the development of 
adaptive immune responses and subsequently influenced Plasmodium infection outcome 
during blood-stage malaria. In particular, these studies aimed to determine cellular and 
molecular factors controlling the development of anti-parasitic humoral immunity in mouse 
models of non-lethal blood-stage malaria. In addition, the current studies aimed to 
determine the role of the mononuclear phagocyte system (MPS) during experimental 
blood-stage malaria.  
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These studies revealed crucial roles for CD4+ T-cells and ICOS-signalling in promoting 
humoral immune responses during experimental blood-stage malaria. In addition, roles for 
IL-6 in optimising antibody responses and parasite control were established. Furthermore, 
these studies revealed roles for IFN-I signalling in repressing the onset of various aspects 
of humoral immune responses during infection. Finally, these studies revealed that the 
monocytes and macrophages were not essential for early parasite control but influenced 
pathology in a mouse model of severe malaria. In summary, this thesis describes novel 
cellular and molecular pathways influencing parasite control during experimental blood-
stage malaria.  
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2 CHAPTER TWO: MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Mice  
Female C57BL/6J and congenic CD45.1+ C57BL/6J mice (6-12 weeks old) were 
purchased from Australian Resource Centre (Canning Vale, Western Australia) and 
maintained under conventional conditions. C57BL/6J Ifnar1-/-, IL-6-/-, LySMcreiDTR and 
CD11ccre+/-Ifnar1fl/fl mouse lines were maintained in-house at QIMR Berghofer Medical 
Research Institute.  
 
2.1.2 Parasites 
Plasmodium chabaudi chabaudi AS (PcAS) and non-lethal Plasmodium yoelii 17X 
(Py17XNL) were used to investigate mechanisms regulating immune responses during 
chronic and acute non-lethal Plasmodium infections. C57BL/6J mice are able to resolve a 
primary PcAS infection within 15 days and a Py17XNL within 30 days. Plasmodium 
berghei ANKA (PbANKA), a transgenic model (231c1l) expressing luciferase and GFP 
under the control of the elongation factor 1-a (ef1-a) promoter was employed in studies of 
experimental severe malaria. C57BL/6 mice infected with this model display symptoms of 
experimental cerebral malaria, approximately within seven days into the infection. 
 
2.1.3 Reagents  
Reagent Source 
Immersion oil  Merck (Darmatadt, Germany) 
CliniPure Haem Kwik Fixative Grale Scientific (Ringwood, VIC, Aus) 
CliniPure Haem Kwik Stain No 1 Grale Scientific (Ringwood, VIC, Aus) 
CliniPure Haem Kwik Stain No 2 Grale Scientific (Ringwood, VIC, Aus) 
Heparin 5000 IU in 5mL Pfizer (New York, NY, USA) 
Trypan Blue 0.4% Thermo Fischer Scientific 
Sodium chloride 0.9% Baxter (Toongabbie, NSW, Aus) 
Deoxyribonuclease 1 100mg Worthington Biochemical Corporation 
(Lakewood, NJ, USA) 
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Collagenase Type 4 100mg Worthington Biochemical Corporation 
(Lakewood, NJ, USA) 
Diphtheria toxin from Corynebacterium 
diphtheriae 
Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Mouse anti-CD4 depleting monoclonal 
antibody (clone GK1.5) 
BioXCell (West Lebanon, NH, USA) 
Mouse anti-CD20 depleting (clone 5D2) Genentech (South San Francisco, CA, 
USA) 
Mouse anti-ICOSL blocking monoclonal 
antibody (clone HK5.3) 
BioXCell (West Lebanon, NH, USA) 
Mouse anti-IgG2a Isotype control 
antibody (clone A23) 
BioXCell (West Lebanon, NH, USA) 
RBC Lysis Buffer Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
BD FACS lysing solution BD Biosciences  (Franklin Lakes, NJ, 
USA) 
Foxp3 Staining Buffer Set eBioscience (San Diego, CA, USA) 
Sucrose Chem-supply (Gillman, SA, Aus) 
Ionomycin calcium salt from 
Streptomyces conglobatus powder  
Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Brefeldin A (BFA) Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Clodronate liposomes Clodronate liposomes.org (Haarlem, 
Netherlands) 
Dulbecco's Phosphate buffered saline 
(dPBS) 
Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Percoll Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
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OPD Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Tween 20 
 
Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Streptavidin-HRP  BD Biosciences  (Franklin Lakes, NJ, 
USA) 
Anti-IgM, total IgG, IgG1, IgG2b and 
IgG3  
Jackson ImmunoResearch (West Grove, 
PA, USA) 
  
2.1.4  Antibodies and conjugates for flow cytometry 
Antibody/conjugate Clone Source 
Rat a-mouse CD4-BV605 RM4-5  BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Hamster a-mouse TCRb-APCCy7 H57-597 Biolegend (San Diego, CA, 
USA) 
Biotin Rat a-mouse CXCR5 2G8 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Hamster a-mouse CD279 (PD-1)- 
APC-eFluor 780 
J43 eBioscience (San Diego, CA, 
USA) 
Rat a-mouse CD279 (PD-1)-APC  29F.1A12 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse ICOS-PE  7E.17G9  eBioscience (San Diego, CA, 
USA) 
Rat a-mouse ICOS-AF647 C398.4A eBioscience (San Diego, CA, 
USA) 
Mouse a-mouse CD45.1-FITC A20  Biolegend (San Diego, CA, 
USA) 
Streptavidin-PeCy7  Biolegend (San Diego, CA, 
USA) 
Mouse a-mouse CD45.2-Alexa 
Fluor 700 
104 Biolegend (San Diego, CA, 
USA) 
Hamster a-mouse CD11c-APC N418  Biolegend (San Diego, CA, 
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USA) 
Rat a-mouse MHCII (I-A/I-E)-Pacific 
Blue  
M5/114-15.3 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse MHCII (I-A/I-E)-APC M5/114-15.3 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse Ly6C-FITC HK1.4 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse Ly6G-PE 1A8  Biolegend (San Diego, CA, 
USA) 
Rat a-mouse B220-APCCy7 RA3-6B2 Biolegend (San Diego, CA, 
USA) 
Hamster a-mouse TCRβ-BV605 H57-597 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Hamster a-mouse TCRβ-APCCy7 H57-597 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD8a-PECy7 53-6.7  Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD172a (Sirpα)-FITC P84 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD11b-PercpCy5.5 M1/70  Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD86-PE GL1 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD40-PE  1C10 eBioscience (San Diego, CA, 
USA) 
Rat a-mouse CD38- Pacific Blue 90 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse B220-Alexa Fluor 700 RA3-6B2 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD138-BV605 281-2 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD80-PercpCy5.5 16-10A1 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD73-PE TY/23 BD Biosciences  (Franklin 
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Lakes, NJ, USA) 
Rat a-mouse CD19-FITC 6D5 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse GL7-eFluor660 GL-7  eBioscience (San Diego, CA, 
USA) 
Hamster a-mouse CD95 (FAS)- 
PeCy7 
Jo2  BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Rat a-mouse CD23-APC B3B4 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD21/CD35-
PercpCy5.5 
7E9 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse IFNg-BV421  XMG1.2 Biolegend (San Diego, CA, 
USA) 
Mouse a-human/mouse Tbet-
eFluor660 
eBio4B10 eBioscience (San Diego, CA, 
USA) 
Rat a-mouse FOXP3-Alexa Fluor 
647 
MF-14 Biolegend (San Diego, CA, 
USA) 
Rat a rat/mouse Ki67-PE SolA15 eBioscience (San Diego, CA, 
USA) 
Mouse a-human/mouse Bcl6-
PercpCy5.5 
K112-91 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Mouse a-human/mouse Bcl6-PE K112-91 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Rat a-mouse CD11a FiTC M17/4 Biolegend (San Diego, CA, 
USA) 
Biotin Rat a-mouse CD49d R1-2 Biolegend (San Diego, CA, 
USA) 
Goat a-mouse IgG Poly 4053 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse IgD PeCy7 11-26c.2a Biolegend (San Diego, CA, 
USA) 
Rat a-mouse CD273 (PD-L2)  Ty25 Biolegend (San Diego, CA, 
USA) 
Rat a-mouse F4/80 FiTC C1:A3-1 Biolegend (San Diego, CA, 
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USA) 
Syto-84  Life Technologies (Carlsbad, 
CA, USA) 
Hoechst 33342  Sigma Aldrich Pty Ltd (St 
Louis Missouri, USA) 
Zombie Aqua Dye   Biolegend (San Diego, CA, 
USA) 
 
2.1.5 Disposable products/consumables 
Consumable Source 
5ml tubes  Greiner Labortechnik (Frickenhausen, 
Germany) 
30mL tubes Sarstedt (Pookara, Australia) 
1mL Syringe Terumo (Tokyo, Japan) 
26 gauge needle Terumo (Tokyo, Japan) 
1mL Insulin syringe   Terumo (Tokyo, Japan) 
18 gauge needle  Terumo (Tokyo, Japan) 
10mL tubes Sarstedt (Pookara, Aus) 
1.5mL micro centrifuge tubes VWR (Radnor, PA, USA) 
Petri dishes Greiner Labortechnik (Frickenhausen, 
Germany) 
Falcon Yellow 100uM Nylon Strainer Fischer Scientific (Waltham, MA, USA) 
5ml syringe Terumo (Tokyo, Japan) 
CELLSTAR Falcon tube (50mL) Greiner Labortechnik (Frickenhausen, 
Germany) 
Falcon Centrifuge tubes (5mL) Corning (Corning, NY, USA) 
Pipette 5mL Sarstedt (Pookara, Aus) 
Pipette 10mL Sarstedt (Pookara, Aus) 
Pipette 25mL Sarstedt (Pookara, Aus) 
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Corning Costar U bottom 96-well plates Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Corning Costar V bottom 96-well plates Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Corning Costar Flat bottom 96-well 
plates 
Greiner Labortechnik (Frickenhausen, 
Germany) 
 
 
2.1.6 Buffers and media  
FACS Buffer: Bovine serum albumin (BSA) (Life Technology) 100g/L; 10%w/v Sodium 
Azide 1ml/L; 0.5M EDTA in PBS pH8 (Sigma)10ml/L; 1L PBS; filtered and de-gassed 
through 0.2μm bottle-top filter at 4oC for 20 minutes. 
ELISA coating buffer: 1L PBS; 1.59g Na2CO3; 2.93g NaHCO3; adjusted pH to 9.6; filtered 
ELISA blocking buffer: 1L PBS; 1% BSA; 0.05% Tween 20; filtered  
ELISA wash buffer: 05mL Tween20; 1L PBS. 
Fetal Calf Serum (FCS): Fetal calf serum (Bovogene) was heat inactivated at 56oC for 1 
hour. 
FACS Block: Generated in-house by harvesting supernatant of 120/G8 hybridoma to block 
against Fc receptor.  
1.6% saline: 0.16g saline; 100mL sterile milli-Q water 
12% saline: 1.2g saline; 100mL sterile milli-Q water 
33% Percoll: 1:3 v:v of Percoll in PBS 
4% PFA: Paraformaldehyde powder (MP Biomedicals, USA) 4g/100mL; PBS 100mL; 
added ~20μL NaOH while gently heating and stirring until powder dissolved. Added HCL 
until pH 7. Aliquots were stored at -20oC until use.  
PBS: Prepared in-house by QIMRBerghofer core services 
RPMI/PS: 10mL penicillin; 1L RPMI prepared in-house by QIMRBerghofer core services 
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2.2 Methods 
 
2.2.1 Ethics statement 
All animal procedures were approved by the QIMR Berghofer Medical Research Institute 
Animal Ethics Committee, under approval numbers A02-633M and A1503-601M, in 
accordance with the “Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes” (Australian National Health and Medical Research Council).  
 
2.2.2 Passaging parasitized RBCs 
Non-lethal Py17XNL and PcAS parasites were used following one in vivo passage in wild 
type C57BL/6J mice. In order to conduct this procedure, 350ul of the frozen stabilates 
were firstly thawed at room temperature – one fifth the blood volume of sterile 12% NaCl 
(w/v) (BDH chemicals, Kilsyth, Victoria, Australia) was then added drop-wise into each 
thawed stabilate and incubated on ice for five minutes. RBCs were transferred into a 10ml 
falcon tube and washed in ten times the blood volume of 1.6% NaCl (w/v) at 1200rpm for 
10 minutes. Supernatants were discarded and RBCs were then resuspended in 1ml of 
sterile PBS. 200ul of this preparation was then injected intravenously (i.v) into naïve mice. 
Parasitemia was assessed on day 4 post infection - Mice were culled and used in 
subsequent procedures if the parasitemias were between 1-5%. In some experiments, 
lethal PbANKA parasites were used following one in-vivo passage in C57BL/6 mice. For 
these passages, one vial containing approximately 350ml of frozen PbANKA parasites was 
thawed, and 200ul of this was injected via i.p route into C57BL/6 mice. Similarly, mice 
were culled and used in subsequent procedures at 1-5% parasitemia. 
 
2.2.3 Preparation and examination of thick and thin blood smears 
Blood parasitemia was measured in Diff-Quick or giemsa-stained thin blood smears 
obtained from tail bleeds. Briefly, a drop of blood was collected and smeared on a labelled 
glass slide. Slides were air dried for 5-10 minutes prior to fixing then with Clinipure fixative 
solution for 1-2 minutes. Next, slides were stained in Clinipure solution one for, 1-2 
minutes and thereafter in Clinipure solution two for 1-2 mins. For Giemsa staining, fixed 
slides were treated with a 1/10 diluted Giemsa stain (Kinetik, Nambour, Australia) for 20 
minutes. Slides were then washed under tap water for 15 secs, blotted on tissue and air 
dried at room temperature for 10-20 minutes. The percentage of parasitized RBCs 
(pRBCs) was determined by light microscopy under a x100 oil immersion objective lens.  
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2.2.4 Infection of mice with parasitized RBCs 
First, passage mice were culled by CO2 inhalation. Blood was then collected by cardiac 
puncture using an insulin syringe and washed in 10 mls of RPMI culture media containing 
heparin, penicillin and streptomycin, at 1200rpm for seven minutes, at room temperature. 
Supernatants were discarded and pRBCs resuspended in 1ml of RPMI/PS. Next, the total 
numbers of RBCs and parasitised RBCs were determined. Naïve mice were infected i.v. 
with either 104 pRBCs (Py17XNL) or 105 pRBCs (PcAS) or 105 pRBCs (PbANKA). 
 
2.2.5 Flow cytometric based quantification of parasitized RBCs 
A modified protocol of a previously established flow cytometric method was employed to 
measure parasitemia more rapidly [292]. Briefly, a single drop of blood, from a tail bleed or 
cardiac puncture, was diluted and mixed in 250µl RPMI containing 5U/ml heparin sulphate. 
Diluted blood was simultaneously stained with Syto84 (5µM; Life Technologies) to detect 
RNA/DNA, and Hoechst33342 (10µg/ml; Sigma) to detect DNA, for 30 minutes, in the dark 
at room temp. Staining was quenched with 10x volume of ice cold RPMI, and samples 
were immediately analysed by flow cytometry, using a BD FACSCantoII analyser (BD 
Biosciences) and FlowJo software (Treestar, CA, USA). pRBC were readily detected as 
being Hoechst33342+ Syto84+, with white blood cells excluded on the basis of size, 
granularity and much higher Hoechst33342/Syto84 staining compared to pRBC. 
Parasitemias were routinely measured daily for up to 50 days post infection. 
 
2.2.6 Cryopreservation of parasitized RBCs 
Naïve mice were infected i.v. with either 104 pRBCs (Py17XNL) or 105 pRBCs (PcAS) as 
described above. At 20% parasitemia, mice were culled and blood was collected from all 
mice by cardiac puncture into heparinized RPMI media. RBCs were washed in RPMI at 
1200rpm for 10 minutes at room temperature. Supernatants were discarded and the 
packed cell volume (PCV) was then estimated, e.g. 1.5ml. A two times PCV (e.g. 3ml) of 
sterile glycerolyte solution (Baxter Healthcare Corporation, Deerfield, USA) was added 
dropwise while swirling the tube in order to prevent the blood from clotting at the bottom of 
the tube. Tubes were then incubated on ice for five minutes. Blood was aliquoted into 
labelled cryovials that were then placed into Mr. Frosty containers and stored at -80°C 
overnight. Vials were later transferred to labelled boxes and stored at -80°C until use. 
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2.2.7 Preparation of mononuclear single cell suspension from spleens 
Spleen mononuclear cells were prepared as previously described [293]. Briefly,  
spleens from naïve and infected mice were asceptically collected into 10ml of RPMI/PS. 
These contents were then poured into a petri dish, through a 100um cell strainer (Becton 
Dickinson Labware). Using a plunger from a 5ml syringe, spleens were mashed through 
the cell strainer. Using a plastic transfer pipette, the cell homogenate was transferred into 
a labelled 10ml falcon tube. Cells were then washed at 12000rpm, for seven minutes at 
room temperature. The supernatant was discarded, cells were resuspended and lysed in 
1ml of Red Cell Lysis buffer (Sigma) for five minutes. 9ml of RPMI were added into the 
lysed cells and these were washed at 12000rpm, for seven minutes at room temperature. 
Finally, cells were resuspended in 5-10mls of RPMI and stored on ice until use. Of note, 
for studies on DCs, monocytes and macrophages, spleens were treated with 
deoxyribonuclease I (0.5mg/ml; Worthington Biochemical) and collagenase type 4 
(1mg/ml; Worthington Biochemical) for 25-40 minutes at room temperature, prior to 
purifying mononuclear cells as described above. 
 
2.2.8 Isolation of peritoneal macrophages  
Peritoneal macrophages were collected using a peritoneal lavage technique. Briefly, mice 
were euthanized by CO2 inhalation. Using scissors and forceps the peritoneal cavity was 
exposed and 5ml of ice cold 1x D-PBS (Sigma-Aldrich) was injected into the peritoneal 
cavity using 27g needle. The peritoneum was then gently massaged in order to wash off 
the peritoneal macrophages into the PBS. The fluid containing peritoneal cells was then 
collected using a 5 ml syringe and 18g needle. Cells collected were then washed with ice 
cold D-PBS. The supernatant was discarded and cells were resuspended in ice cold RPMI 
and used in subsequent procedures. 
 
2.2.9 Cell counts 
Red or white blood cells were stained with 0.1% w/v trypan blue (Sigma, St. Louis, Mo, 
USA) in PBS and counted using a haemocytometer under x10 objective on a light 
microscope. Dead cells were excluded based on the uptake of trypan blue. Viable cells in 
all 25 small squares on the hemocytometer were counted. The total number of cells in 1ml 
of blood was calculated as:  
Cell count on haemocytometer x dilution factor x 1000 (volume of blood) x volume of 
chamber (104) 
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2.2.10 Staining of cells for flow cytometric analysis 
Cell surface and intracellular IFNg, T-bet, FOXP3 and Bcl6 staining was performed as 
previously described [293, 294]. Briefly, for cell surface staining, 100ul of cell 
homogenates prepared, as described above were added into wells on a 96-well plate. 
Plates were centrifuged at 1200rpm for 4 minutes at room temperature. Supernatants were 
discarded, cells resuspended in 200ul D-PBS and washed at 1200rpm for 4 minutes at 
room temperature. Supernatants were discarded and cells were then stained with 50ul of 
Zombie Aqua fixable viability dye (diluted in PBS) for 15 minutes in the dark. Cells were 
washed in FACS buffer for 4 minutes at 4°C, and incubated in FACS block for 10 minutes 
on ice. Thereafter, cells were washed in FACS buffer and stained with 50µl of antibodies 
(diluted in FACS buffer), for 20 minutes on ice. Cells were then washed twice in FACS 
buffer and either stored at 4oC in 1%PFA solution or further processed for identification of 
intracellular molecules. 
 
For intracellular staining, cells were first incubated in BFA for 3hrs at 37oC prior to staining 
them for surface molecules as described above. Cells were then fixed and permeabilised 
using 100ul of 1x fixation/permeabilisation buffer (eBioscience), for 30 minutes on ice. 
Cells were then washed twice in perm wash at 1200rpm, for 3-4mins. Cells were then with 
antibodies specific for intracellular molecules, for 40 minutes on ice. Next, cells were 
washed twice in FACS buffer prior to their fixation in 1% PFA. Cells were acquired on a BD 
LSR Fortessa flow cytometer and data analysed in FlowJo Software.  
  
Standard Th1/Tfh staining cocktail used 
Antibody/conjugate Clone Stock Dilution 
Live/Dead (Zombie-Aqua)   1:200 
Rat a-mouse CD4-BV605 RM4-5 0.2mg/ml 1:200 
Hamster a-mouse TCRβ-
Alex Fluor 700 
H57-597 0.5mg/ml 1:200 
Hamster a-mouse CD279 
(PD-1)- APC-eFluor 780 
J43 0.2mg/ml 1:100 
Biotin Rat a-mouse CXCR5 2G8 0.5mg/ml 1:50 
Streptavidin-PeCy7  0.2mg/ml 1:200 
Rat a-mouse IFNg-BV421  XMG1.2 0.2mg/ml 1:400 
Mouse a-human/mouse eBio4B10 0.2mg/ml 1:40 
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Tbet-eFluor660 
Mouse a-human/mouse 
Bcl6-PE 
K112-91 0.2mg/ml 1:10 
 
Alternative Th1-Tfh staining cocktail used 
Antibody/conjugate Clone Stock Dilution 
Live/Dead (Zombie-Aqua)   1:200 
Rat a-mouse CD4-BV605 RM4-5 0.2mg/ml 1:200 
Hamster a-mouse TCRβ-
Alex Fluor 700 
H57-597 0.5mg/ml 1:200 
Hamster a-mouse CD279 
(PD-1)- APC-eFluor 780 
J43 0.2mg/ml 1:100 
Biotin Rat a-mouse CXCR5 2G8 0.5mg/ml 1:50 
Streptavidin-PeCy7  0.2mg/ml 1:200 
Rat a-mouse IFNg-BV421  XMG1.2 0.2mg/ml 1:400 
Mouse a-human/mouse 
Tbet-eFluor660 
eBio4B10 0.2mg/ml 1:40 
Rat a-mouse ICOS-PE 7E.17G9 0.2mg/ml 1:200 
 
Standard T-cell activation and Proliferation staining cocktail used 
Antibody/conjugate Clone Stock Dilution 
Live/Dead (Zombie-Aqua)   1:200 
Rat a-mouse CD4-BV605 RM4-5 0.2mg/ml 1:200 
Hamster a-mouse TCRβ-
Alex Fluor 700 
H57-597 0.5mg/ml 1:200 
Rat a-mouse CD11a FiTC M17/4 0.5mg/ml 1:200 
Biotin Rat a-mouse CD49d R1-2 0.5mg/ml 1:200 
Streptavidin-PeCy7  0.2mg/ml 1:200 
Rat a rat/mouse Ki67-PE SolA15 0.2mg/ml 1:600 
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Standard B-cell staining cocktail used 
Antibody/conjugate Clone Stock Dilution 
Live/Dead (Zombie-Aqua)   1:200 
Rat a-mouse B220-Alexa 
Fluor 700 
RA3-6B2 0.5mg/ml 1:200 
Rat a-mouse CD19-FITC 6D5 0.5mg/ml 1:200 
Rat a-mouse CD138-BV605 281-2 0.5mg/ml 1:200 
Rat a-mouse IgD-APCCy7 11-26c.2a 0.2mg/ml 1:200 
Rat a-mouse IgM-PECy7 RMM-1 0.2mg/ml 1:200 
Rat a-mouse GL7-
eFluor660 
GL-7 0.2mg/ml 1:200 
Hamster a-mouse CD95 
(FAS)- PeCy7 
Jo2 0.2mg/ml 1:200 
 
Alternative B-cell staining cocktail used 
Antibody/conjugate Clone Stock Dilution 
Live/Dead (Zombie-Aqua)   1:200 
Rat a-mouse B220-Alexa 
Fluor 700 
RA3-6B2 0.5mg/ml 1:200 
Rat a-mouse CD19-FITC 6D5 0.5mg/ml 1:200 
Rat a-mouse CD23-APC B3B4 0.2mg/ml 1:200 
Rat a-mouse CD21/CD35-
PercpCy5.5 
7E9 0.2mg/ml 1:200 
Rat a-mouse IgM-PECy7 RMM-1 0.2mg/ml 1:200 
Rat a-mouse IgD-APCCy7 11-26c.2a 0.2mg/ml 1:200 
Rat a-mouse CD38- Pacific 
Blue 
90 0.5mg/ml 1:200 
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Standard Myeloid cell staining cocktail used 
Antibody/conjugate Clone Stock Dilution 
Live/Dead (Zombie-Aqua)   1:200 
Hamster a-mouse CD11c-
APC 
N418 0.2mg/ml 1:200 
Rat a-mouse MHCII (I-A/I-
E)-Pacific Blue 
M5/114-
15.3 
0.5mg/ml 1:200 
Rat a-mouse Ly6C-FITC HK1.4 0.5mg/ml 1:200 
Rat a-mouse Ly6G-PE 1A8 0.2mg/ml 1:200 
Rat a-mouse B220-APCCy7 RA3-6B2 0.2mg/ml 1:200 
Hamster a-mouse TCRβ-
BV605 
H57-597 0.2mg/ml 1:200 
Rat a-mouse F4/80-PECy7 C1:A3-1 0.2mg/ml 1:200 
Rat a-mouse CD11b-
PercpCy5.5 
M1/70 0.2mg/ml 1:200 
 
 
2.2.11 Generation of mixed bone marrow chimeric mice 
Mixed bone marrow (BM) chimeric mice were prepared as previously described [238]. 
Briefly, 2x106 fresh syngeneic BM cells from femurs of CD45.1+ wild type and CD45.2+ 
Ifnar1-/- mice, mixed at a 50:50 ratio were intravenously (i.v.) transferred into lethally 
irradiated [11Gy (137Cs source)] C57BL/6J Rag1-/- recipient mice. These mice were then 
treated for 14 days with Baytril (provet) in drinking water. Engraftment was assessed after 
8-12 weeks by flow cytometry. Chimeras were infected 12 weeks after bone marrow 
transplantation.   
  
2.2.12 Preparation of crude parasite antigen 
Crude antigenic extract from Py17XNL or PcAS-infected RBCs was prepared using an 
adapted version of a previously described protocol [295, 296]. Briefly, mice were infected 
with Py17XNL or PcAS as described above. When parasitemias reached 20-30%, blood 
was collected by cardiac puncture into heparinized tubes. RBCs were washed once in 
RPMI at 1200rpm for 7 minutes at room temperature, and then lysed using ultrapure water 
followed by four washes in ice cold PBS at 16,000xg for 25 minutes at 4oC, as well as 
three cycles of freezing (2 hours at -80oC) and thawing (30 minutes at room temperature). 
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Extracts were also processed from RBCs of uninfected C57BL/6J mice, for use as 
negative controls in ELISA. All extracts were stored at -80oC until use.  
 
2.2.13 Quantification of protein concentration 
The concentration of proteins in the purified extracts was determined by Bradford assay 
(Thermo scientific) according to the manufacturer’s instructions. Briefly, two microliters of 
serially diluted test sample or bovine serum albumin (BSA) (Sigma) proteins were added 
into a 96 well flat bottomed tissue culture plate (Becton Dickinson Labware) that contained 
200ul per well of the protein assay reagent. Absorbance at 595nm was read on a Biotek 
synergy H4 ELISA plate reader (Biotek, USA) and the concentration of the test sample 
calculated from the BSA protein standard curve. 
 
2.2.14 Antibody ELISA 
Costar EIA/RIA 96-well flat bottom plates were coated overnight at 4oC with 2.5μg of 
soluble antigen/ml in bicarbonate coating buffer (pH9.6). Wells were washed three times 
(all washes in 0.005% Tween in PBS) and then blocked for 1hr at 37oC with 1% BSA in 
PBS. Wells were washed three times, 100ul of sera diluted 1/400, 1/800, 1/1600 or 1/3200 
was added and incubated for 1hr at 37oC. Following six washes, wells were incubated in 
the dark with biotinylated anti-IgM, total IgG, IgG1, IgG2b and IgG3 (Jackson 
ImmunoResearch) for one hr at room temperature. Unbound antibodies were washed off 
(six times) prior to incubating wells in the dark with streptavidin HRP (BD pharmagen) for 
30 minutes at room temperature. Wells were washed six times prior to development 
(100ul, OPD; Sigma-Aldrich) for 5 minutes in the dark before termination with an equal 
volume of 1M HCl. Absorbance was determined at 492nm using a Biotek synergy H4 
ELISA plate reader (Biotek, USA). Data were analysed using Gen5 software (version 2) 
and GraphPad Prism (version 6). 
 
2.2.15 Preparation of tissue for immunofluorescence and Immunohistochemistry 
Mice were sacrificed and splenic tissue was collected onto Tissue-Tek Optimal Cutting 
Tempearture embedding media (OCT) (Sakura Finetek, CA, USA) on dry ice (CO2). The 
OCT was allowed to set and blocks were transferred to -80°C until sectioning. 10-20um 
sections were cut on a cryostat microtome (Bright OTF cryostat, Bright, huntingdon, UK) 
and placed on positively charged microscope slides (Knittle Glasser). Sections were air 
dried overnight and encircled with a hydrophobic pen (immedge pen – Vector 
Laboratories, Burlingame, CA, USA) prior to wrapping the slides in adhesive plastic film, in 
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order to protect tissues from condensation. Wrapped slides were then stored at -80°C until 
use. 
2.2.16 Confocal microscopy 
Confocal microscopy was performed on 10–20 µm frozen sections as previously described 
[297, 298]. Briefly, frozen sections were firstly air-dried for 30 minutes at room 
temperature. Sections were then fixed in ice-cold 100% acetone (BDH chemicals) for 10 
minutes and air-dried at room temperature for 30 minutes. Sections were rehydrated by 
immersion in three, five-minute long changes of PBS. Non-specific binding was blocked by 
incubation in 5% (v/v) normal rat serum (stem cell technologies, Vancouver, Canada), in 
PBS for 30 minutes at room temperature. To further prevent non-specific binding, sections 
were washed once in PBS, for two minutes and then incubated in biotin and avidin 
blocking solutions for 15 minutes, respectively. Sections were washed once in PBS prior to 
labelling with antibodies against CD3-Biotin (clone-17A2), B220-PE (clone-RA3-6B2) and 
ICOS-APC (clone-C398.4A), for one hour at room temperature. After three washes in 
PBS, sections were labelled with streptavidin conjugated to Alexa Fluor 594 in order to 
detect then anti-CD3. All antibodies were obtained from Biolegend (San Diego, CA). 
Following three washes in PBS, sections were labelled with DAPI in order to identify white 
pulp areas. Next, sections were washed three times in PBS and mounted in Prolong Gold 
mounting media for fluorescence (Molecular probes). Sections were imaged on a Zeiss 
780-NLO laser-scanning confocal microscope (Carl Zeiss Microimaging and data analysed 
using Imaris image analysis software, version 8.1.2 (Bitplane). Cells were identified using 
the spots function in Imaris, with thresholds <10µM and intensities <150. All objects were 
manually inspected for accuracy before data were plotted and analyzed in graph pad prism 
(version 6).  
 
2.2.17 In vivo cell depletion and blockade via monoclonal antibody.  
Anti-CD4 depleting monoclonal antibody (clone GK1.5) and its isotype control (routinely 
used in-house) were administered in 0.1mg, via i.v. injection in 200ul 0.9% NaCl (Baxter), 
a day before infection. CD4+ T-cell depletion was confirmed in peripheral blood over the 
first 5 days post antibody treatment and absolute numbers subsequently remained >95% 
depleted in the spleen at day 10 post infection compared to isotype-treated controls. For 
ICOSL blockade, α-ICOSL (clone HK5.3, BioXCell) and its isotype control (IgG2a, clone 
2A3, BioXCell) were administered in 0.2mg doses, via i.v. injection in 200ul 0.9% NaCl 
(Baxter) on the day of infection, and then every 3 days for up to 15 days p.i.. To block IL-
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6R signalling, anti-IL-6R blocking monoclonal antibody (clone MR16-1, Chugai, Japan) 
and its isotype control mAb were administered in 0.5mg doses, via intraperitoneal (i.p.) 
injection in 200ul 0.9% NaCl (Baxter) on the day of infection, and subsequently on days 3, 
6, 9 and 12 p.i.. For B-cell depletion, anti-CD20 (Genentech) or isotype control antibody 
was administered in a single 0.5mg dose via i.p. injection (as recommended by the 
manufacturer) in 200ul 0.9% NaCl (Baxter), 5 days prior to infection. For Ifnar1 blockade, 
α-Ifnar1 blocking monoclonal antibody (clone MAR1-5A3) and its isotype control mAb were 
administered in 0.1mg doses, via i.p. injection in 200ul 0.9% NaCl (Baxter) on the day of 
infection, and subsequently on days 2, 4 and 6 p.i.. For Diptheteria toxoid (DT) treatment 
experiments, mice were treated i.p. with 20ng/g of DT in 200ul 0.9% NaCl (Baxter) a day 
before infection. 
 
2.2.18 Statistical analysis 
Comparisons between two groups were performed using non-parametric Mann-Whitney 
(unpaired datasets or Wilcoxon (paired datasets) tests. Where depicted, one-way or two-
way ANOVA and Tukey’s post-test were employed for multiple comparisons among three 
or more groups. p< 0.05 was considered significant (p<0.05 = *; p<0.01=**; p<0.001=***; 
P<0.0001=****). Graphs depict mean values ± SEM, except where individual mouse data 
points are depicted, in which case median values are shown. All statistical analyses were 
performed using GraphPad Prism 6 software. 
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3 CHAPTER THREE: INTERLEUKIN-6 OPTIMIZES ICOS-MEDIATED 
HUMORAL IMMUNITY TO BLOOD-STAGE MALARIA 
 
3.1 Introduction 
Interleukin-6 (IL-6) is a pleiotropic innate cytokine, signalling through a membrane-bound 
and/or soluble receptor (IL-6R). The IL-6/IL-6R complex couples onto gp130, activating a 
downstream JAK/STAT-dependent signalling cascade [299, 300]. IL-6 is pro-inflammatory, 
potently modulates immune responses and supports hematopoiesis. IL-6 has been 
associated with onset of various inflammatory and autoimmune disorders, including 
rheumatoid arthritis, multiple sclerosis, and Crohn’s disease [300-307]. Indeed, IL-6 
signalling blockade has been employed as a therapeutic strategy for such disorders. 
Previous reports have shown that IL-6 modulates the balance between Th17 and 
regulatory T-cell formation via regulation of RORgT and FOXP3 expression in CD4+ T-cells 
[308]. This regulated the development of myocarditis [309], rheumatoid arthritis [310] and 
colitis [307, 311]. IL-6 also plays important roles in immunity to infection. For instance, it 
may be important in limiting inflammation and pathology during viral infections [312]. 
Moreover, it has been implicated in activating the acute phase response by hepatocytes, 
an important process during liver regeneration [313, 314]. Soluble gp130 (sgp130) inhibits 
IL-6 trans-signalling, this associated with impaired acute phase response in human chronic 
liver disease [314]. A recent study has also suggested a role for IL-6 in modulating innate-
mediated immunity to listeria monocytogenes infection [315]. 
 
IL-6 has been purported to drive Tfh and humoral immune responses in concert with other 
cytokines [112, 113, 174, 176]. For example, IL-6 stimulates CD4+ T-cell-IL-21 production, 
which is important for Tfh formation, B-cell differentiation and antibody production. Virally-
induced IFN-I and IL-6 from plasmacytoid DCs were also implicated in the generation of 
antibody-secreting plasma cells [183]. A recent report revealed that IFN-I-dependent IL-6 
production by cDCs stimulated Tfh responses following immunization [284]. However, 
STAT3, a transcription factor triggered by several cytokines including IL-6, impaired IFN-I 
dependent humoral responses during viral infection [289]. Studies in mice have identified 
important roles for IL-6 in early and late Tfh formation during LCMV infection [112, 113]. In 
vitro, viral IL-6 analogues enhanced B-cell proliferation in lymphoma cells infected with 
Kaposi’s sarcoma-associated herpes virus [316].  
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IL-6 has been detected in severe malaria patients [225, 226, 232], with even higher levels 
detected in those with uncomplicated malaria [317], the implication being that IL-6 may 
drive more robust immunity to malaria. The effects of Plasmodium-induced IL-6 on the 
development of antibody-mediated immunity have remained relatively unexplored, 
although recombinant IL-6 administration boosted antibody responses during PcAS 
infection [288].   
 
The co-stimulatory molecule ICOS promotes T-cell activation and proliferation. Multiple 
roles for ICOS in T-cell differentiation have been described in the literature. An earlier 
report suggested essential roles of ICOS in Th2 differentiation, via GATA-3 and IL-4 
signalling [318]. Others suggested that ICOS supported Th1 responses [319], the 
formation of Tregs [320] and Tr1 cells [321]. Studies in mice have also described roles for 
ICOS in supporting Tfh cell generation following protein immunization [115] or during viral 
infection [53] and autoimmunity [166]. In these systems, ICOS is essential for GC B-cell 
responses and the production of class-switched antibodies. Until recently, the role of ICOS 
signalling during blood-stage malaria remained undefined. In a recent study, Wikenheiser 
and colleagues suggested roles for ICOS in regulating Th1 and Tfh differentiation during 
PcAS infection [280]. Despite these findings, cell intrinsic and extrinsic factors regulating 
ICOS-dependent immune responses during parasitic infections, including Plasmodium are 
poorly understood.   
 
Studies in this chapter explored the impact of IL-6-signalling on the development and 
maintenance of humoral immune responses during blood-stage malaria. These studies 
identified important roles for ICOS in mediating CD4+ T-cell dependent humoral immunity 
to blood-stage malaria. More significantly, these studies established important roles for IL-
6 signalling in supporting optimal ICOS-dependent humoral immune responses.” 
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3.2 Results 
 
3.2.1 Germinal centre B-cell and plasmablast responses require CD4+ T-cells and 
ICOS signalling during blood-stage Plasmodium infection 
 
CD4+ T-cells are critical for control and resolution of blood-stage Plasmodium infection 
[139, 276, 322], a phenomenon first confirmed in Py17XNL-infected mice, depleted of 
CD4+ T-cells (Figures 3.1A-B). Nonetheless, there remains no formal evidence that these 
cells control B cell differentiation during experimental malaria. To examine this, wild-type 
(WT) mice depleted of CD4+ cells, or given control IgG, were infected with Py17XNL and 
examined for resulting splenic B-cell responses (Figures 3.1C-F). By day 10 post-infection 
(p.i), a timepoint just before the CD4-depleted mice began to succumb to infection, 
plasmablast differentiation was 80% lower in CD4-depleted mice compared to infected 
controls (Figure 3.1D), and GC B-cell formation (Figure 3.1E) was almost abrogated (95% 
reduction compared to controls), with a similar, substantial impairment in immunoglobulin-
class switching (Figure 3.1F). Together, these data formally demonstrated that GC B-cell 
and plasmablast generation was highly dependent upon CD4+ T-cells.  
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Figure 3.1 Splenic GC B-cell and plasmablast responses are strongly dependent on 
CD4+ cells during Py17XNL infection. WT mice (n=5) were pre-treated with anti-CD4 
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monoclonal depleting antibody (a-CD4) or control-IgG before infection with Py17XNL. (A&B) A 
time course of parasitemia (A) and percentage survival (B) in  mice treated with (a-CD4 or control 
IgG. (C) Gating strategy that has been used to analyse B-cells in the spleen, throughout this report. 
(D) Representative FACS plots, proportions and numbers of splenic: (D) plasmablasts (gated as 
B220
+
CD19
+
IgD
lo
CD138
hi
 cells), (E) GC B-cells (gated as B220
+
CD19
+
GL-7
+
Fas
+
 cells) and (F) 
switched B-cells (gated as B220
+
CD19
+
IgD
lo IgMlo cells) of naïve and infected IgG and a-CD4 
treated mice, 10 days p.i.. Data representative of one experiment for A&B and two independent 
experiments for D-F. Statistics: Mann-Whitney U test, *P<0.05, **P<0.01. 
 
Given this observation, cellular and molecular mechanisms controlling CD4+ T-cell 
dependent humoral immunity to blood-stage malaria were next examined. While previous 
studies in mice and humans demonstrated that ICOS expressed on CD4+ T-cells was 
critical for effective humoral responses [53, 115, 156, 158, 323], until recently, no such 
studies had been performed during Plasmodium infection [280]. Therefore, ICOS 
expression by CD4+ T-cells (Figure 3.2A) during Py17XNL infection was determined, 
revealing significant up-regulation by 5-7 days p.i. that was sustained over the following 7-
9 days (Figure 3.2B).  
 
 
Figure 3.2 Surface ICOS expression on CD4+ T-cells during blood-stage malaria. (A) 
Gating strategy that has been used to analyse CD4+ T-cells in the spleen, throughout this report. 
(B) Representative FACS plots and a time-course analysis of cell-surface ICOS expression on 
splenic CD4+ T-cells from WT mice (n=3/time point) during Py17XNL infection. Data representative 
of two independent experiments. 
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To examine a possible functional role for ICOS in the development of humoral immunity, 
WT mice were treated with anti-ICOSL-blocking antibody (a-ICOSL) during Py17XNL-
infection. Consistent with other experimental models [53, 111, 115], ICOSL-blockade 
impaired Tfh differentiation by day 16 post infection (Figure 3.3). Day 16 p.i. was an 
important timepoint during Py17XNL infection because it marked the point at which the 
rate of increase in parasitemia began to slow in WT mice, thus indicating the beginning of 
the resolution of the infection. 
 
Figure 3.3 ICOS signalling supports Tfh formation during blood-stage malaria. WT 
mice (n=6) were treated (i.v) with anti-ICOSL monoclonal blocking antibody (a-ICOSL) or its 
isotype control (rat-IgG2a) prior to and during infection with Py17XNL. Data shows representative 
FACS plots, proportions and numbers of splenic Tfh cells (gated as CD4
+
TCRβ+PD1
+
CXCR5
+
 
cells) of naïve and infected rat-IgG2a and a-ICOSL treated mice, 16 days p.i.. Data representative 
of two independent experiments. Statistics: Mann-Whitney U test, **P<0.01 
 
The loss of Tfh cells at day 16 associated with reduced frequencies and numbers of GC B-
cells (Figure 3.4A) and impaired the formation of class-switched B-cells (Figure 3.4B). 
Moreover, ICOS-L blockade significantly impaired early production of parasite-specific total 
IgG and IgG2b, but not IgM and IgG3 (Figure 3.4C) or IgG1 and IgG2c (data not shown) in 
serum. Importantly, ICOS-L blockade over the first three weeks of infection exacerbated 
parasitemias and delayed resolution of infection (Figure 3.4D). Taken together, these 
findings indicated that ICOS-signalling promoted CD4+ T-cell dependent humoral immune 
responses and parasite control during experimental malaria.  
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Figure 3.4 ICOS signalling is required for optimal humoral immunity to blood-stage 
malaria. WT mice (n=6) were treated (i.v) with anti-ICOSL monoclonal blocking antibody (a-
ICOSL) or its isotype control (rat-IgG2a) prior to and during infection with Py17XNL. (A) 
Representative FACS plots, proportions and numbers of splenic GC B-cells (gated as 
B220
+
CD19
+
GL-7
+
Fas
+
 cells). (B) Number of splenic class switched B-cells (gated as 
B220
+
CD19
+
IgD
lo IgMlo cells)  in naïve and infected rat-IgG2a and a-ICOSL treated mice, 16 days 
p.i. (C) Py17XNL-specific IgM, total IgG, IgG2b and IgG3 levels in serum of naïve and infected 
control IgG or a-ICOSL treated mice, 16 days p.i.. (D) Parasitemias in WT mice (n = 6/group) 
infected with Py17XNL, and treated every three days with a-ICOSL or control IgG until day 21 p.i. 
(depicted by arrows, with estimated period of cover highlighted with shaded grey box - an a-
ICOSL- treated mouse succumbed to infection on each of days 15, 17 and 30 p.i., and one control-
IgG treated mouse succumbed on day 20 p.i. Data representative of two independent experiments 
in (A-B) and two pooled individual experiments in (C). Experiment in (D) was done once. Statistics: 
Mann-Whitney U test, *P<0.05; **P<0.01 
3.2.2 IL-6 supports humoral immunity to blood-stage Plasmodium infection 
Cytokine-signalling via the IL-6 receptor chain, gp130 has been implicated in controlling 
Tfh and B-cell responses during viral infection [324]. Given this observation, the next set of 
experiments determined the impact of IL-6 on CD4+ T-cell dependent humoral immunity to 
blood-stage Plasmodium infection. Firstly, the effect of IL-6 on parasite control was 
examined. Initially, WT and IL-6-/- mice were infected with Py17XNL. Notably, IL-6 was 
required for parasite control during the second and third week of infection (Figure 3.5A), 
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but was not essential for resolution of primary infection. Similar studies were then 
conducted in WT and IL-6-/- mice infected with PcAS. Consistently, IL-6 was also required 
for optimal control of PcAS parasites, particularly during the first wave of recrudescence, 
as observed in IL-6-/- mice (Figure 3.5B).  
 
 
Figure 3.5 IL-6 supports parasite control. WT and IL-6-/- mice (n=6) were infected with 
Py17XNL (A) or PcAS (B&C). (A&B) A time-course analysis of parasitemia in WT and IL-6
-/- 
mice 
infected with (A) Py17XNL or (B) PcAS. (C) A time-course analysis of parasitemia in WT mice 
treated with anti-IL-6R blocking monoclonal antibody or control IgG. Data representative of three 
independent experiments. Statistics: Mann-Whitney U test, *P<0.05; **P<0.01 
 
To further substantiate these findings, WT mice were treated with anti-IL-6R (a-IL-6R) 
blocking antibody or its isotype control antibody (IgG) before and during PcAS infection. 
Similar to IL-6 deficient mice, a-IL-6R blockade impaired optimal parasite control during 
chronic PcAS infection (Figure 3.5C). Together, these data demonstrated that IL-6 played 
a non-redundant role in optimizing parasite control in two models of experimental blood-
stage malaria.  
 
Next, the impact of IL-6 on the development of anti-parasitic antibody responses during 
infection was explored. To undertake this, serum samples were collected from WT and IL-
6-/- mice on day 14 following Py17XNL infection. The levels of parasite-specific antibodies 
in these sera were then determined using an ELISA. Notably, levels of early parasite-
specific IgM, total IgG, IgG2b, IgG2c and IgG3 were significantly reduced in IL-6-/- mice 
compared to WT controls (Figure 3.6A-B). However, IgG1 levels were unaffected by IL-6 
deficiency (Figure 3.6A). Together, these data suggested that IL-6 supported optimal anti-
parasitic antibody responses during blood-stage malaria.  
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Figure 3.6. IL-6 supports anti-parasitic antibody responses. WT and IL-6-/- mice (n=6) 
were infected with Py17XNL. Data shows Py17XNL-specific: (A) IgM, total IgG, IgG1, IgG2b, IgG3 
and (B) IgG2c (serum diluted at 1/400) antibody levels in serum of naïve and infected WT and IL-6
-
/- 
mice, 14 days p.i.. Statistics: Data representative of two independent experiments. Statistics: Two 
way ANOVA and Tukey’s test for multiple comparisons in (A) and Mann-Whitney U test in (B), 
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.  
 
To ascertain whether the observed defects in antibody production associated with similar 
defects in B-cell differentiation, spleens of WT and IL-6-/- mice were collected and their B-
cells examined by flow cytometry, 14 days post Py17XNL infection. Similar to the antibody 
data, the proportions and numbers of GC B-cells were significantly reduced in IL-6-/- mice 
compared to WT controls (Figure 3.7A). To explore this further, similar studies were 
conducted in WT and IL-6-/- mice infected with PcAS. Consistently, the proportions of early 
GC B-cells were reduced in IL-6-/- mice compared to WT controls by day 8 p.i. (Figure 
3.7B) Nonetheless, total numbers of GC B-cells were unaffected by the absence of IL-6 
(Figure 3.7B). More interestingly, proportions and numbers of plasmablasts were 
significantly reduced in IL-6-/- mice compared to WT controls, by day 8 post PcAS infection 
(Figure 3.7C). Moreover, the frequencies of class switched B-cells were also lower in IL-6-/- 
mice compared to WT controls (Figure 3.7D). Together, these data implied that IL-6 was 
required for early plasmablast formation, GC B-cell differentiation and immunoglobulin 
class switching during blood-stage malaria.  
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Figure 3.7. IL-6 supports anti-parasitic humoral immune responses. WT and IL-6-/- mice 
(n=5-6) were infected with Py17XNL (A) or PcAS (B-D). (A&B) Representative FACS plots, 
proportions and numbers of splenic GC B-cells (gated as B220+CD19+GL-7
+
Fas
+
) in naïve and 
infected spleens, 14 days post Py17XNL (A) and 8 days post PcAS infection (B). (C) 
Representative FACS plots, proportions and numbers of splenic plasmablasts 
(B220
+
CD19
+
IgD
lo
CD138
hi
) in WT and IL-6-/- mice, 8 days p.i.. (D) Proportions of switched B-cells 
(gated as B220
+
CD19
+
IgD
lo IgMlo cells) in WT and IL-6-/- mice, 8 days p.i.. Data representative of 2-
3 independent experiments. Statistics: Mann-Whitney U test, *P<0.05; **P<0.01. 
 
Considering that these observed IL-6-dependent effects on humoral immunity occurred 
early during infection, longer-term effects of IL-6 signalling on humoral responses during 
infection were next examined. To undertake this, serum antibody levels were examined in 
WT and IL-6-/- mice at later timepoints (days 22 and 27 p.i.) - IL-6 deficiency had no effect 
on antibody levels at these later timepoints (Figure 3.8). This suggested that IL-6 signalling 
was not essential for antibody responses during and after resolution of primary infection. 
Together, these data demonstrated for the first time that IL-6 supports the generation of 
early robust humoral immune responses during blood-stage Plasmodium infection. 
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Figure 3.8. IL-6 is not essential for antibody responses during and after resolution of 
infection. WT and IL-6-/- mice (n=6) were infected with Py17XNL. Plots show Py17XNL-specific 
IgM, total IgG, IgG2b and IgG2c antibody levels in serum of naïve and infected mice, 22 and 27 
days p.i.. Experiment done once. Statistics: Mann-Whitney U test. 
 
3.2.3 IL-6 supports ICOS expression on emerging Tfh cells  
Since IL-6 supported GC B-cell responses, isotype class switching, and parasite-specific 
IgG production in earlier experiments, described above, the effect of IL-6 on Tfh cell 
responses was then examined. Firstly, WT and IL-6-/- mice were infected with Py17XNL 
and 14 days post infection, splenic T-cells were examined by flow cytometry for the 
expression of different Tfh-defining markers. In contrast to earlier reports in the literature, 
especially from the viral models, IL-6 was not essential for the generation of Tfh cells 
(Figure 3.9A). However, the qualitative nature of the Tfh response was affected by IL-6 
signalling, since ICOS expression was modestly reduced on Tfh cells in IL-6-/- mice 
compared to controls (Figure 3.9B). This suggested a role for IL-6 in supporting ICOS 
expression on Tfh cells.  
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Figure 3.9. IL-6 supports ICOS expression by Tfh-cells. WT and IL-6-/- mice (n=6) were 
infected with Py17XNL. (A) Representative FACS plots, proportions and numbers of splenic CD4
+ 
TCRβ+PD1
+
CXCR5
+
 Tfh cells in naive and infected WT and IL-6-/- mice, 14 days p.i.. (B) ICOS 
expression on CD4
+
TCRβ+PD1
+
CXCR5
+
 Tfh cells, 14 days p.i.. Data representative of two 
independent experiments. Statistics: Mann-Whitney U test, **P<0.01. 
 
To examine this further, WT and IL-6-/- mice were infected with PcAS. By day 8 p.i., bulk 
CD4+ T cells in IL-6-/- mice exhibited significantly reduced ICOS expression (Figure 3.10A). 
Interestingly, the absence of IL-6 did not affect Tfh cell differentiation in this second model 
(Figure 3.10B). Moreover, IL-6 was not essential for Bcl6 expression in Tfh cells during 
infection (Figure 3.10C). However, ICOS expression on Tfh cells was significantly reduced 
in the absence of IL-6 (Figure 3.10D). A requirement for IL-6 in inducing IL-21 production 
has been reported elsewhere [175]. Therefore, to examine the effect of IL-6 on IL-21 
production, IL-21 levels in splenic lysates of WT and IL-6-/- mice were assessed using an 
IL-21 specific ELISA, 8 days post PcAS infection. Despite a trend towards reduced IL-21 
levels in IL-6-/- mice compared to WT control mice, IL-6 was not essential for IL-21 
production in the spleen (Figure 3.10E). Together, these data suggested that IL-6 was not 
essential for Tfh cell differentiation but supported early ICOS expression on emerging Tfh 
cells.  
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Figure 3.10. IL-6 supports ICOS expression by CD4+ T-cells. WT and IL-6-/- mice (n=5-6) 
were infected with PcAS. (A) ICOS expression by CD4+ T cells, 8 days p.i.. (B) Representative 
FACS plots, proportions and numbers of CD4
+
TCRβ+PD1
+
CXCR5
+
 Tfh cells, 8 days p.i.. (C) Bcl-6 
expression in non Tfh (CD4+TCRβ+PD1-CXCR5-) and Tfh (CD4+TCRβ+PD1+CXCR5+) cells (D) 
ICOS expression on CD4
+
TCRβ+PD1
+
CXCR5
+
 Tfh cells, 8 days p.i.. and (E) IL-21 protein levels in 
splenic lysates from naïve and infected WT and IL-6-/- mice, 8 days p.i.. Data representative of two 
independent experiments for (A-D) and once for (E). Statistics: Mann-Whitney U test, *P<0.05; 
**P<0.01.  
 
3.2.4 IL-6 supports T-cell co-localization with B-cells in the spleen  
Given the reported roles for ICOS in positioning Tfh cells adjacent to and within B-cell 
follicles [116, 158], splenic T-cell responses in WT and IL-6-/- mice were examined via 
confocal microscopy, 8 days post PcAS infection. Noticeably, there was a clear reduction 
in the density of ICOS-expressing T-cells at the T/B border and within B-cell follicles in 
spleens of IL-6-/- mice compared to WT infected controls (Figure 3.11). These data 
suggested a role for IL-6 in T-cell positioning close to B-cells within the spleen.  
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Figure 3.11. IL-6 supports positioning of CD4+ T-cells within B-cell areas within the 
spleen. WT and IL-6-/- mice (n=5-6) were infected with PcAS. Figure shows representative 
distribution pattern and densities of ICOS expressing T-cells in splenic T-B borders and B-cell 
follicles of naïve, WT and IL-6
-/-
mice, 8 days p.i.. Each symbol represents one T-B border or follicle 
in the spleen. Data pooled from 3-4 T-B borders or follicles per mouse with n=2 for naïve and n=4 
for WT and n=5 for IL-6-/- mice. T-B border defined by region between CD3+ cells farthest into 
follicle (dotted white line, bottom) and B220+ cells farthest into the T-cell zone (dotted white line, 
top). Scale bar, 100µM. Statistics: Mann-Whitney U test, ****P<0.0001.  
 
3.3 Discussion 
These studies revealed several important observations that enhance our understanding of 
humoral immunity during blood-stage malaria. First, crucial roles for CD4+ T-cells in driving 
B-cell responses were revealed. Depletion of CD4+ T-cells abrogated plasmablasts, GC B-
cells and class switched B-cells. Next, essential roles for ICOS expression on CD4+ T-cells 
in promoting Tfh cell formation, GC B-cell differentiation and the production of anti-
parasitic class switched antibodies were identified. Finally, roles for IL-6 in optimising the 
quality of Tfh cells, via support of ICOS signalling and plasmablast formation, GC B-cell 
responses as well as the production of class-switched parasite-specific antibodies were 
observed. 
 
It is likely that mouse models of malaria will be informative for studies of cytokine-mediated 
effects on humoral immunity, as recently epitomized in studies of T cell-derived IL-21 
[264]. These reports and our new data complement studies of T-cell co-stimulatory 
molecules, such as PD-1 and LAG-3, and strengthen the idea that multiple molecular 
targets exist, which could be harnessed to boost humoral immunity to malaria [139, 193].  
Similarly, the current studies revealed essential roles for ICOS in promoting humoral 
immunity to blood-stage malaria. These findings were consistent with those in a recent 
study, in which ICOS sustained humoral immunity to PcAS [280]. ICOS signalling blockade 
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associated with significantly reduced total IgG and IgG2b levels in serum but had no effect 
on IgM and IgG3 production. This suggests that Plasmodium stimulates both ICOS-
dependent and ICOS-independent humoral responses during infection. The reduction in 
numbers of Tfh cells, GC B-cells and class-switched B-cells, following transient ICOS 
blockade, suggests that majority of the follicular B-cell responses during infection are 
partly ICOS-dependent. However, extrafollicular responses, resulting in parasite-specific 
IgM and IgG3 production are more likely ICOS-independent. Regardless, these findings 
suggest that ICOS may be a crucial target for harnessing immunity to malaria. 
  
Mechanisms controlling ICOS-induced humoral responses are poorly understood. These 
studies postulated that innate cytokines (in this case IL-6), may influence ICOS-induced 
humoral immunity during blood-stage malaria. Much of our current understanding of 
cytokine-mediated control of humoral immunity derives from studies of viral infection or 
experimental immunization in mice [112, 113, 174, 179, 284]. However, it remains difficult 
to infer from these studies how cytokine-signalling impacts upon antibody responses 
during parasitic infection. In a recent report, Perez-Mazliah et al demonstrated a pivotal 
role for T cell-derived IL-21 in mediating GC B-cell responses and IgG class switching but 
not for generating Tfh cells during blood-stage Plasmodium infection [264]. Similarly, this 
current study revealed no defect in Tfh differentiation in the absence of IL-6. This suggests 
that either IL-6 plays no role in Tfh differentiation, or possibly, that other gp130 and/or 
STAT3-activating cytokines, such as IL-27 can compensate for IL-6 deficiency [178, 179]. 
Importantly, however, the current study revealed clear roles for IL-6 in controlling parasite 
numbers, positioning CD4+ T cells close to B-cells, and promoting ICOS expression by Tfh 
cells. Together, these data are consistent with IL-6 playing a supporting role, not in the 
differentiation of naïve CD4+ T cells into Tfh cells, but in optimizing the early ICOS-
dependent positioning of emerging Tfh cells in B-cell areas of the spleen. This process 
would then be expected to affect Tfh cells within the B-cell follicle, for example by 
facilitating IL-21 production, as noted by a trend towards IL-6 supporting splenic IL-21 
production in, depicted in Figure 3.10. Further investigation into these possibilities is 
needed. 
 
While IL-21 appeared to play little or no role in controlling early humoral responses [264], 
the current study found a role for IL-6 in supporting parasite-specific IgM production and 
plasmablast responses. Given that IL-6 was previously known as B-cell stimulatory factor-
2 and B-cell Growth Factor, it is important to note its capacity for signalling directly to B-
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cells to support plasmablast responses and immunoglobulin class switching [325-327].  In 
this work, IL-6 supported GC B-cell and plasmablast responses effectively, and was 
required for optimal boosting of plasmablast responses. It is possible, therefore that IL-6 
signalled directly to activated B-cells during infection. At present, however, the extent to 
which this may have occurred in vivo, or whether extrafollicular plasmablast responses 
and GC B cell responses were solely supported by IL-6 via increased positioning of CD4+ 
T cells at the T/B border and within B-cell follicles remain unclear. Future experiments, 
perhaps using B-cell-specific IL-6R-deficient mice may shed light on this issue. 
Nonetheless, the current work postulates that IL-6 may act earlier than IL-21, to support 
activated CD4+ T cells, emerging Tfh cells, and rapid plasmablast and IgM responses. 
Therefore, IL-6 possibly mediates an early attempt by the host to control parasite numbers 
prior to slower, IL-21-dependent development of high affinity antibody. Moreover, given a 
recent report that complement-fixing, Plasmodium-specific antibodies mediate immunity to 
malaria in humans [262], it is intriguing that IL-6 supports the production of complement-
fixing Ig subclasses, IgM and IgG2b in mice.  
 
In summary, studies in this chapter have described essential roles for CD4+ T-cells, ICOS 
and IL-6 in influencing humoral immunity to blood-stage malaria. Therapeutic targeting of 
ICOS and IL-6 signalling pathways might improve antibody-mediated immunity to malaria. 
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4 CHAPTER FOUR: TYPE I INTERFERON SIGNALLING OBSTRUCTS 
ICOS-INDUCED HUMORAL IMMUNITY TO MALARIA 
 
4.1 Introduction 
It has been more than 50 years since the discovery of Type I interferons (IFN-I) [283]. 
There are 14 IFNa isoforms and IFNb in mice and humans, previously thought to signal 
through a widely expressed heterodimeric receptor, with IFNAR1 and IFNAR2 chains [282, 
283]. Recently, IFNb has been shown to independently bind and signal through IFNAR1 
[328]. Although signalling goes through IFNAR1/2, clearly much unexplained complexity 
exists in how different IFNa isoforms signal via this receptor. Almost all cell types in the 
body produce IFN-I in response to multiple stimuli from transmembrane or cytosolic 
receptors including, toll-like receptors (TLRs) and RIG-1 like receptors [282, 283, 329].  
 
Type I interferons are able to amplify both innate and adaptive immune responses [281-
283]. While IFN-I are renowned for their potent antiviral properties, they have been 
implicated in facilitating survival of other pathogens, including Mycobacterium tuberculosis 
[330], Listeria [331], lymphocytic choriomeningitis virus (LCMV) [332, 333] and Leishmania 
[334]. Although their functional relevance in humans remains to be established, recent 
studies showed in ex vivo cultures of PBMC from P. falciparum-infected humans, that 
signalling via IFNAR2 was immunoregulatory [335]. Earlier studies also demonstrated 
associations between single nucleotide polymorphisms, particularly within the intronic 
regions of the IFNAR1 gene and protection from severe malaria in P. falciparum infected 
individuals [285, 336, 337]. In mice, IFN-I-signalling has been associated with reduced Th1 
responses during PbANKA, and PcAS [217, 238, 251].  
 
The role of IFN-I signalling on humoral responses is incompletely elucidated. Earlier 
studies identified roles for IFN-I in promoting primary antibody responses and 
immunoglobulin class switching following injection of mice with soluble proteins [180, 181]. 
In vitro, IFN-I induced Bcl6, CXCR5 and programmed cell death 1 (PD1) expression in 
naïve CD4+ T cells following stimulation with anti-CD3 and anti-CD28 [128]. In addition, 
IFN-I activity has been implicated in the expansion of auto-reactive B-cells and excessive 
production of autoantibodies, facilitating autoimmunity [185, 281, 338]. However, B-cell 
specific IFN-I signalling was not important for experimental autoimmune encephalomyelitis 
(EAE) development [339]. A protective role for IFN-I-activated MZ and follicular B-cells has 
also been reported during bacterial induced sepsis [189]. In this report, rag1-/- and B-cell 
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deficient mice showed impaired inflammatory responses and reduced survival during 
sepsis – adoptive transfer of B-cells into these mice restored IFN-I production, increased 
bacterial killing and improved their survival. A large body of work has also suggested 
various roles for IFN-I supporting anti-viral humoral immune responses [182, 183, 188, 
190]. Previously, IFN-I signalling in DCs and non-hematopoietic cells elicited IL-6 
production, which subsequently stimulated Tfh development within lymph nodes of mice 
immunized with protein antigen [284]. In a recent report, chronic IFN-I production 
supported Tfh cell differentiation at the expense of Th1 formation during a persistent 
LCMV infection [190]. In contrast, a more recent report suggested that IFN-I signalling 
suppressed STAT-3 mediated Tfh cell formation in favour of Th1 cell differentiation during 
LCMV infection [114].  
 
The immunomodulatory activities of IFN-I on humoral responses during Plasmodium 
infections are completely unknown. However, the above highlighted reports suggested a 
model in which IFN-I suppress Th1 responses by promoting Tfh-dependent humoral 
immunity during blood-stage Plasmodium infection. Studies in this chapter examined this 
hypothesis in mice infected with either Py17XNL or PcAS and revealed unexpected roles 
for IFN-I signalling in repressing multiple aspects of humoral immune responses during 
infection. Type I interferon signalling in cDCs restricted early Tfh differentiation, 
plasmablast formation, GC B-cell generation, and the formation of parasite-specific, class-
switched antibodies. Mechanistically, IFN-I repressed ICOS-dependent co-localisation of 
CD4+ T-cells and B-cells in the spleen, thereby restricting the maintenance of the 
emerging Tfh and GC B-cell phenotype. 
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4.2 Results 
4.2.1 IFN-I signalling impairs humoral immunity during blood-stage Plasmodium 
infection 
Previous reports have highlighted interplay between IL-6 and IFN-I cytokine signalling in 
controlling humoral immunity, particularly during viral infection [114, 183, 289]. Therefore, 
using Ifnar1-/- mice, the impact of IFN-I signalling on humoral immunity to blood-stage 
Plasmodium infection was next examined. To undertake this, the impact of IFN-I signalling 
on parasite control was firstly explored, by infecting WT and Ifnar1-/- mice with Py17XNL 
and monitored them for changes in parasitemia for up to 31 days post infection. Ifnar1-/- 
mice displayed similar initial parasitemias to WT controls for the first two weeks of 
infection, but thereafter exhibited faster resolution of infection than WT controls (Figure 
4.1A). Similar effects were observed during PcAS infection (Figure 4.1B). These data 
showed that IFN-I had suppressed parasite control, with effects on Py17XNL-infection 
becoming manifest during the third week of infection when humoral immunity is known to 
act [139, 276].  
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Figure 4.1. IFN-I signalling limits parasite control and antibody production. WT and 
Ifnar1
-/- 
mice (n=5-6) were infected with Py17XNL or PcAS. (A&B A time-course analysis of 
parasitemia in blood of WT and Ifnar1
-/-
mice infected with (A) Py17XNL or (B) PcAS. (C&D) 
Py17XNL-specific IgM, total IgG, IgG1, IgG2b, IgG3 and IgG2c (serum diluted at 1/400) antibody 
levels in serum of naïve and infected WT and Ifnar1
-/- 
mice, 16 days p.i.. Data representative of 
three independent experiments for (A-C) and one for (D). Statistics: Mann-Whitney U test (A, 
B&D), Two way ANOVA and Tukey’s test for multiple comparisons in (C), *P<0.05; **P<0.01; 
***P<0.001; ****P<0.0001.  
 
Consistent with this, parasite-specific IgM and total IgG levels were elevated in the sera of 
Py17XNL-infected Ifnar1-/- mice compared to WT controls by day 16 p.i. (Figure 4.1C). 
More specifically, levels of parasite-specific IgG1, IgG2b, IgG2c and IgG3 were all higher 
in Ifnar1-/- mice compared to WT controls (Figures 4.1C-D). These findings suggested that 
IFN-I limited the production of anti-parasitic antibodies during blood-stage malaria. To 
ascertain whether these defects were due to impaired B-cell responses, splenic B-cells in 
WT and Ifnar1-/- mice were next examined using flow cytometry. Consistently, the 
proportions and total numbers of GC B-cells (Figure 4.2A) and switched B-cells (Figure 
4.2B) were significantly increased in Ifnar1-deficient spleens by day 16 p.i.. In addition, 
IFN-I signalling impaired early plasmablast formation at day 6 p.i. (Figure 4.2C).  
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Figure 4.2. IFN-I signalling limits B-cell differentiation during Py17XNL infection. WT 
and Ifnar1
-/- 
mice (n=5-6) were infected with Py17XNL. FACS plots, proportions and numbers of 
splenic: (A) GC B-cells (B220
+
CD19
+
GL7
+
Fas
+
) and (B) class-switched B-cells 
(B220
+
CD19
+
IgD
lo
IgM
lo
) infected WT and Ifnar1
-/- 
mice, at day 16 p.i.. (C) Proportions and numbers 
of plasmablasts (B220
+
CD19
+
IgD
lo
CD138
hi
) in spleens of WT and Ifnar1
-/- 
mice, 6 days p.i.. Data 
representative of three independent experiments for (A&B) and once for (C). Statistics: Mann-
Whitney U test, **P<0.01. 
 
To further corroborate these findings, similar experiments were conducted in WT and 
Ifnar1-/- mice infected with PcAS. Indeed, similar effects on plasmablast formation (Figure 
4.3A) and emerging GC B-cells (Figure 4.3B) were respectively observed at day 6 and 8 
post infection.  
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Figure 4.3. IFN-I signalling represses plasmablast and GC B-cell formation during 
PcAS infection. WT and Ifnar1-/- mice (n=5-6) were infected with PcAS. (A) Proportions and 
numbers of splenic plasmablasts (B220
+
CD19
+
IgD
lo
CD138
hi
) in WT and Ifnar1
-/- 
mice, 6 days p.i.. 
(B) FACS plots, proportions and numbers of GC B-cells (B220
+
CD19
+
GL7
+
Fas
+
) in the spleens of 
WT and Ifnar1
-/- 
mice, 8 days p.i.. Data representative of three independent experiments. Statistics: 
Mann-Whitney U test, **P<0.01.  
 
Taken together, these data suggested that IFN-I impede plasmablast and GC B-cell 
responses during blood-stage malaria. Finally, in order to explore the longer-term effect of 
IFN-I signaling on parasite-specific antibody production, a time-course analysis of levels of 
parasite-specific antibodies was conducted on sera from both WT and Ifnar1-/- mice 
infected with Py17XNL. At day 25 p.i., Ifnar1-/- mice maintained higher serum IgG levels, 
including IgG2b and IgG3, but not IgM, compared to WT controls (Figure 4.4). By day 40 
p.i., total IgG, IgG2b and IgG3 concentrations had risen further, but to similar levels in WT 
and Ifnar1-/- mice, while IgM levels had dropped, again with no differences between groups 
(Figure 4.4), suggesting that IFN-I suppressed antibody responses during but not after 
resolution of infection. In summary, these findings indicated that IFN-I-signalling delayed 
parasite control, obstructed early B-cell differentiation and limited the onset of antibody 
production during Plasmodium infection. 
 75 
 
 
Figure 4.4. IFN-I signalling limits antibody responses during but not after the 
resolution of infection. WT and Ifnar1-/- mice (n=6) were infected with Py17XNL. Data shows a 
time course analysis of IgM, total IgG, IgG2b and IgG3 levels in naïve and infected WT and Ifnar1-/- 
mice. Statistics: Mann-Whitney U test, *P<0.05; **P<0.01. 
 
4.2.2 IFN-I signalling limits Tfh differentiation 
Next, the impact of IFN-I signalling on Tfh cell responses was examined, firstly, in WT and 
Ifnar1-/- mice infected with Py17XNL. Consistently, Ifnar1-/- mice exhibited increased 
proportions and numbers of Tfh cells compared to WT controls by day 16 post infection 
(Figure 4.5A). To examine this further, WT and Ifnar1-/- mice were also infected with PcAS 
and their splenic T-cells examined eight days post infection. 
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Figure 4.5. IFN-I signalling limits Tfh formation. WT and Ifnar1-/- mice (n=5-6) were infected 
with Py17XNL (A) or PcAS (B). (A) Representative FACS plots, proportions and numbers of 
CD4+TCRβ+PD1
+
CXCR5
+ 
Tfh cells in WT and Ifnar1
-/- 
mice 16 days post-Py17XNL. (B) 
Representative FACS plots, proportions and numbers of splenic CD4+TCRβ+PD1
+
CXCR5
+  
or 
CD4+TCRβ+Bcl-6
+
CXCR5
+  
Tfh cells in WT and Ifnar1
-/- 
mice 8 days P.i.. Data representative of 3 
independent experiments. Statistics: Mann-Whitney U test, *P<0.05; **P<0.01.  
 
Consistently, the proportions of Tfh cells in Ifnar1-/- mice were significantly higher than 
those in WT controls (Figure 4.5B). Together, these data suggest that IFN-I signalling 
restrained early Tfh cell differentiation and responses during blood-stage malaria.  
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4.2.3 IFN-I signalling limits ICOS expression and CD4+ T cell positioning close to B-
cells in the spleen  
Considering that ICOS signalling was required for optimal CD4+ T-cell dependent humoral 
immune responses (Figure 3.4), the next set of studies investigated the impact of IFN-I 
signalling on ICOS expression. Firstly, WT and Ifnar1-/- mice were infected with Py17XNL 
and their splenic T-cells assessed six days post infection. Strikingly, ICOS expression was 
significantly enhanced on Ifnar1-/- CD4+ T-cells compared to WT controls (Figure 4.6A). 
Similarly, Ifnar1-/- CD4+ T-cells exhibited significantly higher ICOS expression levels than 
WT controls, early during PcAS infection (Figure 4.6B). These findings demonstrated that 
IFN-I signalling repressed early ICOS expression during blood-stage malaria.  
 
Figure 4.6. IFN-I signalling limits ICOS expression during blood-stage malaria. WT 
and Ifnar1
-/- 
mice (n=6) were infected with Py17XNL (A) or PcAS (B). (A) Proportions, numbers and 
ICOS expression levels of TCRβ+CD4+ICOS+ in naïve, WT and Ifnar1
-/-
mice, 6 days post-Py17XNL 
infection (B) Representative FACS plots, proportions, numbers and ICOS expression levels of 
TCRβ+CD4+ICOS+ cells in naïve, WT and Ifnar1
-/-
mice, 6 days post-PcAS infection. Data 
representative of 3 independent experiments. Mann-Whitney U test **P<0.01.  
 
To determine the functional outcome of this IFN-I mediated defect on ICOS expression, 
the effect of IFN-I signalling on the positioning of T-cells within B-cell areas in spleens of 
mice infected with PcAS was determined. Using confocal microscopy, higher densities of 
ICOS+ T-cells were observed at the T/B border in Ifnar1-/- mice compared to WT controls 
(Figure 4.7). In addition, similar, although more modest effects were observed within the B-
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cell follicles of these mice (Figure 4.7). Taken together, these data suggest that IFN-I 
signalling repressed ICOS expression, Tfh cell differentiation as well as their positioning 
adjacent to and within B-cell follicles.   
 
Figure 4.7. IFN-I signalling limits co-localisation of T-cells with B-cells in the spleen. 
WT and Ifnar1
-/- 
mice (n=6) were infected with PcAS. Representative distribution pattern and 
densities of ICOS expressing T-cells in splenic T-B borders and B-cell follicles of naïve, WT and 
Ifnar1
-/-
mice, 5 days post-PcAS infection. Each symbol represents one T-B border or follicle in the 
spleen. Data pooled from four T-B borders per mouse with n=2 for naïve and n=5 for WT and 
Ifnar1-/- mice. T-B border defined by region between CD3+ cells farthest into follicle (dotted white 
line, bottom) and B220+ cells farthest into the T-cell zone (dotted white line, top). Scale bar, 
100µM. Mann-Whitney U test *P<0.05; **P<0.01.  
 
4.2.4 IFNAR1-blockade boosts T- and B-cell responses 
To rule out possible developmental or immune homeostatic defects in Ifnar1-/- mice 
accounting for the phenomena described above, PcAS-infected WT mice were treated with 
an Ifnar1-blocking antibody [217, 238]. IFNAR1-blockade enhanced early ICOS expression 
on CD4+ T-cells (Figure 4.8A) and Tfh cell responses, though not their Bcl-6 expression 
(Figure 4.8B). Furthermore, IFNAR1-blockade boosted early plasmablast differentiation 
(Figure 4.8C) and GC B-cell formation (Figure 4.8D). Together, these data supported the 
hypothesis that IFNAR1-signalling regulated ICOS expression by CD4+ T-cells, limited Tfh 
differentiation and restricted splenic B-cell responses.    
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Figure 4.8. IFNAR1 blockade boosts Tfh formation and B-cell differentiation. WT mice 
(n=5) were treated with anti-Ifnar1 blocking antibody (a-Ifnar1) or control IgG prior to and during 
infection with PcAS. (A) Representative FACS plots, proportions, numbers and ICOS expression 
levels of splenic CD4+TCRβ+ICOS
+
 cells in naïve and infected mice, 6 and 7 p.i. (B) 
Representative FACS plots, proportions and numbers splenic of CD4+TCRβ+PD1
+
CXCR5
+ 
Tfh 
cells naïve and infected mice, 7 days p.i. and Bcl-6 expression in histograms of 
CD4+TCRβ+PD1+CXCR5+ (Tfh cells; red gate) and CD4+TCRβ+PD1-CXCR5- (non-Tfh cells; blue 
gate). (C and D) Respectively, show numbers of splenic plasmablasts and GC B cells in naïve and 
infected, 7 days p.i.. Data representative of two independent experiments. Statistics: Mann-
Whitney U test *P<0.05; **P<0.01  
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4.2.5 IFN-I signalling simultaneously limits Th1 and Tfh differentiation 
Elevated IFNg responses during blood-stage malaria have been associated with impaired 
humoral immune responses [191-193]. Since IFN-I-signalling has previously been 
associated with impaired Th1 responses during blood-stage malaria [217, 238], the effect 
of IFN-I on concurrent Th1 and Tfh responses was next examined. Ifnar1-/- mice exhibited 
increased Th1 responses compared to WT controls as expected [217], following 6 days of 
infection with PcAS (Figure 4.9A). Importantly, emerging Tfh responses at day 6 p.i. were 
also higher in these Ifnar1-/- mice compared to WT controls (Figure 4.9B). This indicated 
that IFN-I signalling had simultaneously limited Th1 and Tfh cell formation, rather than 
skewing CD4+ T-cell differentiation to either helper subset. Moreover, elevations in ICOS 
up-regulation amongst bulk CD4+ T cells in PcAS-infected Ifnar1-/- mice compared to WT 
controls was reflected in both the Th1 and Tfh compartments (Figure 4.9C). In addition, 
ICOS+ Tfh cell numbers were also regulated by IFN-I signalling during Py17XNL infection 
(Figure 4.9D). Of note, similar frequencies and absolute numbers of T-cells were detected 
in spleens of naïve WT and naïve Ifnar1-/- mice (data not shown). Collectively, these data 
suggested that IFN-I-signalling simultaneously repressed Th1 and Tfh responses, rather 
than favouring one response over the other.  
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Figure 4.9. IFN-I signalling simultaneously limits Th1 and Tfh differentiation. WT and 
Ifnar1
-/- 
mice (n=5-6) were infected with PcAS (A-C) or Py17XNL (D). Representative FACS plots, 
proportions and numbers of splenic (A) Th1 (gated as CD4+TCRβ+Tbet
+
IFNg
+
) cells and (B) 
CD4+TCRβ+PD1
+
CXCR5
+
Tfh cells, 6 days post infection (C) Numbers of ICOS+Th1 (gated as 
CD4+TCRβ+ICOS+Tbet
+
IFNg
+
) and ICOS+Tfh (gated as CD4+TCRβ+ICOS+PD1
+
CXCR5
+) cells, 6 
days post infection (D) Numbers of ICOS+Tfh cells (gated as CD4+TCRβ+ICOS+PD1
+
CXCR5
+), 16 
days post-Py17XNL infection. Data representative of two independent experiments. Statistics: 
Mann-Whitney U test *P<0.05; **P<0.01  
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4.2.6 IFN-I signalling suppresses T-cell activation and proliferation 
Given the simultaneous effect of IFNAR1-signalling on Th1 and Tfh differentiation, the 
general effect of IFNAR1-signalling on CD4+ T-cells was explored. At the peak of the T-
helper response during PcAS infection (day 8 p.i.), the proportion of CD4+ T-cells that were 
activated, via CD11a/CD49d co-expression (Figure 4.10A) was modestly higher in Ifnar1-/- 
mice compared to WT controls. Similarly, Py17XNL-infected WT mice treated with 
IFNAR1-blocking antibody also exhibited increased numbers of activated cells compared 
to mice treated with isotype control antibody, at day 6 post infection (Figure 4.10B). 
Interestingly, at day 6 p.i. during PcAS infection, the proportion of CD4+ T-cells that were 
proliferating, as assessed by Ki-67 staining (Figure 4.10C), was modestly higher in Ifnar1-/- 
mice compared to WT controls. Similar observations were also made in mice infected with 
Py17XNL (Figure 4.10D). Taken togther, these data suggested that IFN-I signalling limited 
early CD4+ T-cell activation and proliferation. 
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Figure 4.10. IFN-I signalling limits CD4+ T-cell activation and proliferation during 
PcAS and Py17XNL infection. (A&C) WT and Ifnar1-/- mice (n=6) were infected with PcAS. 
(B&D) WT mice (n=5) were treated with anti-Ifnar1 blocking antibody (a-Ifnar1) or control IgG prior 
to and during Py17XNL infection. (A) Representative FACS plots, proportions and numbers of 
splenic activated CD4+ T-cells (CD4+TCRβ+CD11a
+
CD49d
+
) 8 days p.i.. (B) Proportions and 
numbers of splenic activated CD4+ T-cells (CD4+TCRβ+CD11a
+
CD49d
+
) 6 days p.i.. (C) 
Representative FACS plots, proportions and numbers of proliferating CD4+ T-cells (CD4+TCRβ+Ki-
67
+
) 8 days p.i.. (D) Proportions and numbers of proliferating CD4+ T-cells (CD4+TCRβ+Ki-67
+
) 
cells 6 days p.i.. Data representative of two independent experiments. Statistics: Mann-Whitney U 
test, *P<0.05; **P<0.01.  
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More importantly, there were no substantial differences in cellularity of the spleen, or bulk 
CD4+ T-cell or B-cell numbers, in WT versus Ifnar1-/- mice during PcAS infection (Figure 
4.11A), Py17XNL infection (Figure 4.11B) or in un-infected mice (Figure 4.11C). Taken 
together, these data supported the idea that any increases in Th1 or Tfh cells observed 
above were not due to generalized increases in splenic cellularity, but instead were 
associated with specific regulation of CD4+ T-cell activation and proliferation.  
 
Figure 4.11. IFNAR1 deficient mice display normal splenic cellularity. (A) Absolute 
numbers of splenocytes, CD4+ T-cells and B-cells in WT naïve, and infected WT and Ifnar1
-/- 
mice, 
6 days (n=17-18, pooled from three independent experiments (n=5-6 per experiment) and 8 days 
(n=29, pooled from five independent experiments whereby n=5-6 per experiment) following 
infection with PcAS. (B) Absolute numbers of splenocytes, CD4+ T-cells and B-cells in WT naïve, 
and infected WT and Ifnar1
-/- 
mice, 16 days post infection with Py17XNL (n=17-18, pooled from 
three experiments whereby, n=5-6 mice experiment). (C) Total number of splenocytes, B-cells, GC 
B-cells and plasmablasts in un-infected WT and Ifnar1-/- mice (n=5), experiment performed once. 
Statistics: Mann-Whitney U test, *P<0.05.  
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4.2.7 IFN-I signalling proceeds via cDCs, but not B -cells or T-cells 
Next, cell types through which IFN-I signalling proceeded were explored, with unique focus 
on cDCs based on previously published data using lethal PbANKA [238]. Firstly, mixed 
bone marrow chimeric mice, which harboured equal proportions of WT and Ifnar1-/- splenic 
cDCs were generated (Figure 4.12A). These mice were infected with Py17XNL and 
expression of co-stimulatory molecules was assessed at the peak of the cDC response (at 
2 days p.i.) on splenic WT and Ifnar1-/- cDC subsets (Figure 4.12B). Up-regulation of CD86 
in particular, which was previously shown to be highly dependent on IFN-I signalling [238], 
was again substantially impaired in Ifnar1-/- CD8+ and CD8- cDC subsets compared to WT 
cDCs (Figure 4.12C). A similar pattern of expression was noted for PD-L1, while minimal 
expression of ICOSL was observed (Figure 4.12C). Intriguingly, IFN-I signalling exhibited 
differential effects on PD-L2 and CD40 expression on cDCs, with PD-L2 repressed by IFN-
I signalling in CD8- cDC subsets, and CD40 expression being mediated by IFN-I signalling 
in CD8+ cDCs (Figure 4.12C). To corroborate these findings, similar studies were 
conducted in chimeric mice infected with PcAS - these showed similar expression patterns 
of CD86, CD40 and ICOSL (data not shown). These data suggested that IFN-I signalling in 
splenic cDC subsets influenced their upregulation of co-stimulation molecules during non-
lethal blood-stage Plasmodium infection. 
 
To study the possibity of IFN-I signalling in B-cells, early plasmablast responses in 
WT:Ifnar1-/- mixed bone marrow chimeric mice were examined following PcAS infection. At 
day 7 p.i., there was no consistent increase in plasmablast formation by Ifnar1-/- cells 
compared to WT counterparts (Figure 4.12D), suggesting that IFN-I signalling in B-cells 
played no major role in regulating plasmablast differentiation. Notably, in these same mice 
equal proportions of WT and Ifnar1-/- CD4+ T cells upregulated ICOS and CXCR5 (Figure 
4.12E). This suggested that restriction of ICOS expression in emerging Tfh cells was not 
mediated by IFN-I signalling directed to CD4+ T-cells.  
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Figure 4.12. IFN-I signalling proceeds directly through CD11chi cDCs. 
(A) Schematic outline of experimental mixed bone marrow chimeric approach: 50:50 Ifnar1+/+
 
(CD45.1)/Ifnar1
-/- 
(CD45.2) mixed bone marrow chimeras (n=6) were generated and then infected 
with Py17XNL or PcAS. (B) Gating strategy for splenic Ifnar1+/+
 
and Ifnar1
-/- 
conventional CD8
+
 
(TCRb-B220-CD11c
hi
MHC-II
hi
CD8a
+
) and CD8
-
 (TCRb-B220-CD11c
hi
MHC-II
hi
Sirpa
+
CD8
-
) cDCs. 
(C) Surface expression of CD86, PD-L1, PD-L2, CD40 and ICOS-L on CD8+ and CD8- DCs, two 
days post-Py17XNL infection. (D-E) 50:50 Ifnar1+/+
 
(CD45.1)/Ifnar1
-/- 
(CD45.2) mixed bone marrow 
chimeras (n=5) were generated and then infected with PcAS. (D) Representative FACS plots and 
proportions of Ifnar1+/+ and Ifnar1-/- plasmablasts, seven days post infection (E) Representative 
FACS plots and proportions of splenic Ifnar1+/+ and Ifnar1-/- Tfh (CD4+TCRβ+ICOS+CXCR5+) cells, 
7 days post infection (experiment performed once). Levels in uninfected chimeras are denoted by 
open symbols. Experiments in A-D were done twice while E was done once. Statistics: Wilcoxon 
test, *P<0.05. 
  
Finally, the in vivo effect of IFN-I signalling in cDC on emerging humoral responses in the 
spleen was explored. CD11cCre+/-ifnar1f/f mice and CD11cCre-/-ifnar1f/f littermate controls 
were infected with Py17XNL, and splenic Tfh and GC B-cell differentiation assessed 6 
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days p.i.. IFN-I signalling in CD11chi cells (more likely cDCs) limited both Tfh (Figure 
4.13A) and early GC B-cell (Figure 4.13B) differentiation. Together, these observations 
strongly suggested that regulation of humoral immune responses by IFN-I signalling was 
mediated through cDCs, not B-cells or CD4+ T-cells.  
 
Figure 4.13. IFN-I signalling cDCs regulates Tfh and GC B-cell responses. CD11cCre+/-
ifnar1f/f mice and CD11cCre-/-ifnar1f/f littermate controls were infected with Py17XNL. (A) 
Representative FACS plots (gated on CD4+TCRβ+ live singlets), proportions and absolute numbers 
of splenic Tfh cells and (B) splenic GC B-cells (gated on B220+CD19+ live singlets) in CD11cCre+/-
ifnar1f/f mice and CD11cCre-/-ifnar1f/f littermate controls, on day 6 p.i.. Statistics: Mann-Whitney U 
test, *P<0.05; **P<0.01. 
 
4.2.8 IFN-I blockade improves humoral immunity partly via IL-6.  
Next, molecular mechanisms leading to improved humoral immunity after IFN-I blockade 
were investigated. Considering that IFN-I and IL-6 generally exhibited contrasting effects 
on humoral responses as highlighted above, the hypothesis that IFN-I signalling perhaps 
impaired humoral immunity to malaria by directly regulating some IL-6 dependent 
responses was examined. In these studies, PcAS-infected WT and IL-6-/- mice were 
treated with a-Ifnar1 or control IgG antibody throughout infection. Their splenic CD4+ T and 
B-cell responses examined at 8 days p.i. (Figure 4.14). IFN-I blockade augmented ICOS 
expression (Figure 4.14A), Tfh responses (Figure 4.14B), early GC B-cell responses 
(Figure 4.14C) and plasmablast responses (Figure 4.14D) in WT and IL-6-/- mice. 
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However, it was evident that optimal boosting of plasmablast responses via IFN-I blockade 
required IL-6 during PcAS infection (Figure 4.14D). More importantly, IFN-I blockade mildly 
improved parasite control during the resolution phase of primary PcAS infection in IL-6-/- 
mice (Figure 4.14E).  
 
Figure 4.14. IFNAR1 blockade boosts humoral immune responses, partly via IL-6. 
WT and IL-6-/- mice were treated with anti-Ifnar1 blocking antibody (a-Ifnar1) or control IgG prior to 
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and during infection with PcAS. Splenic T and B-cell responses were assessed 8 days p.i.. Data 
pooled from two independent experiments (with n=6 in each experiment). Proportions and 
numbers of splenic (A) CD4+TCRβ+ICOS+ T-cells, (B) CD4+TCRβ+PD1+CXCR5+ Tfh cells, (C) GC 
B-cells (B220+CD19+GL-7+Fas+) and (D) plasmablasts (B220+CD19+IgDloCD138hi) in naïve and 
infected mice. (E) A time course analysis of parasitemias in IL-6-/- mice treated with a-Ifnar1 or 
control IgG. Statistics: One-way ANOVA, Tukey’s test for multiple comparisons in (A-D), Mann-
Whitney U test in (E), *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 
 
However, during Py17XNL infection neither boosting of ICOS expression on T-cells nor 
plasmablast responses required IL-6 (Figure 4.15). Taken together, these data indicated 
that IFN-I blockade boosted humoral immunity with only a modest requirement for IL-6, 
specifically for improved plasmablast responses.   
 
Figure 4.15. IFN-I blockade restores optimal T and B-cell function in IL-6 deficient 
mice. WT and IL-6-/- mice (n=6) were treated with anti-Ifnar1 blocking antibody (a-Ifnar1) or 
control IgG prior to and during infection with Py17XNL. Proportions and numbers of splenic (A) 
CD4+TCRβ+ICOS+ T-cells and (B) plasmablasts (B220+CD19+IgDloCD138hi) in naïve and infected 
mice, 6 days p.i.. Data representative of one experiment. Statistics: One-way ANOVA, Tukey’s test 
for multiple comparisons, *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 
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4.2.9 IFN-I blockade improves humoral immunity via enhanced ICOS-signalling.  
Given that IFN-I blockade enhanced ICOS levels on CD4+ T-cells, the next set of studies 
investigated whether ICOS-signalling enhanced humoral immunity in Ifnar1-/- mice. These 
studies adopted a recent approach in which a titrated dose of a-ICOSL blocking antibody 
was employed to lower, but not abolish ICOS-signalling in mice exhibiting higher than WT 
levels of ICOS [167]. To undertake this, PcAS-infected Ifnar1-/- and WT mice were treated 
with a moderate dose of α-ICOSL blocking antibody (100µg) and at day 8 p.i. assessed 
antibody production and parasitemia. There was no significant effect on parasite-specific 
IgM production or parasitemias in WT mice (Figures 4.16A-B), but some impairment of 
emerging parasite-specific IgG responses at this early time-point (Figure 4.16A). In 
contrast, ICOS-blockade in Ifnar1-/- mice abrogated any improvements in parasite-specific 
IgM or IgG production (Figure 4.16A), and importantly, impaired parasite control compared 
to control-treated Ifnar1-/- mice (Figure 4.16B). Consistent with these observations, 
enhanced Tfh cell and GC B-cell formation in Ifnar1-/- mice was strongly dependent on 
ICOS-signalling (Figures 4.16C-D). Taken together, these data support a model in which 
IFN-I signalling limited humoral immune responses and parasite control by regulating 
ICOS-signalling. 
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Figure 4.16. IFN-I signaling blockade boosts humoral immunity via enhanced ICOS-
signalling. WT and Ifnar1-/- mice (n=6 per group), infected with PcAS, and treated with a-ICOSL 
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(100ug) or control IgG2a throughout infection (days 0, 2, 4 and 6 p.i.), were assessed on day 8 p.i. 
for (A) parasite-specific IgM and IgG, as well as (B) parasitemias. (C&D) WT and Ifnar1-/- mice 
(n=6 per group) were infected with PcAS and treated with a-ICOSL or control IgG2a as in (A&B). 
(C) Representative FACS plots (gated on CD4+TCRβ+ live singlets), proportions and numbers of 
splenic Tfh cells, and (D) proportions and numbers of GC B-cells (gated on B220+CD19+ live 
singlets) on day 6 p.i.. Statistics: One-way ANOVA, Tukey’s test for multiple comparisons (data 
representative of three independent experiments), *P<0.05; **P<0.01; ****P<0.0001. 
 
4.3 Discussion 
These studies have provided the first form of evidence that the onset of protective humoral 
immunity to Plasmodium can be restricted by an innate cytokine signalling pathway, in this 
case IFN-I-signalling via IFNAR1. This observation was evident in two models of non-lethal 
blood-stage malaria. Release from IFN-I-mediated suppression enhanced humoral 
immune responses and parasite control in a manner largely dependent upon ICOS-
signalling.    
 
Although parasite-specific antibodies can control blood-stage Plasmodium parasite 
numbers in vivo, protective humoral immunity can take months or years to develop in 
humans. Explanations for this have focused on parasite mechanisms such as antigenic 
variation, rather than possible sub-optimal host immune responses. IFN-I responses have 
been well documented in malaria patients [232, 285, 336]. Polymorphisms in the Ifnar1 
gene have been associated with reduced risk of severe malaria [285, 336]. Although the 
location of polymorphisms did not indicate the direction of their effect on IFN-I-signalling, 
the implication was that changes in IFN-I-signalling could mediate improved parasite 
control. Indeed, recent work using C57BL/6J mice suggested that IFN-I signalling via IRF7 
but not IRF3 limited parasite control during PcAS infection [217, 238], although other 
recent work, using a different route of infection [340] or a different genetic background 
[341] suggested more modest roles for IFN-I-signalling in mice. These different outcomes 
suggest possible context-dependent effects for IFN-I-signalling during PcAS infection.  
 
The observation that IFN-I signalling restricts the onset of humoral immunity to malaria is 
the first description of cytokine-mediated suppression of Tfh, GC B-cell and plasmablast 
responses during parasitic infection. More generally, while the vast majority of viral and 
experimental immunization studies highlight a positive role for IFN-I-signalling in driving 
humoral immunity, the current dataset emphasizes that depending on the experimental 
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context, IFN-I-signalling can also limit humoral immune responses. Previous studies using 
a lethal model of malaria demonstrated that IFN-I signalling occurred via cDC, which 
resulted in potent suppression of Th1-immunity, and was associated with effects on PDL1, 
PDL2 and IL-10 expression by cDC subsets [238]. However, the lethal model was not 
suitable for studying humoral immunity, since mice became moribund within the first week 
of infection. Using non-lethal models, the current study similarly revealed that IFN-I 
signalling more likely proceeded directly via cDCs. Given that cDCs are critical for early 
Tfh differentiation and initiation of humoral immune responses [53, 107, 108], this study 
suggests that IFN-I signalling within splenic cDC impairs CD4+ T-cell proliferation, ICOS 
expression, and Th1 and Tfh responses. Cellular sources of IFN-I mediating these defects 
were not identified in the current study. However, previous studies in models of blood-
stage malaria [342] and other experimental systems suggested that pDCs were major 
sources of these cytokines [183, 184, 343, 344]. Thus, future experiments aiming to 
determine the role of pDC-derived IFN-I on humoral immunity to blood stage malaria are 
warranted.  
 
It was recently reported during LCMV infection that IFN-I promoted Th1 responses, which 
then suppressed Tfh and GC B-cell responses via IFNg [114]. A more recent report using a 
mouse model of malaria demonstrated that therapeutic release from PD-1 exhaustion, 
coupled with stimulation via OX40 dramatically increased IFNg production by Th1 cells, 
which destabilized Bcl-6 in established Tfh cells and resulted in defective humoral immune 
responses [193]. Elsewhere, circulating ‘Th1-like’ Tfh cells were associated with impaired 
humoral responses in children living in malaria endemic areas [191]. Most recently, Ryg-
Cornejo et al., implicated a combined effect of IFNg and TNF in driving sub-optimal 
humoral responses during severe malaria infections in mice [192]. Together, these data 
suggest that Th1 responses might interfere with Tfh responses. However, in the current 
studies, release from IFN-I suppression triggered a concurrent increase in both Th1 and 
Tfh responses. This apparent discrepancy between these current findings and other recent 
studies could be explained by the differential kinetics of the elevated Th1 responses in 
these respective studies. For instance, OX40- and PD1-targeted therapy was initiated from 
the second week of infection, a period of time after which Th1/Tfh priming would likely 
have occurred [193]. In the current studies, elevated Th1 responses, as a result of Ifnar1-
deficiency, occurred relatively transiently within the first week of infection. Therefore, it is 
possible that elevated Th1 responses in Ifnar1-deficient mice did not destabilize Tfh 
responses because they occurred early and were not prolonged. Of further note, Lee and 
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colleagues previously reported an accumulation of pathogenic Tfh cells, GC B-cells and 
elevated the production of autoantibodies in models of SLE [194]. In their studies, 
increased IFNgR signalling led to overexpression in Tfh cells and their precursors. 
 
Numerous studies across a range of experimental systems have established a pivotal role 
for ICOS signalling in CD4+ T-cells in mediating T-cell dependent humoral immunity, via 
effects on Tfh generation, maintenance and trafficking [53, 115, 157, 158]. The importance 
of ICOS-signalling is further highlighted by the existence of multiple layers of regulation 
within the T-cell for limiting its expression, for example via Roquin 1, Roquin 2 and 
microRNA146a [165-167]. To date, however, evidence of T-cell extrinsic mechanisms for 
controlling ICOS levels on CD4+ T-cells has been limited. The current dataset reveals the 
existence of a cytokine-signalling pathway, mediated by IFN-I, which serves to limit the 
level of ICOS on CD4+ T-cells. Currently, the mechanism by which ICOS levels are 
modulated by IFN-I-signalling during blood-stage malaria is unclear, but could theoretically 
involve Roquin1, Roquin 2 or microRNA146a.  
 
Although substantial early ICOS expression by activated CD4+ T-cells was evident in these 
studies, there was minimal upregulation of ICOSL on cDC (Figure 4.12C). This might 
suggest that boosting ICOS expression by CD4+ T-cells did not encourage further 
interaction with splenic cDC. Instead, given that IFNAR1-deficiency increased the 
frequency of ICOS+ T-cells close to and within B-cell follicles, which were themselves 
essential for supporting Tfh responses, and since ICOSL-expressing B-cells are located at 
the periphery of B-cell follicles [116], these observations suggest that IFN-I limits ICOS-
mediated positioning of emerging Tfh cells adjacent to and within B-cell follicles during 
Plasmodium infection. However, further experiments will be required to examine the effect 
of ICOS-signalling on CD4+ T-cell trafficking in the spleen during experimental malaria.  
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Figure 4.17. Schematic view of a proposed model of type I interferon-mediated 
regulation of humoral immune responses during blood-stage malaria. (A) During 
blood-stage malaria, parasitised red blood cells are internalised by myeloid and/or phagocytic cells, 
secreting type I interferons (IFN-I). (B) This process activates IFN-I signalling, via IFNAR1 in cDCs, 
impairing optimal DC function. (C) These defects regulate Tfh formation and function, in particular 
via restrained ICOS signalling, which subsequently restricts plasmablast differentiation, GC B-cell 
generation, immunoglobulin class switching and the production of anti-parasitic antibodies. (D) 
Notably, IFN-I signalling via cDCs also restrains Th1 responses. (E) Together, these effects 
contribute to impaired parasite control.  
 
In the current study, IFN-I-deficiency accelerated early production of parasite-specific IgM 
and IgG. If such mechanisms could be induced in humans, this might improve control of 
parasite numbers and prevention of clinical malaria. However, the duration of this effect 
would require further scrutiny, since in the mouse models, antibody levels normalized 
between Ifnar1-/- and WT mice by the seventh week of infection. Furthermore, whether 
acceleration in early antibody production would increase the rate of acquisition of immunity 
to clinical malaria is also unclear, particularly given the phenomenon of antigenic variation. 
However, if subsequent infections were sufficiently similar from an antigenic perspective to 
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previously encountered parasites, short-term elevations in parasite-specific antibodies 
could be beneficial. Finally, although these studies focused on examining the magnitude of 
parasite-specific antibody responses within a given antibody sub-class, neither antibody 
affinity nor avidity was examined. Therefore, further experimentation will be needed to 
determine whether beneficial changes in antibody affinity and avidity can be brought about 
via cytokine modulation.  
 
During the preparation of this report, four other studies complemented the current findings 
[345-348]. Among these, Zander and colleagues demonstrated that IFN-I limited 
accumulation of Tfh cells, thereby impairing humoral immune responses in Py17XNL-
infected mice [346]. Mechanistically, these defects associated with IFN-I induced Tr1 
formation and the production of both IL-10 and IFNg, via Blimp1 and T-bet signalling. 
Collectively, these data and those from the current study suggest that IFN-I signalling most 
likely acts as a general immune-suppressive mechanism during blood-stage infection, 
which limits the onset of cellular and humoral immunity. These findings were supported by 
similar observations in mice, during LCMV infection [345, 347, 348].  
 
In summary, studies in this chapter have demonstrated that early cytokine-signalling 
during Plasmodium infection restricts the generation of CD4+ T-cell-dependent antibody 
responses (Figure 4.17). This work suggests that antibody-mediated immunity to malaria 
might be improved by targeting cytokine-signalling pathways, particularly in the context of 
natural infection. 
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5 CHAPTER FIVE: ROLE OF THE MONONUCLEAR PHAGOCYTE 
SYSTEM IN EXPERIMENTAL MALARIA 
 
5.1 Introduction 
 
The mononuclear phagocyte system (MPS) is crucial for the induction of immunity and 
maintenance of tolerance. This system is comprised of DCs, monocytes and 
macrophages. These cells are closely related, sharing many phenotypic features and to a 
large extent a common developmental origin [290, 291, 349, 350]. Murine DCs and 
macrophages arise from the same hematopoietic progenitor, known as the macrophage-
DC progenitor (MDP) [291]. However, they either diverge to a common DC progenitor 
(CDP), which gives rise to DCs or monocytes [349]. The formation of DCs is Flt3L-
dependent while monocytes are CSF1-dependent [351, 352]. DC progenitor cells develop 
into pDCs or preDCs, which migrate from the bone marrow into lymphoid and non-
lymphoid organs and differentiate into cDCs [349]. In contrast, monocytes leave the bone 
marrow, circulating in blood and through tissues from where they are activated and 
differentiate into several cell types, including some macrophage populations [291, 351].     
 
Despite a closely related lineage, monocytes, DCs and macrophages in lymphoid tissues 
can be distinguished based on their differential expression of cell surface molecules such 
as MHCII, CD11c, CD11b, F4/80, Ly6c and CD68 [290, 291, 351]. For instance, cDCs 
express high levels of CD11c and MHC-II but lack F4/80, which is highly expressed on 
macrophages. On the other hand, monocytes express high levels of CD11b and Ly6c but 
lack F4/80. The expression of these molecules, in particular on cells circulating in blood, 
significantly changes during inflammatory conditions. For instance, monocytes may 
acquire DC-like features by upregulating MHC-II and expressing high levels of CD11c 
[290, 353]. Although the function of DCs in immunity has been extensively explored, that of 
macrophages and monocytes is not well defined. This is partly due to the lack of 
appropriate tools and reagents to examine these cell types in vivo. For instance, CCR2 
deficient mice used to study monocytes in-vivo may be confounded by the fact that CCR2 
is also expressed on some cDC subsets, activated CD4+ T-cells and NK cells [353-355]. 
Therefore, new tools are needed in order to better understand the individual roles of 
monocytes and macrophages during infection. 
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Various studies have explored the role of the MPS during blood-stage malaria. From such 
studies, a requirement for DCs in priming T-cells and initiating anti-parasitic immunity was 
established [237, 356]. However, signalling through DCs has also been associated with 
influencing pathology during severe malaria [238, 357]. In mice infected with PcAS, 
recruitment of inflammatory monocytes associated with improved parasite control [358]. 
Roles for splenic macrophages in parasite clearance and regulating immune responses 
during blood-stage malaria have also been suggested [359]. Red pulp macrophages are 
associated with the removal of infected erythrocytes and cellular debris during infection 
[360]. Studies in splenectomised mice and humans reported a reduction in the capacity to 
clear infected red blood cells and diminished immune responses during blood-stage 
malaria, suggesting vital roles for the spleen in driving these processes [361, 362]. Indeed, 
maintenance of splenic architecture associated with improved clearance of infected RBCs 
during infection [192]. Tissue resident macrophages, in particular, red pulp macrophages, 
marginal zone macrophages (MZM) and marginal zone metallophilic macrophages (MMM) 
within the spleen are partly associated with the clearance of infected RBCs during malaria 
[359]. More recently, Gupta and colleagues reported an important role for tissue resident 
CD169+ macrophages in controlling PbANKA infection in mice [363]. Despite of this body 
of work, the role of the MPS, in particular, macrophages and monocytes, during blood-
stage malaria is not well understood. This study examined an in vivo genetic approach for 
depleting monocytes and macrophages during experimental severe blood-stage malaria. 
Considering that effects of monocyte and macrophage depletion on parasite control and 
pathology were key goals of these studies, the lethal PbANKA model was employed in 
these studies.  
 
5.2 Results 
 
5.2.1 The MPS modulates parasite control during severe blood-stage malaria 
It is believed that the spleen is a vital organ for clearing blood-borne pathogens such as 
Plasmodium parasites and Plasmodium-infected RBCs. It harbours different populations of 
MPS cells, which may be important for parasite clearance. To examine the role of the 
spleen during blood-stage malaria, splenectomised Rag1-/- mice and sham operated Rag1-
/- mice were infected with PbANKA and monitored for changes in parasitemia. 
Interestingly, splenectomised mice exhibited reduced parasitemia in their peripheral blood 
compared to sham operated mice (Figure 5.1A), early during infection. These observations 
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suggested that contrary to expectation, certain elements within the spleen supported early 
parasite growth during PbANKA infection.  
 
Considering that the spleen is a major site for MPS cells, the impact of MPS cell ablation 
on early parasite growth, during PbANKA, was next investigated. To undertake this, 
C57BL/6 WT mice were treated with liposomes containing the cytotoxic drug, clodronate 
prior to infection with PbANKA. Clodronate liposomes are internalised by MPS cells in 
vivo, these cells undergo apoptosis and thus are functionally depleted. Mice treated with 
clodronate liposomes displayed significantly reduced parasitemia compared to those 
treated with control PBS liposomes (Figure 5.1B), suggesting MPS cells promoted parasite 
growth during infection. Similarly, clodronate-treated Rag1-/- mice exhibited significantly 
lower parasitemia compared to control mice (Figure 5.1A). Together, these data suggested 
an unexpected role for the MPS, in restricting early parasite control during blood-stage 
malaria.  
 
Figure 5.1. Effect of MPS depletion on parasite control during PbANKA infection. (A) 
C57BL/6 Rag1-/- mice (n=5) were either treated with clodoronate liposomes or splenectomized 
before infection with PbANKA. Data shows a time course analysis of parasitemia in Rag1-/- control, 
clodronate-treated and splenectomised mice. (B) C57BL/6 mice (n=5) were treated with 
clodoronate liposomes or PBS loaded liposomes three days prior to infection with PbANKA. Data 
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shows parasitemia in PBS and clodronate treated mice at day four post infection. Experiments 
were done once. Statistics: Mann-Whitney U test, *P<0.05, **P<0.00 and #P<0.05 (Rag sham 
versus splenectomized mice). 
 
5.2.2 Generation and validation of the lysMCrexiDTR mouse system  
Treating mice with clodoronate liposomes depletes all splenic phagocytic cells and DCs, 
making it difficult to delineate roles of individual MPS cells using this approach. Given this 
caveat, another MPS cell depletion approach was required to further examine roles for the 
MPS during blood-stage malaria. For these studies, a lysMCrexiDTR mouse, (herein known 
as LDTR mouse) was generated, by crossing transgenic C57BL/6 mice (LysmCre), which 
express Cre recombinase under the control of lysM, with transgenic C57BL/6 mice (iDTR), 
that carry a human diphtheria toxin receptor (DTR), preceded by a loxP-flanked 
transcriptional Stop element, inserted within the ROSA26 locus. In these mice, Cre-
mediated deletion of the STOP cassette allows expression of a functional DTR in myeloid 
cells, in particular, macrophages, monocytes and neutrophils. Thus, application of DT 
induces DTR-driven ablation of such cells.  
 
In order to examine functional ablation of myeloid cells in the LDTR system, C57BL/6 mice 
and LDTR mice were treated with either 8ng/g or 20ng/g of DT or control saline. Cells in 
the peritoneal wash, spleen, liver and blood, were examined by flow cytometry 24 hours 
later. An 8ng/g dose of DT had no effect on myeloid cells in both LDTR and C57BL/6 mice 
(data not shown). However application of 20ng/g of DT to each mouse abrogated 
peritoneal macrophages (Figure 5.2A), significantly depleted liver kupffer cells (Figure 
5.2B) and partially reduced the proportions and numbers of splenic macrophages (Figure 
5.2C) in LDTR mice treated with DT compared to saline-treated control mice. However, the 
same dose of DT had no effect on macrophages in C57BL/6 mice (data not shown). Lower 
levels of F4/80 staining were detected on splenic cells compared to cells in the peritoneal 
wash and liver. Therefore, immunofluorescence microscopy, (described in section 5.2.4 
below) was used as additional technique to examine the level of depletion of splenic 
macrophages. Nonetheless, these observations collectively suggested that DT treatment 
depleted tissue resident macrophages in the LDTR mouse system. 
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Figure 5.2. Depletion of macrophages in LDTR mice. LDTR mice were pre-treated with DT 
(n=6) or saline (n=5). Macrophages in the peritoneum, liver and spleen were examined 24h after 
DT injection. (A) Representative FACS plots, proportions of peritoneal macrophages (gated on 
CD11b+F4/80hi live singlets), (B&C) Representative FACS plots, proportions and numbers of (B) 
Kuppfer cells (gated on B220
lo
TCRb
lo
CD11b+F4/80hi live singlets) and (C) splenic macrophages 
(gated on B220
lo
TCRb
lo
CD11b+F4/80hi live singlets) of saline and DT treated LDTR mice. Data 
representative of three independent experiments. Statistics: Mann-Whitney U test, **P<0.01. 
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To determine the effect of DT treatment on other myeloid cell populations, DC, neutrophil 
and monocyte populations in the liver, spleen and blood from both LDTR mice treated with 
DT or saline were next examined. Notably, DT treatment had no effect on DCs in the liver 
or spleen (Figures 5.3A-B).   
 
Figure 5.3. Effect of DT treatment on DCs and neutrophils in LDTR mice. LDTR mice 
were pre-treated with DT (n=6) or saline (n=5). DCs and neutophils in the spleens and livers were 
examined 24h after DT injection. (A-C) Representative FACS plots, proportions and numbers of: 
(A) splenic conventional DCs (gated on B220
lo
TCRb
lo
CD11chiMHC-II+ live singlets), (B) DCs in the 
livers (gated on B220
lo
TCRb
lo
CD11chiMHC-II+ live singlets) and (C) neutrophils in the spleens 
(gated on B220
lo
TCRb
lo
CD11bhiLy6G+ live singlets) of saline and DT treated LDTR mice. Data 
representative of three independent experiments for A and B and two for C. 
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Similarly, DT treatment had no effect on neutrophils in the spleen (Figure 5.3C), liver (data 
not shown) and blood (data not shown). In contrast, the proportions and numbers of 
monocytes were significantly reduced in spleens (Figure 5.4A), livers (Figure 5.4B), and 
blood (Figure 5.4C) of LDTR DT-treated mice compared to saline-treated control mice. 
However, this effect was short-lived (lasting 24 hours), given that monocytes resurfaced in 
blood of DT-treated mice 48hours post DT treatment (Figure 5.4D). Indeed, frequencies of 
monocytes remained higher in the blood of DT-treated mice compared to saline-treated 
control mice for the next four days post initial DT treatment (Figure 5.4D). These 
observations suggested that DT treatment transiently depleted monocytes but had no 
effect on DCs and neutrophils of the LDTR system.  
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Figure 5.4. Depletion of monocytes in LDTR mice. LDTR mice were pre-treated with DT 
(n=6) or saline (n=5). Monocytes in the spleen, liver and whole blood were examined 24h following 
DT injection. Data representative of three independent experiments. (A-C) Representative FACS 
plots, proportions and numbers of monocytes in: (A) spleens (B220
lo
TCRb
lo
CD11bhiLy6c+ live 
singlets), (B) livers (gated on B220
lo
TCRb
lo
CD11bhiLy6c+ live singlets) and (C) blood of (gated on 
B220
lo
TCRb
lo
CD11bhiLy6c+ live singlets) in saline and DT treated LDTR mice. (D) Shows a time 
course analysis of monocytes in blood of DT and saline treated mice following a single DT 
injection. Statistics: Mann-Whitney U test, *P<0.05, **P<0.01. 
 
5.2.3 Kinetics of myeloid cells in LDTR mice following DT treatment 
Having observed the repopulation of monocytes in blood of LDTR mice, 48 hours post DT 
treatment, the efficacy of DT treatment on other myeloid cells, in particular, tissue resident 
macrophages and monocytes in LDTR mice was next examined. In the same experiments, 
the effect of blood-stage Plasmodium infection on monocytes and macrophages was also 
examined. In these studies, LDTR mice were treated with 20ng/g DT, one day prior to 
infection with PbANKA infected red blood cells. The proportions and numbers of 
monocytes and macrophages in the blood, peritoneal cavity (macrophages only), liver and 
spleen were then determined for the next 3 days following DT treatment. Peritoneal 
macrophages were completely absent in DT-treated mice throughout the three days of 
assessment (Figure 5.5A). In addition, the 50% reduction in splenic and liver macrophages 
observed 24 hours post DT treatment was still evident for the next 2 days (Figures 5.5B-
C). Consistent with earlier observations, DT treatment had no effect on DCs (Figures 5.5D-
E) and neutrophils (data not shown) in the spleen and liver. In addition, although DT 
treatment significantly reduced monocytes in blood, spleen and liver within the first 24 
hours (Figure 5.4), these cells resurfaced in these tissues and blood 48 hours post DT 
treatment (Figures 5.5F-H). Together, these data further suggested that DT treatment 
transiently depleted macrophages and monocytes in the LDTR mice system. Nonetheless, 
more repeat experiments are recommended to further verify these phenotypes. 
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Figure 5.5. Kinetics of macrophages, DCs and monocytes in LDTR mice. LDTR mice 
were pre-treated with DT (n=5) or saline (n=5). A time course analysis of macrophages, DCs and 
monocytes was conducted 24h, 48hr and 72hrs following DT injection. (A-C) Show the kinetics of 
macrophages in (A) peritoneum (gated on CD11b+F4/80hi live singlets), (B) spleens (gated on 
B220
lo
TCRb
lo
CD11b+F4/80hi live singlets) and (C) livers (gated on B220
lo
TCRb
lo
CD11b+F4/80hi live 
singlets) of saline and DT treated LDTR mice. (D-E) Represent the kinetics of DCs (gated on 
B220
lo
TCRb
lo
CD11chiMHC-II+ live singlets) in (D) spleens and (E) livers of saline and DT treated 
mice. (F-H) represents a time course analysis of monocytes (gated on B220
lo
TCRb
lo
CD11bhiLy6c+ 
live singlets) in blood (F), spleens (G) and livers (H) of DT and saline treated mice. Experiments 
were done once. Statistics: Mann-Whitney U test, *P<0.05, **P<0.01. 
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5.2.4 Histological analysis of splenic macrophages in LDTR mice 
Considering that weaker levels of F4/80 staining were detected by flow cytometry in the 
spleen compared to peritoneal wash and liver (as highlighted in section 1.2.2 above), the 
effect of DT treatment on specific macrophage populations was next examined by 
immunofluorescence. In particular, marginal zone macrophages (MZM), marginal zone 
metallophilic macrophages (MMM) and red pulp macrophages, in the spleens of LDTR 
mice were assessed. To undertake this, LDTR mice were infected with PcAS and treated 
with 20ng/g of DT or saline at three days post infection. A day later, splenic tissues were 
harvested and prepared for immunohistological analysis. Splenic tissues were cut into 
sections and examined by confocal microscopy using antibodies specific for red pulp 
(CD68+ or F4/80+), MZM (SIGNR1+) and MMM (CD169+) macrophages. Densities of red 
pulp macrophages were substantially reduced in sections of LDTR mice treated with DT 
compared to saline-treated control mice (Figures 5.6A-B). However, similar densities of 
MZM and MMM were observed in sections from DT and saline treated mice (Figures 5.6C-
D). These data suggested that DT treatment depleted splenic red pulp macrophages but 
had no effect on MZM and MMM populations.  
 
Figure 5.6. Depletion of macrophages in LDTR mice.  LDTR mice were pre-treated with 
DT (n=6) or saline (n=6) prior to their infection with PcAS. (A) Representative micrographs and 
densities of splenic CD68+ red pulp (green) macrophages of saline and DT-treated LDTR mice. (B) 
Densities of F4/80+ macrophages in the spleens of saline and DT-treated LDTR mice. (C) 
Representative micrographs of SIGNR1+ (green), marginal zone macrophages in spleens of saline 
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and DT-treated LDTR mice. (D) Densities of MOMA-1+ macrophages in the spleens of saline and 
DT-treated LDTR mice. Each data point represents the average density of cells from four individual 
follicles enumerated in a spleen. Statistics: Mann-Whitney U test, **P<0.01. 
 
5.2.5 Role of macrophages and monocytes on parasite control and pathology  
The effect of myeloid cell depletion in the LDTR system on the course of PbANKA infection 
was examined. To undertake this, LDTR mice were infected with PbANKA and then 
treated with DT or saline. They were then examined daily for changes in parasitemia, 
symptoms of experimental cerebral malaria (ECM) and survival. Parasite growth (between 
days 4-8 post infection) in blood of DT-treated mice was significantly reduced compared to 
saline-treated mice (Figure 5.7A). This difference in parasitemia peripheral blood could 
have been due to increased parasite sequestration in tissues of DT than saline treated 
mice. To test this, a whole body imaging analytical approach (IVIS spectrum in vivo 
imaging system) was used to determine the whole body parasite burden in DT and saline 
treated mice (Figure 5.7B). A trend in lower parasite densities was observed in DT treated 
mice compared to saline treated controls (Figure 5.7B), even though this quantification 
technique may have missed out on schizont stages in both groups of mice due to the use 
of this specific PbANKA-GFP model. Nonetheless, this observation suggested that the 
early reduction in parasitemia detected in peripheral blood of DT-treated mice was 
probably not due to sequestration of parasites in tissues of these mice. DT-treated mice 
were completely protected against ECM symptoms, unlike mice treated with saline, which 
eventually succumbed to infection (Figures 5.7C-D). The protection in the DT-treated mice 
associated with reduced levels of IFNg and MCP-1 in sera of these mice compared to 
saline-treated mice (Figure 5.7E). However, TNF levels were unaffected by the DT 
treatment. Together, these data suggested that macrophages and/or monocytes promoted 
parasite growth and pathology during severe blood-stage malaria.  
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Figure 5.7. Macrophages and monocytes regulate parasite control and pathology 
during severe blood-stage malaria. LDTR mice were pre-treated with DT (n=6) or saline 
(n=6) prior to infection with PbANKA. (A) A time course analysis of parasitemia in saline and DT 
treated mice LDTR mice during PbANKA infection. (B) Whole body parasite burden in saline and 
DT treated LDTR mice, 7 days post PbANKA infection. (C) ECM scores and (D) survival curves of 
saline and DT treated LDTR mice, infected with PbANKA.(E) Serum IFNg, MCP-1 and TNF levels 
in saline and DT LDTR mice, 4 days post PbANKA infection. 
 
5.3 Discussion 
Considering its functions in inducing immunity and maintaining tolerance, the MPS 
remains a fundamental immunological research area. Studies have suggested various 
physiological and pathophysiological roles of the MPS in experimental models. However, 
its specific role during Plasmodium infections remains unclear. The present study 
employed a variety of in vivo cell depletion strategies to examine the role of the MPS in 
mice infected with models of blood-stage malaria. Contrary to expectation, studies 
conducted in splenectomised mice suggested that the spleen was non-essential for early 
parasite control during lethal blood-stage malaria. This observation was corroborated by 
observations in mice lacking T and B-cells, treated with clodronate liposomes. Moreover, 
induced depletion of macrophages and/or monocytes, using a transgenic system, 
suggested that these cells most likely promoted parasite growth during early PbANKA 
infection and the development of ECM.  
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Splenic myeloid cells, such as monocytes, macrophages and DCs are important in both 
innate and adaptive immunity against various pathogens. However, their individual roles in 
immunity remain unclear due to their overlapping phenotypic features and lack of specific 
genetic tools. Genetic depletion of CCR2 has been used to study the function of 
monocytes in vivo [291]. Nonetheless, degree of confidence for interpretation of findings in 
this system is impacted by some of its caveats. For instance, the absence of CCR2 
prevents monocyte recruitment into peripheral tissues but facilitates their accumulation in 
the bone marrow [364]. In addition, CCR2 is expressed on NK cells, T-cells, activated Th1 
cells and CD103+ DCs [353-355]. Macrophages and monocytes may be targeted through 
genetic deletion of Csf1r and Csf1 [290, 365, 366]. However, mice with deficiencies in 
these molecules display severe skeletal abnormalities, infertility, and osteoporosis, making 
it difficult to interpret findings from such systems [366]. Alternatively, less specific 
approaches such as treatment of mice with clodronate liposomes and use of anti-CSF1R 
blocking antibodies have been used to deplete macrophages and monocytes [365, 367]. 
Other studies have targeted the CX3CR1 gene to study monocytes and macrophages in 
vivo [351], however, NK cells and CD11b+ cells also express this gene [368]. 
 
In the present study, the observed reduction in parasitemia of splenectomized mice or 
those treated with clodronate liposomes suggested a surprising role for macrophages 
and/or monocytes in supporting parasite growth during lethal Plasmodium infection. These 
observations led to generation of the LDTR mouse system, characterized by a restricted 
expression of function DT receptor in myeloid cells of these mice. In this system, Cre 
recombinase under the control of lysM promoter, mediated expression of functional DT 
receptor on myeloid cells. LysM-driven Cre recombinase exocises a loxP-flanked 
transcriptional STOP cassette in front of the DTR open reading frame, allowing expression 
of a DT-sensitive DTR in the myeloid cell lineage of the LDTR mouse.  
 
A variety of DT receptor-based systems have previously been used to target different 
myeloid cells [353, 369, 370]. The present study established functional expression of an 
inducible DT receptor on tissue resident macrophages and monocytes of LDTR mice, 
making such cells susceptible to DT treatment. Although DT treatment was significantly 
effective on macrophage populations in the peritoneal cavity and liver, it had mild effects 
on splenic macrophages in this transgenic system. Indeed, confocal microscopy revealed 
mild effects of DT treatment on splenic red pulp macrophages but none on MZM and MMM 
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macrophages in the LDTR system. However, monocytes were effectively depleted from all 
tissues and blood, though this effect was short lived. Application of DT had no effect on 
DC populations suggesting that DC function remains intact in this system. Importantly, 
although lysM is expressed on neutrophils, DT treatment had no effect on these cells in 
the LDTR system. This may suggest lower activity of the lysM promoter in neutrophils, as 
suggested elsewhere [371]. However, one notable caveat of this system was the 
enhanced repopulation of inflammatory monocytes in blood and tissues, 48 hours post DT 
treatment. Additional DT treatment had no effect on these newly recruited inflammatory 
monocytes. These monocytes may impact the function and/or responses of different cell 
populations in the LDTR system during infection. Despite this caveat, these collective data 
suggested that the LDTR system may be useful for transient depletion of monocytes.   
 
Tissue resident macrophages are believed to be important in clearing infected RBCs and 
cellular debris during Plasmodium infection [359]. However, data from these studies 
suggests a potential role of macrophages and/or monocytes in promoting early parasite 
control during the acute phase of infection. This suggestion was first supported by the 
reduced parasitemia in splenectomised mice, which lacked both T and B-cells and then in 
Rag1-/- mice, treated with clodronate liposomes. However, in the absence of the spleen, 
other organs such as the liver might compensate this loss, hence making it difficult to 
accurately interpret data from splenectomised mice. In addition, considering that 
clodronate liposomes disrupt the integrity of splenic tissues, it is not easy to examine 
macrophage function using this technique. To overcome these caveats, the LDTR system 
was used to examine the effect of myeloid cell depletion on the course of PbANKA 
infection. Application of DT significantly reduced the parasitemia in LDTR mice. Although 
the MPS may be dispensable for early parasite control, as suggested by the current 
dataset, it may be essential for effective control of parasites at later stages of infection, as 
reported elsewhere.  
 
The observations of enhanced protection against ECM symptoms and complete survival of 
LDTR mice post DT treatment were surprising and interesting. Note that flow cytometric 
analysis revealed a 50% reduction in proportions and numbers of macrophages in spleens 
of LDTR mice treated with DT. Confocal microscopy further suggested that DT treatment 
targeted CD68+F4/80+ red pulp macrophages but not SIGNR1+ MZM or CD169 (MOMA-
1)+ macrophages. A recent study in mice suggested that tissue resident CD169+ 
macrophages were important for parasite control and protection against severe pathology 
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during lethal blood-stage malaria [363].  Mice lacking these cells displayed elevated levels 
of sequestered parasites, increased hemozoin deposition and recruitment of inflammatory 
cells and enhanced immunopathology. However, an earlier study that employed MAFIA 
transgenic mice to deplete macrophages/granulocytes via a drug inducible suicide gene 
observed no role for these cells in ECM-associated pathology [372]. Discrepancies 
between the current studies in this thesis and these earlier reports may be attributed to 
differences in myeloid cell depletion strategies that were employed across these studies. 
Roles for MZM in clearance of blood-borne parasites, including protozoa infections have 
been suggested elsewhere [373]. Whether this is true for blood-stage malaria is yet to be 
examined. Considering that DT treatment affected red pulp macrophages in the LDTR 
system, but not MZM or MMM, the current study postulates a potential role for red pulp 
macrophages in facilitating the development of ECM symptoms and pathology during 
severe blood-stage malaria. These observations warrant further investigation.  
 
In summary, the current study examined the potential of the LDTR system for depletion of 
MPS cells during experimental blood-stage malaria. This approach was embarked on due 
to caveats in alternative MPS cell depletion techniques that had earlier been employed. 
Observations from this study suggested that LDTR system may be useful for transient 
depletion of monocytes and macrophages. This study also suggested that the MPS may 
limit optimal parasite control and facilitate development of ECM symptoms and pathology 
during experimental severe malaria. Further assessments aiming to validate these findings 
and understanding potential mechanisms through which the MPS influences pathology 
during severe malaria are recommended. 
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6 CHAPTER SIX: CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
Cellular and molecular mechanisms influencing parasite control during Plasmodium 
infection are not well defined and yet such factors could be manipulated to improve natural 
and vaccine-immunity. Using mouse models of blood-stage malaria, the current study 
examined factors influencing the development of anti-parasitic humoral immunity and 
explored roles for the MPS during infection. Studies in chapter three demonstrated that 
CD4+ T-cells and ICOS-signalling were critical components of antibody mediated parasite 
control during infection. Studies in the same chapter also described roles for IL-6 in 
supporting optimal CD4+ T-cell dependent humoral immune responses and parasite 
control during Plasmodium infection. In contrast, studies in chapter four described the 
repressive effects of IFN-I-mediated signals on several aspects of the humoral immune 
response, which associated with impaired parasite resolution. Studies in chapter five 
described a transgenic mouse system for depleting monocytes and macrophages. Using 
this system, unexpected roles for the MPS in restricting early parasite control and 
facilitating the development of symptoms of ECM during severe malaria were revealed. 
Collectively, these data have provided novel insights into the cellular and molecular 
mechanisms governing parasite control and pathology during Plasmodium infection.  
 
These current studies revealed crucial roles for CD4+ T-cells in driving parasite control and 
B-cell responses during infection. These findings are important because they suggest that 
effective anti-parasitic immunity to Plasmodium parasites may be difficult to generate in 
immunocompromised individuals such as HIV patients with reduced CD4+ T-cell numbers. 
Therefore, these findings suggest that harnessing CD4+ T-cell responses CD4+ T-cells 
may be an important strategy for improving immunity to Plasmodium parasites. This could 
be achieved through studies aiming to establish cellular and molecular mechanisms that 
could be manipulated to boost immune responses during infection. Considering that Tfh 
cells are critical for the establishment of long-lived antibody responses, studies focussing 
on identifying signals important for the formation and maintenance of this CD4+ T-cell 
subset may be useful and thus are recommended. Other T-helper cell subsets such as 
Th1, Treg and Tr1 cells also influence parasite control during infection. Understanding 
cellular and molecular mechanisms that regulate their formation and function may also be 
useful.  
 
 113 
 
Although parasite-specific antibodies can control blood-stage Plasmodium parasite 
numbers in vivo, protective humoral immunity can take months or years to develop in 
humans. Identification of factors that can be manipulated in order to boost these 
responses remains crucial. Studies in chapter three provide the first description on the role 
of ICOS signalling in the development antibody-mediated control of parasite numbers in 
mouse models of blood-stage malaria. These findings extend on findings in a recent report 
suggesting roles for ICOS signalling in sustaining humoral immune responses in mice 
infected with PcAS [280]. Furthermore, the current study complements previous work on 
co-stimulatory molecules such as PD1, LAG-3 and OX-40 [139, 193], which were 
suggested as potential targets for improving humoral immunity to malaria. A more recent 
transcriptomic study suggested substantial downregulation of the ICOS-ICOSL signalling 
pathway in humans with clinical malaria [374]. This observation and data from the current 
study suggests that enhancing ICOS signalling may serve as a potential target for 
improving immunity against Plasmodium infection. Future studies may consider exploring 
strategies for immunotherapeutic overexpression of roquin and/or its paralogues in CD4+ 
T-cells because these molecules have been implicated in regulating ICOS signalling [165, 
166]. The current study also established novel roles for IL-6 in supporting ICOS expression 
on CD4+ T-cells, (described in chapter three), and for IFN-I in repressing ICOS expression, 
(described in chapter four). Future studies focused on determining mechanisms through 
which IL-6 supported and IFN-I repressed ICOS-expression on CD4+ T-cells are 
recommended. In particular, it would be interesting to establish if the observed IL-6 and 
IFN-I effects on ICOS expression are mediated via roquin, its paralogues and/or 
MicroRNA-146a [167].  
 
The impact of innate-cytokine signalling on the development of humoral immune 
responses during Plasmodium infection has largely been unknown. Indeed, the effects of 
IL-6 and IFN-I-signalling, as described in chapters three and four, respectively, are the first 
form of evidence that innate-cytokine signalling pathways influence humoral immune 
responses and parasite control during Plasmodium infection. These findings are significant 
because much of our current understanding of cytokine-mediated control of humoral 
immunity derives from studies of viral infection or experimental immunization in mice but 
not parasitic infections. IL-6 is a pleiotropic cytokine. However its role in malaria is not well 
defined, despite its existence in serum samples of mice and humans. In the current study, 
IL-6 was implicated in supporting optimal control of parasite numbers and antibody 
responses during experimental blood-stage malaria. This is the first mechanistic 
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description of the role of IL-6 in immune responses to blood-stage malaria. Nonetheless, 
the source of IL-6 and the cells through which IL-6 acted to mediate these effects were not 
examined and thus warrant further investigation. In such studies, the possibility that IL-6 is 
produced by myeloid cells and acts directly on B-cells to induce B-cell differentiation, in 
particular plasma cells, could be examined. Another possibility that may be explored is that 
myeloid cell-derived IL-6 acts on T-cells inducing IL-21 which drives B-cell differentiation 
and antibody production. The current study illustrated that IL-6 was dispensable for Tfh 
formation in mouse models of blood-stage malaria. However, a recent report suggested 
that in the presence of IL-6 signalling, IL-21 was not essential for Tfh formation in mouse 
models of blood-stage malaria [264]. These observations suggest existence of other 
redundant signals that may compensate loss of IL-6 or IL-21 to support Tfh formation in 
these systems. One possibility is that IL-27 compensates the loss of IL-6 and/or IL-21 
signalling to support Tfh formation as has been suggested in the LCMV model [324]. 
Future studies aiming to examine this possibility are recommended. Although the current 
study focussed on Tfh differentiation, it may also be interesting to explore the effect of IL-6 
signalling on the formation and function of other T-helper subsets (Th1, Tregs and Tr1), 
considering these also influence parasite control. 
 
The current study has provided the first description of a mechanism in this case, IFN-I 
signalling pathway that significantly represses parasite control during experimental blood-
stage malaria. Although the current study focused on IFN-I-mediated effects on the 
development of humoral immune responses, its findings extend earlier studies that 
identified important roles for this signalling pathway in controlling other CD4+ T-cell 
responses (Th1 and Tr1), in Plasmodium-infected mice and humans [217, 238, 251, 375]. 
The current study revealed that IFN-I impaired CD4+ T-cell dependent humoral immune 
responses via direct signalling in cDCs, but not B- or T-cells. One question that remains 
unanswered is how the interaction between cDCs and CD4+ T-cells is altered by IFNAR1 
signalling at molecular level. Findings in this study and others in the PbANKA system [238] 
revealed multiple changes in the co-stimulatory landscape on the surface of cDC, including 
a substantial shift in the ratio of PDL1:PDL2 expression on CD8- cDC. A recent report 
suggested that PDL2-signalling can compete against regulatory effects of PDL1, and 
indeed can protect against experimental malaria [357]. Therefore, it is possible that IFN-I-
signalling in cDC regulates CD4+ T cell activation by favouring PDL1-signalling over the 
protective PDL2. Future experiments may test this possibility.  
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The absence of IFN-I signalling boosted ICOS-signalling in CD4+ T-cells, which associated 
with improved humoral immune responses and parasite control during infection. The 
mechanism through which enhanced ICOS signalling mediated these effects in IFNAR1 
deficient mice remains unclear and warrants further investigation. Nonetheless, the current 
data suggested that enhanced ICOS signalling supported the localisation of T-cells in 
splenic B-cell areas as suggested elsewhere [116]. It might be interesting to explore 
whether this was due to accelerated speed with which T-cells in the Ifnar1-/- mice migrated 
from T-cell areas into B-cell areas of the spleen. In addition, determining whether 
enhanced ICOS signalling in the Ifnar1-/- mice altered the behaviour patterns (such as the 
duration of T-B interactions at the T-B border or within the follicles) of T-cells upon their 
localisation in B-cell areas may be interesting. These possibilities may be examined by 
intra-vital imaging microscopy. Future experiments may also examine whether the 
improved humoral responses and parasite control in the absence of IFN-I signalling was 
due to enhanced ICOS-induced PI3K signalling in T-cells. Recent studies in mice infected 
with chronic LCMV infection suggested that IFN-I signalling restricted humoral immunity by 
deleting B-cells or restricting the survival of antibody secreting cells [345, 347, 348]. Future 
experiments may consider validating these observations in models of Plasmodium 
infection. 
 
The current studies did not explicitly assess the effect of IFNAR1-depletion on the antigen-
specificity of responding CD4+ T cells. Therefore, it is theoretically possible that within the 
polyclonal population of Th1 and Tfh cells assessed, that antigen-specificity may have 
been altered in IFNAR1-deficient animals compared to WT mice.  However, in a previous 
report [238], it was shown using TCR transgenic T cells of defined specificity (OTII cells 
and TEa T cells) that cDCs encouraged Th1 priming more effectively ex vivo if IFNAR1-
signals were abrogated in vivo. These data suggest that IFNAR1-signalling can limit Th 
responses independently of TCR affinity. Future experiments using recently developed 
Plasmodium-specific TCR transgenic CD4+ T cells (termed as PbTII cells) [376] will be 
able to directly test these ideas in vivo.  
 
The functional relevance of IFN-I signalling during Plasmodium infection in humans 
remains to be established. However recent studies in ex vivo cultures of PBMC from P. 
falciparum-infected humans suggested an immunoregulatory role for signalling via IFNAR2 
[375]. Polymorphisms in the Ifnar1 gene were associated with reduced risk of severe 
malaria [285, 336]. Although, the location of these polymorphisms did not indicate the 
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direction of their effect on IFN-I-signalling, the implication was that changes in this 
signalling pathway could mediate improved parasite control. Given that the absence of 
IFN-I signalling accelerated early production of parasite-specific antibodies, it could be 
interesting to determine whether these effects directly increase the rate of acquisition of 
immunity to clinical malaria in humans. Transient IFN-I-blockade could be a potential 
strategy of improving humoral immunity in humans. Longitudinal studies aiming to examine 
the relationship of IFN-I levels and antibody levels in Plasmodium-infected humans may be 
useful in identifying the right window in which IFN-I blockade may be administered and 
how its potency may be boosted. 
 
The role of macrophages and monocytes in different infections is not well defined. This is 
partly due to the lack of appropriate tools and reagents to examine these cell types in-vivo. 
Studies in chapter five described a novel in-vivo transgenic system (LysMcreiDTR) for 
depleting these cells. This reagent could be useful in future in vivo investigations aiming to 
define roles of these cells and their influence on other cell types in different experimental 
models. Using this reagent, the current study revealed that monocytes and macrophages 
were not essential for early parasite control during PbANKA infection. Instead, these cells 
may have facilitated early parasite growth. These observations were consistent in 
splenectomised mice and in mice treated with clodronate liposomes. The reduced 
parasitemia detected in splenectomised and clodronate treated mice could have been 
caused by increased sequestration of parasites in tissues, as has been suggested 
elsewhere [363]. Probably, this was not the case in LDTR mice treated with DT. 
Nonetheless, further experiments are clearly needed to directly determine parasite 
burdens in individual organs of these mice given that a constitutive luciferase expressing 
parasite, with schizont stages that are not easily detected by whole body imaging was 
used for the above studies. Collectively, these observations are intriguing because they 
challenge the current dogma in which monocytes and macrophages have been purported 
to be essential for controlling parasite numbers Plasmodium infection. Although 
explanations for these findings remain unclear, they could theoretically involve interactions 
between Plasmodium parasites (through PAMPS) and macrophages and/or monocytes 
(through PRRs), which subvert optimal function of these cells. Alternatively, it could involve 
activation cell extrinsic and/or intrinsic signalling pathways, which may alter optimal 
monocyte and macrophage function, facilitating parasite growth. These possibilities could 
be considered for future exploration. Studies aiming to validate these results in other 
experimental models of blood-stage malaria such as PcAS and Py17XNL are also 
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recommended. Future experiments may also explor the impact of monocyte and 
macrophage depletion on antibody mediated control of parasites during blood-stage 
malaria given that these mechanisms are believed to facilitate phagocytosis and clearance 
of infected RBCs. 
 
The depletion of monocytes and macrophages completely protected mice against ECM 
during PbANKA infection, as described in chapter five. This observation is significant 
because it not only describes a new mechanism of influencing pathology, but also opens 
up a new area of research that requires further investigation. For instance, future 
experiments may consider examining the impact of monocyte and macrophage depletion 
on the recruitment of CD8+ T-cells in the brain because this process has been associated 
with the establishment of ECM symptoms during PbANKA infection [377-379]. In addition, 
it would be interesting to determine the impact of monocyte and macrophage depletion on 
the expression adhesion molecules on microvascular cells in the brain because 
upregulation of these adhesion molecules in the brain has also been associated with the 
development of ECM pathology in mice infected PbANKA [378]. Furthermore, future 
experiments may consider examining whether monocytes and macrophages are recruited 
in the brain during severe malaria and whether direct interactions of these cells with CD8+ 
T-cells contribute to the development of pathology. These questions may be explored 
using the LDTR system and intravital imaging microscopy. Lastly, the CD8+ T-cell cytotoxic 
molecule, granzyme B, has been associated with the development of ECM [377]. 
Therefore, it may be interesting to explore the effects of monocyte and macrophage 
depletion on CD8+ T-cell responses, in particular, the production of granzyme B, during 
PbANKA infection.  
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Figure 6.1 Schematic view of a proposed model of innate cytokine signalling and the 
mononuclear phagocyte system on parasite control during experimental blood-
stage malaria. IFNAR1 signalling suppresses humoral immune dependent parasite control 
during infection. Conversely, IL-6 supports the development of optimal humoral responses which 
are required for parasite control. Monocytes and/or Macrophages regulate early parasite control 
and drive pathology during lethal blood-stage malaria. 
 
In summary, the current studies have provided three major outcomes: (A) They have 
challenged the existing dogma that monocytes and/or macrophages play active roles in 
controlling parasite numbers and suggested their capacity to influence pathology in severe 
malaria. (B) They have provided an insight into mechanisms governing antibody-mediated 
parasite control in models of blood-stage malaria. (C) They have highlighted novel 
strategies through which antibody-mediated parasite control may be harnessed to boost 
immunity to malaria. These findings may have significant implications in improving both 
natural and vaccine-induced immunity to Plasmodium infections.   
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